,date,information,related
0,2022-09-23,"Headline: Solicitor general recommends Supreme Court shouldn't review Amgen patent case, source:Thefly.com, summary: The U.S. solicitor genera... AMGN, Headline: Amgen (NASDAQ:AMGN) shareholders have earned a 7.3% CAGR over the last five years, source:Yahoo, summary: If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to..., Headline: Amgen Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. shed 0.34% to $226.97 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Don't Fight The Fed: 2 Blue Chip Dividend Buys And 1 Strong Sell, source:SeekingAlpha, summary: Fed took the most hawkish stance yet, as Powell takes a page out of Volcker's book. Find out couple of high-quality dividend names to pick up ahead of any turbulence.",AMGN
1,2022-09-24,"Headline: The Near-Perfect Portfolio: Sleep Well During Turbulent Times, source:SeekingAlpha, summary: The principles of NPP revolve around sustainable income, lower drawdowns, capital preservation, and reasonable growth over the long. Read more here.",AMGN
2,2022-09-26,"Headline: MDA Breakout Stocks Week 39 - September 2022: Short-Term Picks To Give You An Edge, source:SeekingAlpha, summary: Two new Breakout Stocks for Week 39 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now down to +108.7% YTD., Headline: 10 Best Biotech Stocks Under $10, source:Yahoo, summary: In this article, we will look at the 10 best biotech stocks under $10. If you want to explore similar biotech stocks with promising prospects that you can get for under $10, you can also take a look at 5 Best Biotech Stocks Under $10. The Global Biotech Industry According to an industry analysis report […], Headline: Dow Jones ETF Avoids Bear Market: 4 Stocks in Green, source:Yahoo, summary: Both the S&P 500 and the tech-heavy Nasdaq Index are in bear market while the Dow Jones in the only of the three main indexes not to have bear market status.",AMGN
3,2022-09-27,"Headline: The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market, source:InvestorPlace, summary: Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market., Headline: Wall Street Breakfast: Dollar Vs. Stocks, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Dollar vs. Stocks The U.S., Headline: Warning! A Housing Market Crash Will Tank These 3 Stocks., source:InvestorPlace, summary: Don't be complacent about a potential black-swan event. A housing market crash would send these three stocks plunging., Headline: Amgen Inc. (NASDAQ:AMGN) insiders sold US$4.9m worth of stock suggesting impending weakness., source:Yahoo, summary: Many Amgen Inc. ( NASDAQ:AMGN ) insiders ditched their stock over the past year, which may be of interest to the..., Headline: Amgen (AMGN) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: In the latest trading session, Amgen (AMGN) closed at $225.99, marking a -0.39% move from the previous day.",AMGN
4,2022-09-28,"Headline: Cantor Fitzgerald healthcare analysts to hold KOL luncheon panel, source:Thefly.com, summary: In conjunction with Canto... AZN, AMGN, MRTX, GILD, IMAB, NVS, SURF, PFE, ALXO, RHHBY, MRK, Headline: 3 Biotech Stocks to Buy and Hold for the Next 10 Years, source:Yahoo, summary: Several biotech stocks have outperformed the struggling market this year.  This list includes Vertex Pharmaceuticals (NASDAQ: VRTX), Exelixis (NASDAQ: EXEL), and Amgen (NASDAQ: AMGN).  Let's consider why these three biotechs are solid buys for the next decade., Headline: Amgen management to meet virtually with Oppenheimer, source:Thefly.com, summary: Virtual Meeting to be hel... AMGN",AMGN
5,2022-09-29,"Headline: November 11th Options Now Available For Amgen, source:Stock Options Channel, summary: Staff article entitled November 11th Options Now Available For Amgen , about stock options, from Stock Options Channel.",AMGN
6,2022-10-01,"Headline: How To Aim For A Million Dollar Portfolio And Retire At 62, source:SeekingAlpha, summary: Click here to read more about several strategies and model portfolios that can help you retire with a one million dollar portfolio., Headline: Amgen Inc. (NASDAQ:AMGN) Looks Just Right, source:Yahoo, summary: With a price-to-earnings (or ""P/E"") ratio of 18.3x Amgen Inc. ( NASDAQ:AMGN ) may be sending bearish signals at the..., Headline: Bristol-Myers Squibb: A Gem In A Period Of Macroeconomic Uncertainties, source:SeekingAlpha, summary: The company's medicines received over 10 regulatory approvals in Europe, Japan, and the US in the first half of 2022. Read more to see our price target on BMY.",AMGN
7,2022-10-02,"Headline: IGA: Value-Oriented Portfolio Leading To Outperformance, source:SeekingAlpha, summary: IGA has been performing relatively well during the challenging 2022 market. See why I believe the CEF is a worthwhile candidate for adding to one's portfolio.",AMGN
8,2022-10-03,"Headline: Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?, source:Yahoo, summary: AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023., Headline: Could This Biosimilar Drug Candidate Be a Hit for Novartis?, source:Yahoo, summary: On Sept. 19, Novartis (NYSE: NVS) shared positive news with investors regarding the clinical trial results for its biosimilar drug candidate to Amgen's (NASDAQ: AMGN) osteoporosis medicine Prolia.  With Prolia set to lose exclusivity in the U.S. in 2025, Novartis could be close to booking some revenue from its biosimilar drug.  Let's go over the outcome of the clinical trial and the U.S. osteoporosis market to figure this out., Headline: My 27-Stock $334k Retirement Portfolio's September Disaster Saved Somewhat By Dividends, source:SeekingAlpha, summary: My portfolio, built specifically for my retirement ~20+ years from now, had a crushing September, along with the rest of the market, in spite of amazing Petrobras dividends.",AMGN
9,2022-10-04,"Headline: Amgen (AMGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed at $233.02 in the latest trading session, marking a +1.12% move from the prior day.",AMGN
10,2022-10-05,"Headline: Amgen (NASDAQ:AMGN) jumps 3.1% this week, though earnings growth is still tracking behind five-year shareholder returns, source:Yahoo, summary: When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore..., Headline: Buy 4 October Dogs Of The Dow And Watch 4 More, source:SeekingAlpha, summary: The Dow adds a stock if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Read more here., Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.34% higher to $233.82 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",AMGN
11,2022-10-06,"Headline: Amgen opens new R&D site in San Francisco's Oyster Point, source:Thefly.com, summary: Amgen announced the openi... AMGN, Headline: Birch Capital Management, LLC  - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: High Yield Stock Watchlist - October 2022, source:SeekingAlpha, summary: There are 24 stocks on my high yield watchlist for October 2022, and 2 stocks are down more significantly and now may be a good time to buy. Click here to know the stocks., Headline: AMGEN OPENS NEW STATE-OF-THE-ART RESEARCH AND DEVELOPMENT LABORATORY SITE IN SAN FRANCISCO BAY AREA, source:Yahoo, summary: (Oct. 6, 2022) – Amgen (NASDAQ:AMGN) today announced the opening of a new research and development site in San Francisco's Oyster Point, continuing the company's nearly two-decade presence in the region. The new site will constitute the company's second largest research and development facility, which focuses on discovering therapeutics for patients living with cancer, inflammatory disease and cardiometabolic disorders., Headline: Top 20 Drug Companies in the World in 2022, source:Yahoo, summary: In this article, we will be taking a look at the top 20 drug companies in the world in 2022. To skip our detailed analysis, you can go directly to see the top 5 drug companies in the world in 2022. While major pharmaceutical companies have always been derided for considering profits over the well-being […], Headline: Amgen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. slid 1.23% to $230.94 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Amgen's short, big move designed to execute at corner of tech and biotech, source:Yahoo, summary: Amgen Inc. Chairman and CEO Bob Bradway acknowledges the company's move to a new R&D site in South San Francisco isn't a big deal — at least as far as geography — but as far as culture, recruitment, retention and the chance to deliver scientifically, it's huge.  Amgen officially opened its new research-and-development and office building Thursday in BioMed Realty's Gateway of Pacific complex., Headline: Buy Illumina Stock. The Biotech Is Lowering the Cost of Gene Sequencing., source:MarketWatch, summary: Illumina CEO Francis deSouza told analysts that the company can cut sequencing’s cost without crimping its 60%-plus gross margins.",AMGN
12,2022-10-07,"Headline: Amgen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. sank 0.83% to $229.03 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: U.S. buys radiation sickness drug as part of long-standing program, source:Reuters, summary: The U.S. government this week bought $290 million in supplies of a drug designed to treat blood cell injuries following radiological and nuclear emergencies as part of what it said were long-standing efforts to prepare for potential health impacts from threats to national...",AMGN
13,2022-10-08,"Headline: Wall Street Breakfast: What Moved Markets, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify., Headline: 2 Healthcare Stocks That Could Help Make You a Fortune, source:Yahoo, summary: Contrary to popular belief, the simple approach to many things in life is often the most effective.  An investing quote from Motley Fool contributor Brian Feroldi that I believe is highly underrated goes as follows: ""Good investing is 99% patience and 1% action.""  The pharmaceutical giant Amgen (NASDAQ: AMGN) and medical devices maker Stryker (NYSE: SYK) are two healthcare stocks that appear poised to create wealth for shareholders who are patient and measured enough to let them.",AMGN
14,2022-10-09,"Headline: 7 Value Stocks That Are Too Cheap to Ignore, source:InvestorPlace, summary: With market and economic forces eschewing growth-focused companies, now may be the time to consider cheap value stocks to buy., Headline: Insiders at Amgen Inc. (NASDAQ:AMGN) sold US$4.9m worth of stock, possibly indicating weakness in the future, source:Yahoo, summary: The fact that multiple Amgen Inc. ( NASDAQ:AMGN ) insiders offloaded a considerable amount of shares over the past year...",AMGN
15,2022-10-10,"Headline: Is Amgen (AMGN) a Great Long-Term Bet?, source:Yahoo, summary: Aristotle Capital Management, LLC, an investment management company, released its “Aristotle Global Equity Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here. In the second quarter, the fund returned -13.17% at NAV compared to a -15.66% return for the MSCI ACWI Index and -16.19% return for the MSCI World […], Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. rose 1.36% to $232.15 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index..., Headline: S&P 500 rebounds from earlier losses, tries to snap 4-day losing streak, source:CNBC, summary: Market participants are anticipating key inflation data this week, as well as the release of major bank earnings. , Headline: Amgen (AMGN) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed at $232.15 in the latest trading session, marking a +1.36% move from the prior day., Headline: What You Missed On Wall Street On Tuesday, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. JOBY, DAL, OFIX, SPNE, UBER, LYFT, FORG, FXJ, HZON, META, LULU, AMGN, ZM, RBLX, KLAC, VWAGY, AMZN, LLY, DICE, HL, WBA, SPWR, ANGI, LEG, ZYXI, AAL, NEPH, AZZ",AMGN
16,2022-10-11,"Headline: Amgen upgraded to Overweight from Equal Weight at Morgan Stanley, source:Thefly.com, summary: Morgan Stanley analyst Ma... AMGN, Headline: Top 5 3rd Quarter Trades of CH - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Neumora Therapeutics announces $112M Series B Financing, source:Thefly.com, summary: Neumora Therapeutics anno... AMGN, Headline: Biotech Stocks Well-Positioned For Fourth Quarter, source:SeekingAlpha, summary: Biotechs benefit if a slowdown pushes the longer-term yields lower. Check out why are biotechs relatively well-positioned now., Headline: Early notable gainers among liquid option names on October 11th, source:Thefly.com, summary: Notable gainers among liq... AMGN, ULTA, AAP, AAL, MO, Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: There&#8217;s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (<span class='tr-stock-ticker' style='color:blue; font-we..., Headline: Amgen-partnered neuroscience startup rakes in another $112M, source:Yahoo, summary: A year after emerging from stealth with what would ultimately be the fifth-largest fundraise among local life sciences companies in 2021, Neumora Therapeutics has raised another $112 million to propel its neuropsychiatric drugs forward., Headline: Bullish Two Hundred Day Moving Average Cross - AMGN, source:Dividend Channel, summary: dividend channel,AMGN,, Headline: Dow's 50-point jump led by gains for Amgen, Walgreens Boots stocks, source:MarketWatch, summary: Buoyed by positive growth for shares of Amgen and Walgreens Boots, the Dow Jones Industrial Average is climbing Tuesday morning. Shares of Amgen and..., Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. META, LULU, JOBY, DAL, OFIX, SPNE, UBER, LYFT, FORG, FXJ, HZON, AMGN, ZM, RBLX, NSANY, TOSYY, VWAGY, KLAC, DICE, HL, WBA, SPWR, NOG, LEG, ZYXI, AAL, NEPH, AZZ, DASH, Headline: Amgen, Walgreens Boots share gains contribute to Dow's 284-point jump, source:MarketWatch, summary: Shares of Amgen and Walgreens Boots are trading higher Tuesday morning, propelling the Dow Jones Industrial Average into positive territory. The Dow was most..., Headline: Stocks making the biggest moves midday: Amgen, Uber, Lyft, Zscaler and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: Lululemon Athletica upgrade, Meta Platforms downgrade and Texas Instruments initiation among today's top calls on Wall Street LULU, NKE, ELF, NOW, ABC, SGEN, AMGN, META, QRVO, SWKS, ZM, FFIV, SPWR, TXN, SNOW, BA, SPLK, DT, DDOG, RBLX, Headline: Noteworthy Tuesday Option Activity: AMGN, ULTA, LIN, source:Stock Options Channel, summary: Staff article entitled Noteworthy Tuesday Option Activity: AMGN, ULTA, LIN, about stock options, from Stock Options Channel., Headline: Dow's 387-point rally led by gains for shares of Amgen, Walgreens Boots, source:MarketWatch, summary: The Dow Jones Industrial Average is rallying Tuesday afternoon with shares of Amgen and Walgreens Boots seeing positive gains for the price-weighted average...., Headline: 12 Best Ethical Stocks To Buy Now, source:Yahoo, summary: In this article, we will take a look at 12 best ethical stocks to buy now. If you want to see some more of the best ethical stocks to buy, go directly to 5 Best Ethical Stocks To Buy Now. Sometimes investing is more than about just making money. Investing can also be used to […], Headline: US STOCKS-Wall St set for muted open as economic worries curb risk appetite, source:Yahoo, summary: The three main indexes have been on a loss-making streak in the past few sessions as recent data continues to point to more policy tightening by the U.S. Federal Reserve that could tip the economy into a recession.  Most rate-sensitive growth stocks such as Microsoft Corp , Twitter Inc, Amazon.com, Apple Inc , and Tesla Inc were down between 0.1% and 0.2% in premarket trading.  With recent economic indicators signaling persistent inflation going forward, money markets are pricing in a 92% chance of another 75-basis-point hike at the Fed's meeting in November., Headline: US STOCKS SNAPSHOT-Wall St opens lower on earnings anxiety , source:Reuters, summary: U.S. stock indexes opened lower on Tuesday as investors awaited the earnings season to assess the impact of rising interest rates and inflation on corporate profit, while a rise in shares of drugmaker Amgen limited declines on the Dow., Headline: Amgen stock surges, provides nearly 80-point support to the Dow after Morgan Stanley turns bullish, source:Yahoo, summary: MARKET PULSE Shares of Amgen Inc. (AMGN) leapt 5.2% in morning trading Tuesday, enough to pace the Dow Jones Industrial Average’s (DJIA) gainers, after Morgan Stanley turned bullish on the biotechnology company., Headline: Amgen, Walgreens Boots share gains contribute to Dow's 300-point rally, source:MarketWatch, summary: The Dow Jones Industrial Average is rallying Tuesday afternoon with shares of Amgen and Walgreens Boots leading the way for the blue-chip average. Shares of..., Headline: US STOCKS-Wall St falls on worries of lower third-quarter corporate profit; Amgen jumps, source:Yahoo, summary: U.S. stocks fell on Tuesday in the run-up to third-quarter results from companies as profit expectations drop amid rising interest rates and stubborn inflation, while gains in drugmaker Amgen limited declines on the Dow.  Microsoft Corp, Twitter Inc, Amazon.com , Apple Inc, and Tesla Inc were down between 1% and 3.5%., Headline: Amgen Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. rose 5.72% to $245.44 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: US STOCKS-S&P 500, Nasdaq fall on fears of profit hit from inflation, rate hikes, source:Yahoo, summary: The S&P 500 and the Nasdaq fell on Tuesday in the run-up to a key inflation reading and the start of third-quarter results from companies amid falling profit expectations, while gains in drugmaker Amgen helped boost the Dow.  With recent jobs and inflation data suggesting more big interest rate hikes by the Federal Reserve, Wall Street's main indexes have been clocking losses in the past few sessions on fears of the economy slipping into a recession., Headline: Health Care Up Slightly As Amgen Rallies -- Health Care Roundup, source:MarketWatch, summary: Health-care companies rose slightly, as traders bet the sector was better positioned than most for rising inflation and interest rates. Amgen shares rallied..., Headline: Top Research Reports for Chevron, Amgen & HSBC, source:Yahoo, summary: Today's Research Daily features new research reports on 12 major stocks, including Chevron Corporation (CVX), Amgen Inc. (AMGN) and HSBC Holdings plc (HSBC)., Headline: Why Amgen Is Up More Than 6% Today, source:Yahoo, summary: An upgrade highlights one of the more philosophical reasons you want to bet on this biopharma name right now., Headline: US STOCKS-Dow, S&P 500 rise after recent losses; investors prepare for inflation, earnings data, source:Yahoo, summary: The Dow and S&P 500 were higher in late afternoon trading Tuesday as investors snapped up some beaten-down shares, but volatility was high ahead of U.S. inflation data and the start of third-quarter earnings later this week.  The Nasdaq was lower, extending recent declines., Headline: Amgen Stock Takes Off as Morgan Stanley Flags Room for Gains, source:Yahoo, summary: Analyst Matthew Harrison upgraded shares of the biotechnology company to Overweight from Equal Weight., Headline: Best Stocks To Buy Right Now? 3 Dow Jones Stocks To Watch, source:StockMarket, summary: 3 Dow Jones Stocks to watch in the stock market in October 2022., Headline: Amgen, The Big Name You Need To Know Going Up Against Novo, Lilly In Obesity Treatments, source:Yahoo, summary: Amgen stock surged Tuesday on a reportedly bullish call for its experimental obesity treatment — a potential rival to Novo and Lilly., Headline: US STOCKS-S&P 500, Nasdaq end lower; BoE comments add to market jitters late, source:Yahoo, summary: The S&P 500 and Nasdaq ended lower on Tuesday, with indications from the Bank of England that it would support the country's bond market for just three more days adding to market jitters late in the session.  Trading was volatile, with investors cautious ahead of key U.S. inflation data and the start of third-quarter earnings later this week., Headline: Nasdaq Falls Into Bear Market After Volatile Day, source:Yahoo, summary: U.S. stock indexes turned lower in the final hour of trading after remarks from Bank of England Gov. Andrew Bailey., Headline: Nicholas Ward's Dividend Growth Portfolio: August/September 2022 Update, source:SeekingAlpha, summary: During August, my passive income was up by 2.90% y/y. During September, my passive income was up by 41.14% y/y. Click to see my trades during these two months.",AMGN
17,2022-10-12,"Headline: Amgen price target lowered to $234 from $236 at Barclays, source:Thefly.com, summary: Barclays analyst Carter G... AMGN, Headline: Wealth Advisors of Tampa Bay,  - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Keystone Financial Planning, I - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: The Zacks Analyst Blog Highlights Chevron, Amgen, HSBC, CVS Health and S&P Global, source:Yahoo, summary: Chevron, Amgen, HSBC, CVS Health and S&P Global are included in this Analyst Blog., Headline: Biotech Stocks Well-Positioned For The Fourth Quarter, source:TalkMarkets, summary: The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.
, Headline: AMGEN'S ANNUAL TRENDS REPORT FINDS COMPETITION CREATED BY BIOSIMILARS CONTRIBUTED $21 BILLION IN U.S. HEALTHCARE SYSTEM SAVINGS, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today released the 9th edition of its Biosimilar Trends Report, which examines the current and future state of the U.S. marketplace with biosimilars. This year, in addition to examining important trends in the U.S., the Report also highlights key considerations and learnings from the global marketplace with biosimilars. To access the full Report, visit https://www.amgenbiosimilars.com/commitment/trends-report., Headline: Stock Market News for Oct 12, 2022, source:Yahoo, summary: Wall Street closed mixed on Tuesday after a choppy session., Headline: Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock, source:Yahoo, summary: No summary, Headline: Amgen (AMGN) Recently Broke Out Above the 50-Day Moving Average, source:Yahoo, summary: Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?, Headline: Amgen (AMGN) Crossed Above the 200-Day Moving Average: What That Means for Investors, source:Yahoo, summary: When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?, Headline: Strength Seen in Amgen (AMGN): Can Its 5.7% Jump Turn into More Strength?, source:Yahoo, summary: Amgen (AMGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term., Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.41% higher to $246.44 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P..., Headline: Amgen Stock Shows Market Leadership With Jump To 90 RS Rating, source:Yahoo, summary: On Wednesday, Amgen stock hit an important technical milestone, with its Relative Strength (RS) Rating entering into the 90-plus percentile with an upgrade to 90, a rise from 78 the day before.  When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.  IBD's unique RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database., Headline: AVITY INVESTMENT MANAGEMENT IN - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: ",AMGN
18,2022-10-13,"Headline: Dividend Income Update September 2022, source:TalkMarkets, summary: With the start of the final quarter of 2022, it’s time to take a look back at my previous month of dividend income., Headline: SCHD: Buy Here And Ride Through The Coming Recession (Technical Analysis), source:SeekingAlpha, summary: The Schwab ETF is a high-quality ETF that invests in dividend-paying companies across the growth and value sphere. Read a full investment analysis here., Headline: Amgen Inc. (NASDAQ:AMGN) insiders sold US$4.9m worth of stock, a possible red flag that's yet to materialize, source:Yahoo, summary: Despite a 5.4% gain in Amgen Inc.'s ( NASDAQ:AMGN ) stock price this week, shareholders shouldn't let up. In spite of..., Headline: Amgen Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. rose 2.12% to $251.66 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Health Stock Amgen Has Strong Performance On Drug News; Shares Above Key Levels, source:Yahoo, summary: This health stock is up over 9% for the week and within 3% of a buy point on the chart. Shares soared on news of its obesity treatment.",AMGN
19,2022-10-14,"Headline: Amgen: As A Defensive Play?, source:SeekingAlpha, summary: The 10-year treasury can be a benchmark for investors when weighing positions in dividend yielding stocks, such as Amgen. Read more on the technical viewpoint., Headline: AMGN Crosses Above Average Analyst Target, source:ETF Channel, summary: Staff article entitled AMGN Crosses Above Average Analyst Target, about ETFs, from ETF Channel., Headline: Amgen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. slid 0.13% to $251.34 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Amgen (AMGN) Stock Moves -0.13%: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed the most recent trading day at $251.34, moving -0.13% from the previous trading session.",AMGN
20,2022-10-17,"Headline: Evotec, TIAP expand LAB150 BRIDGE partnership to expand Amgen, source:Thefly.com, summary: Evotec (EVO) and Toronto ... EVO, AMGN, Headline: Evotec, TIAP expand LAB150 BRIDGE partnership to include Amgen, source:Thefly.com, summary: Evotec (EVO) and Toronto ... EVO, AMGN, Headline: Amgen: Did Nancy Pelosi Buy Shares Last Week?, source:SeekingAlpha, summary: In my opinion, Pelosi buying Amgen stock is a rumor. Check here to see why either way, AMGN stock is fairly valued and a Buy now., Headline: The Epic 2021 Bubble Collapse - We Entered The Last Phase, Be Prepared, source:SeekingAlpha, summary: I will discuss which stocks you should absolutely avoid and provide 5 fantastic buying opportunities for the remainder of this bear market., Headline: Video: Dow Movers: AMGN, MSFT, source:Market News Video, summary: In early trading on Monday, shares of Microsoft topped the list of the day's best performing Dow Jones Industrial Average components, trading up 4.3% - Year to date, Microsoft has lost about 29.1% of its value - AMGN,MSFT,JNJ,CRM., Headline: Microsoft stock surges, provides biggest boost to the Dow's price, source:MarketWatch, summary: Shares of Microsoft Corp. undefined surged 3.7% in morning trading Monday, to provide the biggest point boost among Dow Jones Industrial Average's undefined..., Headline: Amgen Inc. (NASDAQ:AMGN) insiders sold US$4.9m worth of stock last year which shareholders may not want to overlook, source:Yahoo, summary: Despite a 9.7% gain in Amgen Inc.'s ( NASDAQ:AMGN ) stock price this week, shareholders shouldn't let up. Even though..., Headline: 10 Best Weight Loss Stocks To Buy Now, source:Yahoo, summary: In this article, we shall discuss the 10 best weight loss stocks to buy now. To skip our detailed analysis of the obesity epidemic and its effects on the weight loss and fitness industry in 2022, go directly and see 5 Best Weight Loss Stocks To Buy Now. The 21st century has seen obesity emerge […], Headline: Amgen Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.63% higher to $252.93 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",AMGN
21,2022-10-18,"Headline: Ideaya Biosciences provides update on IDE397 clinical program, source:Thefly.com, summary: Ideaya Biosciences (IDYA)... IDYA, AMGN, Headline: Top 5 3rd Quarter Trades of Sa - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: 2 Top Healthcare Stocks to Buy for the Long Haul, source:Yahoo, summary: Amgen is more established and has a dividend, while Vertex is one of several companies looking for therapies using the CRISPR Cas/9 gene-editing technique, which won the Nobel Prize just two years ago.  Amgen helped pioneer biotechnology and sells its therapies in more than 100 countries., Headline: Amgen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. shed 0.32% to $252.12 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...",AMGN
22,2022-10-19,"Headline: See How Amgen Ranks Among Analysts` Top Dow 30 Picks, source:ETF Channel, summary: Staff article entitled See How Amgen Ranks Among Analysts' Top Dow 30 Picks, about ETFs, from ETF Channel., Headline: Video: Dow Analyst Moves: AMGN, source:Market News Video, summary: The latest tally of analyst opinions from the major brokerage houses shows that among the 30 stocks making up the Dow Jones Industrial Average, Amgen is the #25 analyst pick - Within the broader S&P 500, when components were ranked in terms of analyst favorites, AMGN claims the #416 spot - AMGN., Headline: 15 Best Drug Stocks to Buy Now, source:Yahoo, summary: In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […], Headline: Amgen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slid 1.56% to $248.19 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Revolution Medicines initiated with an Outperform at Oppenheimer, source:Thefly.com, summary: Oppenheimer analyst Jay O... RVMD, AMGN, MRTX",AMGN
23,2022-10-20,"Headline: HQH: A Dividend Paymaster That Fails To Register Price Growth, source:SeekingAlpha, summary: Tekla Healthcare Investors is able to generate steady yield and currently trades at a good discount to its NAV. Read more to see why HQH is a Buy., Headline: Amgen completes acquisition of ChemoCentryx, source:Thefly.com, summary: Amgen (AMGN) announced th... AMGN, CCXI, Headline: How My Portfolio Is Holding Up Against The Bear Market, source:SeekingAlpha, summary: I explain how my portfolio is doing against the bear market. Read here to see what I own and in what proportions do I own it., Headline: Top 5 3rd Quarter Trades of NO - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Is Amgen Stock a Buy Now?, source:Yahoo, summary: Shares of Amgen (NASDAQ: AMGN) have been rising of late after a recent analyst upgrade generated some bullishness around the biotech company.  Should you buy the stock as it is climbing, or is Amgen's valuation due to fall back down?  Morgan Stanley upgraded Amgen's stock last week, setting a price target of $279 for the company, noting that its weight-loss treatment, AMG 133, has been demonstrating positive results., Headline: Do Options Traders Know Something About Amgen (AMGN) Stock We Don't?, source:Yahoo, summary: Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately., Headline: 10 Best Dividend Stocks on Robinhood, source:Yahoo, summary: In this article, we discuss 10 best dividend stocks on Robinhood. If you want to read about some more dividend stocks on Robinhood, check out 5 Best Dividend Stocks on Robinhood. Stock trading applications like Robinhood Markets, Inc. (NASDAQ:HOOD) have taken the investing world by storm in the past few years, prompting a new generation […], Headline: AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX, source:Yahoo, summary: Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion., Headline: Amgen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. sank 0.30% to $247.45 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: Amgen (AMGN) Stock Moves -0.3%: What You Should Know, source:Yahoo, summary: In the latest trading session, Amgen (AMGN) closed at $247.45, marking a -0.3% move from the previous day.",AMGN
24,2022-10-21,"Headline: Amgen (AMGN) Landed in Smead Capital Management’s Detractors List, source:Yahoo, summary: Smead Capital Management, an investment management company, released its Smead Value Fund third quarter 2022 investor letter. A copy of the same can be downloaded here. For the recent quarter, the Smead Value Fund (SMVLX) lost 1.82% versus a loss of 4.88% for the formerly formidable S&P 500 Index and 5.62% in the Russell 1000 […], Headline: Earnings Tell The Story For Amgen Inc. (NASDAQ:AMGN), source:Yahoo, summary: Amgen Inc.'s ( NASDAQ:AMGN ) price-to-earnings (or ""P/E"") ratio of 20.1x might make it look like a sell right now..., Headline: Johnson & Johnson: Currency, Kenvue, And Cash Allocation Focus Of Q3 2022 Earnings, source:SeekingAlpha, summary: Although buffeted by currency fluctuations, Johnson & Johnson's Q3 earnings were broadly impressive. Check out what will be the smart move for JNJ investors., Headline: Notable Friday Option Activity: AMGN, WMT, PFE, source:Stock Options Channel, summary: Staff article entitled Notable Friday Option Activity: AMGN, WMT, PFE, about stock options, from Stock Options Channel., Headline: Amgen (AMGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Amgen (AMGN) closed at $251.94, marking a +1.81% move from the previous day.",AMGN
25,2022-10-22,"Headline: The Near-Perfect Portfolio: Be Prepared To Weather The Storm, source:SeekingAlpha, summary: The market is going through a period of extraordinary uncertainty. The question is how to preserve wealth without compromising on upside. Click here to read the answer.",AMGN
26,2022-10-23,"Headline: Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV, source:SeekingAlpha, summary: Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV. Read why investors are getting HQL at an attractive valuation.",AMGN
27,2022-10-24,"Headline: See Which Of The Latest 13F Filers Holds Amgen, source:Preferred Stock Channel, summary: Staff article entitled See Which Of The Latest 13F Filers Holds Amgen, about stock options, from Holdings Channel., Headline: Dow jumps 181 points on gains for shares of Amgen, Verizon, source:MarketWatch, summary: Behind positive growth for shares of Amgen and Verizon, the Dow Jones Industrial Average is up Monday morning. Shares of Amgen and Verizon are contributing..., Headline: Can Amgen Finally Make an Upside Breakout?, source:Yahoo, summary: Pharmaceutical giant Amgen Inc. has been trading sideways in the $250-$260 area many times since April. The $64,000 question is whether AMGN can stage an upside breakout. Let's check the charts and the derivative indicators for an answer., Headline: AMGN Dividend Yield Pushes Past 3%, source:Dividend Channel, summary: dividend channel,AMGN,",AMGN
28,2022-10-25,"Headline: Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?, source:Yahoo, summary: A recent poll on prescription drug prices found that 83% of Americans view prescription drug prices as too expensive.  In recent years, U.S. lawmakers and regulatory agencies have worked together to begin tackling the concerns of Americans about the cost of prescription drugs.  When President Obama signed the Affordable Care Act into law in 2010, this opened up an avenue for the first biosimilar drug to ultimately be approved and launched in 2015., Headline: Insiders at Amgen Inc. (NASDAQ:AMGN) sold US$4.9m worth of stock, a potential red flag that needs to be monitored, source:Yahoo, summary: While it’s been a great week for Amgen Inc. ( NASDAQ:AMGN ) shareholders after stock gained 3.3%, they should consider..., Headline: Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know, source:Yahoo, summary: No summary, Headline: Akero: Putting Together The Pieces They Let Us See, source:SeekingAlpha, summary: We believe investors are not getting the full picture from Akeroâs approach to presenting the data from its clinical programs. Find out why we are short AKRO stock.",AMGN
29,2022-10-26,"Headline: Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and HCA Healthcare (HCA), source:TipRanks, summary: There&#8217;s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (<span class='tr-stock-ticker' style='color:blue; font-we..., Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. rose 2.57% to $266.66 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",AMGN
30,2022-10-27,"Headline: Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to Decline, source:Yahoo, summary: Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Amgen Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.21% higher to $267.23 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow..., Headline: Could Amgen Continue To Soar In This Bear Market? , source:TalkMarkets, summary: Amgen did a mini pull back then broke out on 24 Oct and committed above $260. According to the Wyckoff trading method, there is no immediate threatening supply hence the price could continue to climb higher.",AMGN
31,2022-10-28,"Headline: Amgen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. rose 2.46% to $273.81 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index..., Headline: AMGEN ANNOUNCES 2022 FOURTH QUARTER DIVIDEND, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the fourth quarter of 2022. The dividend will be paid on December 8, 2022, to all stockholders of record as of the close of business on November 17, 2022.",AMGN
32,2022-10-29,"Headline: Amgen (NASDAQ:AMGN) jumps 8.7% this week, though earnings growth is still tracking behind five-year shareholder returns, source:Yahoo, summary: Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the..., Headline: Pfizer, Uber and Starbucks Highlight Another Busy Earnings Week, source:Yahoo, summary: Pfizer Uber  Technologies Inc. and  Starbucks  are among the heavyweights headlining another busy earnings week as investors search for insight into the state of the broader economy.  Consumer spending has held up relatively well so far despite inflation, but experts say we’re approaching an inflection point.",AMGN
33,2022-10-30,"Headline: Dogs Of The Dow: A Leading Strategy In 2022, source:SeekingAlpha, summary: Now, with two months left in the year, the 2022 Dogs of the Dow continue to maintain an impressive performance advantage over the Dow Jones and S&P 500 indices.",AMGN
34,2022-10-31,"Headline: GLOBAL BROKER RATINGS: Jefferies raises Reckitt; DB likes BASF, source:Alliance News, summary: No summary, Headline: Take the Zacks Approach to Beat the Market: Caterpillar, Amgen, Inventiva in Focus, source:Yahoo, summary: Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months., Headline: Dow's 150-point drop led by losses for shares of Intel, Amgen, source:MarketWatch, summary: Behind losses for shares of Intel and Amgen, the Dow Jones Industrial Average is down Monday afternoon. Shares of Intel and Amgen have contributed to the..., Headline: Stocks making the biggest moves midday: Wynn Resorts, TuSimple, Newell Brands, First Solar and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Intel, Amgen share losses contribute to Dow's 50-point drop, source:MarketWatch, summary: The Dow Jones Industrial Average is trading down Monday afternoon with shares of Intel and Amgen seeing the biggest declines for the blue-chip average. The..., Headline: Biogen: Super-Strong Momentum In A Defensive Sector, source:SeekingAlpha, summary: Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. See why I would reenter a position in BIIB stock., Headline: Amgen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slid 1.26% to $270.35 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?, source:Yahoo, summary: Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs., Headline: AMGEN ANNOUNCES WEBCAST OF 2022 THIRD QUARTER FINANCIAL RESULTS, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Thursday, Nov. 3, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team., Headline: Deal Activity Could Jumpstart Biotechnology, source:SeekingAlpha, summary: Biotechnology failed to ride the tailwinds of COVID vaccine development. Despite poor sentiment toward biotech, see why we see reasons for optimism., Headline: Dogs Of The Dow: An Outperforming Strategy In 2022, source:SeekingAlpha, summary: From time to time I include an update on the performance of the Dogs of the Dow investment strategy. The last update was more than six months ago, April 16 to be exact., Headline: Amgen Now #47 Largest Company, Surpassing Charles Schwab, source:The Online Investor, summary: the online investor,AMGN,SCHW,",AMGN
35,2022-11-01,"Headline: First International Bank & Tru - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release, source:Yahoo, summary: Tango Therapeutics, Inc. (TNGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.63% higher to $272.06 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500..., Headline: My 24-Stock $354K Retirement Portfolio Makes A Big Bet On Facebook After Faceplant, source:SeekingAlpha, summary: My portfolio, built specifically for my retirement 20+ years from now, invested a new large position in a beaten down big tech stock. Read more to see my reasons., Headline: THQ: Large-Cap Healthcare Stocks Performed Well This Past Year, source:SeekingAlpha, summary: THQ offers a steady payout with a reasonably strong yield. See why Iâd prefer to hold back this stock and wait for a higher discount.",AMGN
36,2022-11-02,"Headline: 6 Stocks With Healthy Dividends and Solid Returns, source:Yahoo, summary: AbbVie, Gilead Sciences, Cardinal Health, Merck, Bristol Myers, and Amgen are large-cap healthcare companies that have the capacity to grow their dividends., Headline: Amgen's (NASDAQ:AMGN) five-year earnings growth trails the decent shareholder returns, source:Yahoo, summary: When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking..., Headline: Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More, source:Yahoo, summary: Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release., Headline: Amgen Inc. stock falls Wednesday, still outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slipped 1.12% to $269.01 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500..., Headline: AMGEN TO WEBCAST INVESTOR CALL AT AHA 2022, source:Yahoo, summary: Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the American Heart Association (AHA) Scientific Sessions at 6:00 p.m. ET on Monday, Nov. 7, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's R&D team and a clinical investigator, will discuss the Phase 2 data on olpasiran, an investigational small interfering RNA molecule designed to lower the body's production of apolipoprotein(a),, Headline: Amgen reports Q3 adjusted EPS $4.70, consensus $4.44, source:Thefly.com, summary: Reports Q3 revenue $6.7B,... AMGN, Headline: Amgen narrows FY22 adjusted EPS view to $17.25-$17.85 from $17.00-$18.00, source:Thefly.com, summary: FY22 consensus $17.50. Na... AMGN",AMGN
37,2022-11-03,"Headline: Mizuho Securities Sticks to Its Hold Rating for Amgen (AMGN), source:TipRanks, summary: In a report released today, Salim Syed from Mizuho Securities maintained a Hold rating on Amgen (AMGN &#8211; Research Report), with a price target of $208.00. The ..., Headline: Top 5 3rd Quarter Trades of Va - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: 2 Dividend Stocks to Hold Through a Recession and Beyond, source:Yahoo, summary: If a recession does come, it won't be the first that these two companies will have survived one., Headline: Notable companies reporting after market close, source:Thefly.com, summary: Notable companies reporti... AMGN, SBUX, PYPL, CTVA, MNST, ILMN, MCHP, SQ, WBD, LYV, DASH, NET, EXPE, COIN, SWKS, BILL, RKT, TWLO, PCTY, DBX, DXC, CVNA, SPCE, Headline: Amgen: Q3 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Amgen Beats on Revenue and Profit Expectations, source:Yahoo, summary: By Liz Moyer, Headline: AMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2022. Key results include:, Headline: REFILE-Amgen posts higher third-quarter revenue and profit, source:Reuters, summary: Biotechnology company Amgen Inc on Thursday said its third-quarter revenue rose 1% as sales volume growth for its cancer, rheumatology and cardiovascular products was somewhat offset by lower prices and foreign exchange losses., Headline: UPDATE 2-Amgen posts higher profit, says obesity drug data coming next month, source:Yahoo, summary: Biotechnology company Amgen Inc on Thursday said its third-quarter revenue rose 1% as higher volume growth for its cancer, rheumatology and cardiovascular products was offset by lower prices and foreign exchange losses.  The company also said data from a Phase I study of its potential obesity treatment AMG133 will be presented at the World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease conference in early December.  ""Our medicines generated 8% volume growth in the quarter globally, with 11 products achieving record quarterly sales,"" Amgen Chief Executive Robert Bradway said in a statement., Headline: Amgen posts higher profit, says obesity drug data coming next month, source:Reuters, summary: Biotechnology company Amgen Inc on Thursday said its third-quarter revenue rose 1% as higher volume growth for its cancer, rheumatology and cardiovascular products was offset by lower prices and foreign exchange losses., Headline: Amgen Inc. (AMGN) Q3 2022 Earnings Call Transcript, source:SeekingAlpha, summary: Amgen Inc. (NASDAQ:NASDAQ:AMGN) Q3 2022 Earnings Conference Call November 03, 2022, 04:30 PM ET Company Participants Arvind Sood - VP, IR Bob Bradway - Chairman and CEO Peter Griffith - CFO..., Headline: Amgen (AMGN) Surpasses Q3 Earnings and Revenue Estimates, source:Yahoo, summary: Amgen (AMGN) delivered earnings and revenue surprises of 6.09% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?, Headline: O'Keefe Stevens Advisory Q3 2022 Update, source:SeekingAlpha, summary: O'Keefe Stevens Advisory's end of Q2 top 5 holdings represented ~35% of assets, with NVDA representing ~11%. Click here to read the full fund letter., Headline: Amgen price target raised to $278 from $265 at Piper Sandler, source:Thefly.com, summary: Piper Sandler analyst Chr... AMGN",AMGN
38,2022-11-04,"Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Fate Therapeutics (FATE) and Intellia Therapeutics (NTLA), source:TipRanks, summary: Companies in the  Healthcare sector have received a lot of coverage today as analysts  weigh in on Amgen (<span class='tr-stock-ticker' style='color:blue; font-weig..., Headline: Amgen Reports Q3 Higher Profit, Despite Slight Fall In Topline Growth, source:Yahoo, summary: Amgen Inc's (NASDAQ: AMGN) Q3 revenue reached $6.65 billion, down 1% Y/Y, due to 8% volume growth offset primarily by a 5% lower net selling price and a 2% negative impact from foreign exchange. Analysts estimated sales of $6.56 billion. Excluding the 2% negative impact of foreign exchange, total revenues increased by 2%. The company reported Q3 adjusted EPS of $4.70, up 15%, beating the consensus of $4.44. Related: Amgen's Lumakras Cuts Risk Of Progression By 34% In KRAS-Mutated Lung Cancer Pat, Headline: Amgen (AMGN) Beats on Q3 Earnings & Sales, Tweaks 2022 View, source:Yahoo, summary: Amgen (AMGN) beats Q3 estimates for earnings and sales. It tightens previously issued revenue and adjusted earnings guidance ranges., Headline: Amgen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. rose 1.19% to $269.04 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index..., Headline: U.S. Supreme Court to hear Amgen bid to revive Repatha patents, source:Yahoo, summary: The U.S. Supreme Court on Friday agreed to hear Amgen Inc's bid to revive patents on its cholesterol drug Repatha that were invalidated due to a legal challenge by rivals  Regeneron Pharmaceuticals Inc and Sanofi SA.  The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents.  Amgen and other drugmakers have called the case a test of their ability to earn and defend patents for important drugs., Headline: RPT-U.S. Supreme Court to hear Amgen bid to revive Repatha patents, source:Yahoo, summary: The U.S. Supreme Court on Friday agreed to hear Amgen Inc's bid to revive patents on its cholesterol drug Repatha that were invalidated due to a legal challenge by rivals  Regeneron Pharmaceuticals Inc and Sanofi SA.  The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents.  Amgen and other drugmakers have called the case a test of their ability to earn and defend patents for important drugs., Headline: UPDATE 3-U.S. Supreme Court to hear Amgen bid to revive cholesterol drug patents, source:Yahoo, summary: The U.S. Supreme Court on Friday agreed to hear Amgen Inc's bid to revive patents on its cholesterol drug Repatha that were invalidated due to a legal challenge by rivals  Regeneron Pharmaceuticals Inc and Sanofi SA.  The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents., Headline: U.S. Supreme Court to hear Amgen bid to revive cholesterol drug patents, source:Yahoo, summary: WASHINGTON (Reuters) -The U.S. Supreme Court on Friday agreed to hear Amgen Inc's bid to revive patents on its cholesterol drug Repatha that were invalidated due to a legal challenge by rivals  Regeneron Pharmaceuticals Inc and Sanofi SA.  The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents., Headline: AMGEN ANNOUNCES WEBCAST OF 2022 CREDIT SUISSE GLOBAL HEALTHCARE CONFERENCE, source:Yahoo, summary: Amgen (NASDAQ:AMGN) will present at the Credit Suisse 31st Annual Global Healthcare Conference at 3:50 p.m. ET on Wednesday, November 9, 2022. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public., Headline: Amgen Sweetens Full-Year Outlook After Narrowly Beating Third-Quarter Forecasts, source:Yahoo, summary: Amgen stock popped Friday after the drugmaker sweetened its 2022 outlook following a third-quarter beat and strong Evenity sales., Headline: 10 Latest Earnings That Surprised Wall Street, source:Yahoo, summary: In this article, we will take a look at the 10 latest earnings that surprised Wall Street. If you want to see more such earnings reports on the list, go directly to 5 Latest Earnings That Surprised Wall Street. All three major U.S. indices struggled to find direction on Friday following the latest jobs data […]",AMGN
39,2022-11-06,"Headline: Amgen (AMGN) Gets a Hold from SVB Securities, source:TipRanks, summary: SVB Securities analyst David Risinger maintained a Hold rating on Amgen (AMGN &#8211; Research Report) on November 3. The company&#8217;s shares closed last Friday ..., Headline: Amgen (NASDAQ:AMGN) shareholders have earned a 13% CAGR over the last five years, source:Yahoo, summary: Stock pickers are generally looking for stocks that will outperform the broader market. And in our experience, buying..., Headline: AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of investigational olpasiran (formerly AMG 890) in adults with elevated lipoprotein(a) [Lp(a)] levels (>150 nmol/L) and a history of atherosclerotic cardiovascular disease (ASCVD). The study was designed to assess safety, tolerability and optimal dose of olpasiran in adults with established ASCVD to reduce Lp(a).1 These data were presented during the Nov. 6 Late-Breaking Science Session of the American, Headline: Amgen presents new Repatha data at AHA 2022, source:Thefly.com, summary: Amgen presented a new ana... AMGN, Headline: Amgen to hold investor conference call, source:Thefly.com, summary: In conjunction with the A... AMGN",AMGN
40,2022-11-07,"Headline: Mizuho Securities Reaffirms Their Hold Rating on Amgen (AMGN), source:TipRanks, summary: In a report released yesterday, Salim Syed from Mizuho Securities maintained a Hold rating on Amgen (AMGN &#8211; Research Report), with a price target of $208.00. ..., Headline: AMGEN TO PRESENT NEW RESEARCH ACROSS SERIOUS INFLAMMATORY AND BONE DISEASES AT ACR 2022, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced that clinical and real-world data across its broad portfolio of established treatments and pipeline assets will be presented at the annual American College of Rheumatology Convergence (ACR), taking place in Philadelphia on Nov. 10-14, 2022., Headline: UPDATE 2-U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead, source:Yahoo, summary: The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc subsidiary Kite Pharma Inc over a lymphoma drug.  The justices turned away Juno's appeal of a lower court's ruling throwing out the award in the litigation over Kite's biologic drug Yescarta, in a case that could have repercussions for the cutting-edge biologic drug industry., Headline: UPDATE 3-U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead, source:Yahoo, summary: The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc subsidiary Kite Pharma Inc over a lymphoma drug.  The justices turned away Juno's appeal of a lower court's ruling throwing out the award in the litigation over Kite's biologic drug Yescarta, in a case that could have repercussions for the cutting-edge biologic drug industry., Headline: Amgen's Olpasiran Reduced Cholesterol Levels In 95% Of Patients In Mid-Stage Study, source:Yahoo, summary: Amgen Inc (NASDAQ: AMGN) presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of olpasiran (formerly AMG 890) in adults with elevated lipoprotein levels and a history of atherosclerotic cardiovascular disease (ASCVD). These data were presented during the Nov. 6 Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions. Patients who received 75 mg or higher every 12 weeks had a 95% or greater reduction in lipoprotein levels compared to placebo at we, Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. advanced 2.97% to $277.02 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today presented a new analysis from the Phase 3 FOURIER and FOURIER open label extension (OLE) studies of Repatha® (evolocumab) in adults with atherosclerotic cardiovascular disease (ASCVD) during the Nov. 7 Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2022 in Chicago, Illinois. These data demonstrated that achieving and sustaining a low-density lipoprotein cholesterol (LDL-C) level of <20 mg/dL was associated with improved cardiov, Headline: Dow Logs Highest Close Since Late August, source:TalkMarkets, summary: The Dow stayed hot today, nabbing its third-straight win on the back of a 333-point gain. ",AMGN
41,2022-11-08,"Headline: Amgen price target raised to $280 from $266 at Truist, source:Thefly.com, summary: Truist analyst Robyn Karn... AMGN, Headline: Amgen price target raised to $300 from $290 at Oppenheimer, source:Thefly.com, summary: Oppenheimer analyst Jay O... AMGN, Headline: GLOBAL BROKER RATINGS: Novo Nordisk is 'conviction buy'; BofA ups VW, source:Alliance News, summary: No summary, Headline: Jefferies Keeps Their Buy Rating on Amgen (AMGN), source:TipRanks, summary: Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN &#8211; Research Report) yesterday and set a price target of $325.00. The company&#8217;s share..., Headline: Jefferies Sticks to Their Buy Rating for Amgen (AMGN), source:TipRanks, summary: Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN &#8211; Research Report) on November 3 and set a price target of $300.00. The company&#8217;s s..., Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Xencor (XNCR) and Beam Therapeutics (BEAM), source:TipRanks, summary: Companies in the  Healthcare sector have received a lot of coverage today as analysts  weigh in on Amgen (<span class='tr-stock-ticker' style='color:blue; font-weig..., Headline: Arrowhead Pharmaceuticals: Olpasiran's Impressive Phase 2 Data, source:SeekingAlpha, summary: Arrowhead's partner Amgen reported positive phase 2 results of olpasiran in patients with elevated Lp[a]. Find out what it means for ARWR stock here., Headline: Amgen, Salesforce share gains lead Dow's nearly 150-point climb, source:MarketWatch, summary: Shares of Amgen and Salesforce are posting positive momentum Tuesday morning, lifting the Dow Jones Industrial Average into positive territory. The Dow was..., Headline: Amgen, Salesforce share gains contribute to Dow's 400-point rally, source:MarketWatch, summary: Buoyed by positive momentum for shares of Amgen and Salesforce, the Dow Jones Industrial Average is rallying Tuesday morning. Shares of Amgen and Salesforce..., Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. TTWO, ATVI, DD, LYFT, KSS, LEVI, HIMS, AMGN, SQ, WSM, NVDA, AAPL, GS, TWTR, BIIB, JNJ, SEDG, CTIC, TASK, RIDE, HNHPF, NSTG, RCM, MAPS, PLNT, TWOU, FIVN, NCLH, TRIP, Headline: Amgen, Salesforce share gains contribute to Dow's nearly 500-point rally, source:MarketWatch, summary: Behind positive growth for shares of Amgen and Salesforce, the Dow Jones Industrial Average is rallying Tuesday morning. Shares of Amgen and Salesforce have..., Headline: Amgen Third Quarter 2022 Earnings: Beats Expectations, source:Yahoo, summary: Amgen ( NASDAQ:AMGN ) Third Quarter 2022 Results Key Financial Results Revenue: US$6.65b (flat on 3Q 2021). Net income..., Headline: Stocks making the biggest moves midday: Lyft, Tripadvisor, Take-Two Interactive and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Dow's 375-point rally led by gains in Amgen, Salesforce shares, source:MarketWatch, summary: The Dow Jones Industrial Average is rallying Tuesday afternoon with shares of Amgen and Salesforce delivering the strongest returns for the index. The Dow is..., Headline: Amgen Q3 Earnings: I Am Less Optimistic Than The Market, source:SeekingAlpha, summary: Amgen reported solid third quarter results. Check out why I am watching AMGN stock closely and will not add to my position at this level., Headline: Amgen, American Express share gains lead Dow's 150-point jump, source:MarketWatch, summary: The Dow Jones Industrial Average is climbing Tuesday afternoon with shares of Amgen and American Express leading the way for the index. Shares of Amgen and..., Headline: Dow's nearly 350-point rally highlighted by gains in Amgen, Boeing shares, source:MarketWatch, summary: Shares of Amgen and Boeing are trading higher Tuesday afternoon, leading the Dow Jones Industrial Average rally. The Dow is trading 342 points higher (1.0%),..., Headline: US STOCKS-Wall St rises as midterm election begins; Amgen hits record high, source:Yahoo, summary: U.S. stock indexes rose for the third straight session on Tuesday as voting began in the crucial midterm election that will determine control of Congress, with investors hoping for a political gridlock that could prevent radical policy changes.  Nonpartisan forecasters and opinion polls suggested a strong chance of Republicans winning a House majority and a tight race for Senate control., Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. rallied 5.55% to $292.39 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Updating Our Amgen Strategy as It Continues to Surge, source:Yahoo, summary: With the shares trading around $295 Tuesday morning another look seems like a good idea.  The trading volume has increased from late September and the On-Balance-Volume (OBV) line has risen from early October telling us that buyers of AMGN have been more aggressive the past month.  The weekly OBV line is bullish and so is the MACD oscillator ., Headline: US STOCKS-Wall St climbs over 1% as midterm election begins; Amgen hits record high, source:Yahoo, summary: U.S. stock indexes rose for the third straight session on Tuesday as voting began in the crucial midterm election that will determine control of Congress, with investors hoping for a political gridlock which could prevent radical policy changes.  Helping the blue-chip Dow outperform its Wall Street peers, shares of drugmaker Amgen Inc climbed 6.5% to a record high after reporting positive data related to its cholesterol drug and obesity treatment.  Nonpartisan forecasts and opinion polls suggested a strong chance of Republicans winning a House majority and a tight race for Senate control., Headline: How Amgen Is Closing In On Rivals Novo Nordisk, Eli Lilly With Obesity Drug, source:Yahoo, summary: Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly.",AMGN
42,2022-11-09,"Headline: Royalty Pharma agrees to acquire royalty interest in olpasiran from Arrowhead, source:Thefly.com, summary: Royalty Pharma (RPRX) and... RPRX, ARWR, AMGN, Headline: SVB Securities Issues a Hold Rating on Amgen (AMGN), source:TipRanks, summary: In a report released on November 7, David Risinger from SVB Securities assigned a Hold rating to Amgen (AMGN &#8211; Research Report). The company&#8217;s shares cl..., Headline: Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It, source:Yahoo, summary: No summary, Headline: Amgen Inc. stock falls Wednesday, still outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slipped 0.94% to $289.65 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500..., Headline: Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on Update, source:Yahoo, summary: Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week.",AMGN
43,2022-11-10,"Headline: Hikari Tsushin, Inc. Goes on B - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: 2 Ultra-Safe Passive Income Stocks to Buy Right Now, source:Yahoo, summary: Loading up on passive income stocks is a great way to ride out a bear market.  Reliable cash distributions are a proven way to minimize losses, and elite dividend stocks tend to be among the first to recover following marketwide downturns.  Which top-tier passive income stocks should investors consider buying right now?, Headline: Amgen Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.47% higher to $291.01 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: Society for Immunotherapy of Cancer to hold a meeting, source:Thefly.com, summary: 37th Annual Meeting SITC ... ABMD, ADPT, ALKS, AMGN, ASND, BMY, CGEN, CLRB, CRL, INKT, INCY, PHIO, INBX, XNCR, VCYT, TXG, TPST, TMO, TIL, SGEN, REGN, REPL, RHHBY, DNA, CUE, IOVA, IPSC, LH, MRK, MXCT, EXEL, FATE, GMAB",AMGN
44,2022-11-11,"Headline: Big Pharma Stocks Are Breaking Out. Here Are Some Winners., source:Yahoo, summary: Drug stocks have been outperforming the market all year since their sales are unaffected by changes in economic demand., Headline: Income Investors Should Know That Amgen Inc. (NASDAQ:AMGN) Goes Ex-Dividend Soon, source:Yahoo, summary: Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Amgen Inc..., Headline: Amgen Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slid 2.06% to $285.02 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...",AMGN
45,2022-11-12,"Headline: AMGN Amgen Q3 2022 - Earnings Call Slides (vFF), source:SeekingAlpha, summary: The following slide deck was published by Amgen Inc., Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of November 13, source:SeekingAlpha, summary: Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Read more see companies with upcoming ex-dividend dates and upcoming pay dates.",AMGN
46,2022-11-13,"Headline: Amgen Inc. (AMGN) Presents at Credit Suisse 31st Annual Healthcare Conference Transcript, source:SeekingAlpha, summary: Amgen Inc. (NASDAQ:NASDAQ:AMGN) Credit Suisse 31st Annual Healthcare Conference Call November 9, 2022 3:50 PM ET Company Participants Peter Griffith - EVP and CFO David Reese - EVP,...",AMGN
47,2022-11-14,"Headline: Arabesque Asset Management Ltd - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: IGD: This Outperforming Fund Has A Lot To Like, source:SeekingAlpha, summary: IGD invests in a portfolio of dividend-paying stocks and options. See why it is worth giving the fund some consideration for an investor seeking income., Headline: Beat the Market Like Zacks: JPMorgan, Berkshire Hathaway, Amgen in Focus, source:Yahoo, summary: Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months., Headline: The Dow is outperforming, which could be a sign that the latest stock-market rally will flame out, source:MarketWatch, summary: While investors seek shelter in more defensively oriented equity names, one market technician sees the Dow's growing margin of outperformance as a sign that..., Headline: Amgen Inc. stock underperforms Monday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.10% higher to $285.30 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: Top 5 3rd Quarter Trades of BE - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: ",AMGN
48,2022-11-15,"Headline: Weaver C. Barksdale & Associat - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Nicholas Ward's Dividend Growth Portfolio: October 2022 Review, source:SeekingAlpha, summary: My passive income was up by 10.16% in October. Read more to know my trades for the month of October., Headline: Amgen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slumped 0.60% to $283.60 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: Stocks In Underlooked Sectors (Not Energy) Are Making New Highs (Technical Analysis), source:SeekingAlpha, summary: The market has been focused on the technology / growth sector, instead of paying attention to stocks in underlooked sectors that have made new all time highs., Headline: 3 Pharmaceutical Stocks For Your November 2022 Watchlist, source:StockMarket, summary: 3 pharmaceutical stocks to watch in the stock market right now., Headline: Coho Relative Value Equity Q3 2022 Commentary, source:SeekingAlpha, summary: Coho Partners' September was a repeat of August but worse, as an early-month rally was erased by continued inflationary concerns. Click here to read the full fund letter.",AMGN
49,2022-11-16,"Headline: Is Amgen Inc. (NASDAQ:AMGN) Trading At A 33% Discount?, source:Yahoo, summary: Today we will run through one way of estimating the intrinsic value of Amgen Inc. ( NASDAQ:AMGN ) by taking the..., Headline: Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?, source:Yahoo, summary: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage., Headline: Top Research Reports for Novo Nordisk, Amgen & ADP, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Amgen Inc. (AMGN) and Automatic Data Processing, Inc. (ADP)., Headline: Amgen Q3: Still Equivalent To 7.5% Equity Bond, source:SeekingAlpha, summary: Amgen delivered another strong quarter in Q3 2022. The company completed the acquisition of ChemoCentryx and added TAVNEOS to its innovative product portfolio, paving the way for continued.",AMGN
50,2022-11-17,"Headline: The Zacks Analyst Blog Highlights Novo Nordisk, Amgen, Automatic Data Processing, Equinor and Illinois Tool Works, source:Yahoo, summary: Novo Nordisk, Amgen, Automatic Data Processing, Equinor and Illinois Tool Works are included in this Analyst Blog., Headline: Coho Relative Value ESG Q3 2022 Commentary, source:SeekingAlpha, summary: Coho Partners' Sept. was a repeat of Aug. but worse, as an early-month rally was erased by continued inflationary concerns. Click here to read the full fund letter., Headline: Key Factors Driving Amgen's (AMGN) Outperformance This Year, source:Yahoo, summary: Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.",AMGN
51,2022-11-18,"Headline: 7 Top-Tier Dividend Stocks to Buy for 2023, source:Yahoo, summary: In a market like this, you always can find dividend stocks to buy. If you’re like most investors, you probably can’t wait for 2023. History books will show that 2022 was a huge disappointment for the stock market, although it did create some compelling opportunities for top-tier dividend stocks. First of all, dividend stocks are a huge benefit in any portfolio. Dividend stocks pay a quarterly or monthly payment to shareholders, who can use the money for income (a great idea for retirees). Or for, Headline: SCHD: No Longer Attractive After The Sharp Recovery Surge (Technical Analysis), source:SeekingAlpha, summary: SCHD has outperformed the S&P 500 since we urged investors to buy its recent September lows., Headline: Credit Suisse Sets Bearish Tone For Amgen; Says Current Setup Not Ideal For Growth, source:Yahoo, summary: Credit Suisse has initiated coverage on Amgen Inc (NYSE: AMGN) with an Underperform rating and a price target of $240. The analysts say that Amgen has had a solid year, with the stock up c.25% year to date, recently driven by early clinical readouts. Related: Amgen's Olpasiran Reduced Cholesterol Levels In 95% Of Patients In Mid-Stage Study. But, the firm believes management's current setup for growth could be better. The company has guided for a 2022-2030 mid-single-digit revenue CAGR (CSe-1%).",AMGN
52,2022-11-19,"Headline: Invest Stress-Free During Turbulent Times: Near-Perfect Portfolio Strategy, source:SeekingAlpha, summary: With index investing, there's no escape from a roller coaster ride. For most people, especially retirees, it's very difficult to tolerate large and deep drawdowns.",AMGN
53,2022-11-20,"Headline: Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 78% of the company, source:Yahoo, summary: To get a sense of who is truly in control of Amgen Inc. ( NASDAQ:AMGN ), it is important to understand the ownership...",AMGN
54,2022-11-21,"Headline: Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know, source:Yahoo, summary: No summary, Headline: SDOG: Dividend ETF Not To Be Confused With 'Dogs Of The Dow', source:SeekingAlpha, summary: SDOG ETF applies the Dogs of the Dow theory on a sector-by-sector basis using the S&P 500 as the starting point. Read if it is a good dividend income opportunity.",AMGN
55,2022-11-22,"Headline: We still think there's more room for biotech to go higher, says Jefferies' Yee, source:CNBC, summary: Michael Yee, Jefferies managing director, joins 'Power Lunch' to discuss what's behind the general move higher in biotech stocks, why biotech stocks were under-owned not long ago and if it's too late to 'nibble' on stocks in the sector.",AMGN
56,2022-11-23,"Headline: Chevron, Amgen share losses contribute to Dow's 50-point fall, source:MarketWatch, summary: The Dow Jones Industrial Average is declining Wednesday afternoon with shares of Chevron and Amgen delivering the stiffest headwinds for the price-weighted..., Headline: Amgen Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slid 1.27% to $283.40 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: AMGEN ANNOUNCES WEBCAST OF 2022 EVERCORE ISI HEALTHCARE CONFERENCE, source:Yahoo, summary: Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 11:20 a.m. ET on Tuesday, November 29, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",AMGN
57,2022-11-24,"Headline: Possible bearish signals as Amgen Inc. (NASDAQ:AMGN) insiders disposed of US$5.2m worth of stock, source:Yahoo, summary: The fact that multiple Amgen Inc. ( NASDAQ:AMGN ) insiders offloaded a considerable amount of shares over the past year...",AMGN
58,2022-11-26,"Headline: Why Millennials Should Aim For $4 Million For Retirement, source:SeekingAlpha, summary: We discuss how young folks in their early 30s can aim and accumulate a large sum by the time they are in their 50s. See how big can be your retirement savings.",AMGN
59,2022-11-28,"Headline: 4 Pharmaceutical Companies Among 19 To Announce Annual Dividend Increases In December, source:SeekingAlpha, summary: Investors were rewarded with double-digit boosts from several companies in the second half of November. Click here to read more., Headline: With Amgen Inc. (NASDAQ:AMGN) It Looks Like You'll Get What You Pay For, source:Yahoo, summary: With a price-to-earnings (or ""P/E"") ratio of 22.2x Amgen Inc. ( NASDAQ:AMGN ) may be sending bearish signals at the..., Headline: Amgen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. slipped 0.39% to $282.62 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index..., Headline: Best Dividend Stocks To Buy Now? 2 To Watch Before December 2022, source:StockMarket, summary: 2 top health care dividend stocks to check out ahead of December 2022., Headline: AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022, source:Yahoo, summary: Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m. ET on Monday, Dec. 5, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's R&D team, will discuss the Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like pe",AMGN
60,2022-11-29,"Headline: The Highest Quality Dividend Achievers, source:SeekingAlpha, summary: Dividend Achievers are companies with a track record of at least 10 straight years of dividend growth. Check out my stock recommendations based on the same., Headline: Amgen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. dropped 0.22% to $281.99 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Amgen Inc. (AMGN) Presents at Evercore ISI HealthCONx Conference (Transcript), source:SeekingAlpha, summary: Start Time: 11:20 End Time: 11:58 Amgen Inc. (NASDAQ:NASDAQ:AMGN) Evercore ISI HealthCONx Conference November 29, 2022, 11:20 AM ET Company Participants David Reese - EVP, Research and..., Headline: Horizon Therapeutics Shares Jump 31% Following News of Takeover Interest, source:MarketWatch, summary: By Stephen Nakrosis Shares of Horizon Therapeutics PLC were trading higher in Tuesday's after-hours market following news the company is engaged in..., Headline: Stocks to Watch: Horizon Therapeutics, Workday, NetApp, Crowdstrike, Wayfair, source:MarketWatch, summary: By Patrick Chu Horizon Therapeutics PLC: The Dublin, Ireland, drug developer said it is ""engaged in highly preliminary discussions with Amgen Inc., [Johnson..., Headline: Horizon Therapeutics Fields Takeover Interest From Pharma Giants, source:Yahoo, summary: The drugmaker recently had a market value close to $18 billion as big pharmaceutical companies rely on acquisitions to expand sales., Headline: Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi, source:Yahoo, summary: Horizon said Tuesday it's considering potential offers from three Big Pharma stalwarts, sending HZNP stock soaring more than 30% after hours., Headline: Horizon Therapeutics fields buyout interest from Amgen, J&J and Sanofi, source:Reuters, summary: Horizon Therapeutics Plc said on Tuesday its board was engaged in highly preliminary discussions with three pharmaceutical giants for potential takeover offers, sending its shares surging 31% in extended trading., Headline: Horizon Therapeutics in Separate Sale Talks With Amgen, Sanofi, J&J, source:Yahoo, summary: (Bloomberg) -- Horizon Therapeutics Plc soared in post-market US trading after the developer of medicines for rare autoimmune and inflammatory diseases said it’s in talks with a trio of potential suitors about a possible sale of the company.Most Read from BloombergScientists Revive 48,500-Year-Old ‘Zombie Virus’ Buried in IceBanks Stuck With $42 Billion Debt Seize Chance to Offload ItThese Are the Best and Worst Cities for Expats to Live and Work InThis Is Where Luxury Property Prices May Rise a",AMGN
61,2022-11-30,"Headline: Horizon Therapeutics Surges on Takeover Talk, With Johnson & Johnson Among Its Suitors, source:MarketWatch, summary: Horizon said it was in talks with Amgen, J&J's Janssen Global Services, and Sanofi., Headline: Horizon Therapeutics in preliminary sale talks with Amgen, Sanofi, J&J, source:CNBC, summary: CNBC's Jim Cramer and the 'Squawk on the Street' team discuss a new report that Horizon Therapeutics is in preliminary talks with major pharmaceutical companies over a potential takeover., Headline: Horizon Therapeutics Draws Big Pharma Interest, source:SeekingAlpha, summary: Shares of Horizon surged after the company announced it is in highly preliminary discussions with three big pharma companies about a potential takeover. Read more here., Headline: UPDATE 3-J&J sues Amgen over plan to sell drug similar to blockbuster Stelara, source:Yahoo, summary: Johnson & Johnson's Janssen unit has sued Amgen Inc over its plan to market a drug for ulcerative colitis and other conditions similar to J&J's top-selling Stelara, saying it would infringe two patents in a lawsuit made public on Wednesday.  Stelara accounted for $9.1 billion of J&J's $52 billion in global drug sales last year.  It is a biologic drug, meaning it is made inside living cells., Headline: Why Horizon Therapeutics Stock Is Skyrocketing Today, source:Yahoo, summary: Shares of Horizon Therapeutics (NASDAQ: HZNP) were skyrocketing 27.2% higher as of 10:48 a.m. ET on Wednesday.  The big jump came after the company announced Thursday evening that it's in discussions with Amgen (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ) subsidiary Janssen, and Sanofi (NASDAQ: SNY) about potentially being acquired.  There were two words in Horizon's press release that investors should note: ""highly preliminary."", Headline: J&J sues Amgen over plan to sell drug similar to blockbuster Stelara, source:Reuters, summary: Johnson & Johnson's Janssen unit has sued Amgen Inc over its plan to market a drug for ulcerative colitis and other conditions similar to J&J's top-selling Stelara, saying it would infringe two patents in a lawsuit made public on Wednesday., Headline: Analyst Forecasts $101-117/Share Offer Price For Horizon Therapeutics' Buyout, source:Yahoo, summary: Horizon Therapeutics Plc (NASDAQ: HZNP) confirmed it's engaged in preliminary talks with Amgen Inc (NASDAQ: AMGN), Janssen Global Service, and Sanofi SA SNY on potential takeover offers for the company. SVB Leerink projects 2023 revenue of $4.0 billion, adj operating income of $1.6 billion, and EPS of $5.51. Assuming no COGS nor R&D synergies but ""fully synergized"" SG&A of 21%, the company's theoretical 2023 fully synergized operating margin would be 54%, and adj EPS would be $7.79. If an acquir, Headline: The Stock Market Keeps Going Up. How to Protect Yourself From Another Drop., source:MarketWatch, summary: Utilities, consumer staples, and healthcare results should hold up in a recession.",AMGN
62,2022-12-01,"Headline: My 24-Stock $353K Portfolio Suffers A Crypto Winter Burn In November, source:SeekingAlpha, summary: My portfolio, built specifically for my retirement ~20+ years from now pretty much goes nowhere as a market uptrend gets squashed by my crypto winter. See more here., Headline: BME: Steady Distributions From This Healthcare Fund, source:SeekingAlpha, summary: BME trading at a premium isn't new, and it continues to trade at a slight premium now. Check here for an investment analysis of the CEF., Headline: AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule. This first-in-human study was designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of AMG 133 in people with obesity and without diabetes (NCT04478708). These data will be presented as part of an oral presentation on Saturday, Dec. 3 at the, Headline: Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Novo Nordisk, Eli Lilly, source:Yahoo, summary: Amgen stock dipped Thursday though the company unveiled promising results for its experimental obesity treatment.",AMGN
63,2022-12-02,"Headline: Is Amgen Stock a Buy for Income Investors?, source:Yahoo, summary: Economic and geopolitical concerns have weighed heavily on investor sentiment throughout the year.  Investors seeking more certainty in an uncertain environment would do well to consider buying safe, high-yielding dividend stocks.  This is because the highest-quality income stocks can provide ever-growing passive income to investors through almost any economic downturn., Headline: Amgen (NASDAQ:AMGN) shareholders have earned a 14% CAGR over the last five years, source:Yahoo, summary: Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the..., Headline: BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns, source:SeekingAlpha, summary: BBH has an asset base of $520 million, posted strong growth over the past 6 months, and is trading much higher than its pre-pandemic price range. Click here to learn more., Headline: 4 Advisors on Their Top Bond Buys Now, source:MarketWatch, summary: Finally, after a long period of ultralow rates, bonds are back. We talked to some top wealth management advisors for what they like.",AMGN
64,2022-12-03,"Headline: Finally, We're Less Fed Up With The Fed, source:SeekingAlpha, summary: It feels like markets are moving in the investorsâ favor. Check out what's working and what's not this week., Headline: Amgen says experimental obesity drug has promising durability, source:Yahoo, summary: Amgen Inc's experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday.  The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133.  Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%., Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of December 4, source:SeekingAlpha, summary: Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Read more to see companies with upcoming ex-dividend dates.",AMGN
65,2022-12-05,"Headline: Which Is Faster: Caterpillar Or Deere?, source:SeekingAlpha, summary: Our view is that Caterpillar and Deere will both reach higher prices in the next 12 months. Check out the fundamentals of both CAT and DE stocks., Headline: 7 Christmas Stocks to Buy for Happy Holidays, source:Yahoo, summary: It makes sense if you haven’t been thinking much about Christmas stocks. You really can’t be blamed for not being in the Christmas spirit this year. The stock market’s challenging 2022 took a toll on a lot of portfolios, leaving many investors feeling more like a Grinch than looking for new stocks to buy. But there’s a glimmer of hope on the horizon – think of it as Rudolph’s red nose, lighting the way for Santa to bring some better tidings for the holiday season. After all, the Dow Jones Indust, Headline: AMGN WCIRDC_Conference_Slides, source:SeekingAlpha, summary: The following slide deck was published by Amgen Inc., Headline: Amgen Inc. (AMGN) World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease Conference (Transcript), source:SeekingAlpha, summary: Amgen Inc. (NASDAQ:NASDAQ:AMGN) World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease Conference Call December 5, 2022 08:00 ET Company Participants David Reese -..., Headline: Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi, source:Yahoo, summary: Johnson & Johnson dropped out of the bidding process for Horizon Therapeutics, pushing HZNP stock into the red on Monday.",AMGN
66,2022-12-06,"Headline: UPDATE 1-Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients, source:Yahoo, summary: Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co's immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday.  The company expects the largest advantage in patients with lower levels of PDL1, the protein targeted by Keytruda, and plans to launch a phase-three trial enrolling only those patients soon, Mirati chief executive officer David Meek told Reuters., Headline: Amgen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. slid 0.57% to $283.29 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...",AMGN
67,2022-12-07,"Headline: Those who invested in Amgen (NASDAQ:AMGN) five years ago are up 86%, source:Yahoo, summary: When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make..., Headline: Mirati (MRTX) Down After 1st-Line Lung Cancer Data on Adagrasib, source:Yahoo, summary: Mirati Therapeutics' (MRTX) preliminary data from the first-line NSCLC study showed that adagrasib plus Merck's Keytruda achieved an objective response rate of 49%., Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.87% higher to $285.76 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the Dow..., Headline: Analyzing 13Fs: Soros Fund Management (George Soros Fund) Q3 2022, source:SeekingAlpha, summary: We analyze Soros Fund Management's Q3 2022 update. Read more to see the strategy deployed by the fund and its new, closed, and reduced positions.",AMGN
68,2022-12-08,"Headline: Amgen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slid 0.07% to $285.57 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: Here's What We Know So Far About Amgen's Obesity Drug As It Trails Novo Nordisk, Eli Lilly, source:Yahoo, summary: Amgen is years behind rivals in developing an obesity treatment, but the company says its experimental drug could prove superior.",AMGN
69,2022-12-09,"Headline: Dow drops 75 points on losses in Chevron, Amgen stocks, source:MarketWatch, summary: Shares of Chevron and Amgen are trading lower Friday afternoon, dragging the Dow Jones Industrial Average into negative territory. Shares of Chevron and..., Headline: Amgen Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slipped 2.42% to $278.65 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index..., Headline: How An Eli Lilly Decision Could Light Up The Red-Hot Obesity Landscape — Again, source:Yahoo, summary: A key decision from Eli Lilly could alight the obesity treatment landscape again, an analyst said Friday as LLY stock lingers near a record.",AMGN
70,2022-12-10,"Headline: Amgen: A Solid Dividend Growth Stock For Your Watchlist, source:SeekingAlpha, summary: Amgen's sales have increased by 52% over the last decade and it equates to ~4% annually. Learn more about AMGN stock and see why it is a Hold.",AMGN
71,2022-12-11,"Headline: Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 82% of the company, source:Yahoo, summary: To get a sense of who is truly in control of Amgen Inc. ( NASDAQ:AMGN ), it is important to understand the ownership..., Headline: Could Amgen's Heart Disease Candidate Generate Billions in Sales?, source:Yahoo, summary: In early November, Amgen (NASDAQ: AMGN) broke some encouraging news to shareholders.  Phase 2 clinical trial results revealed that the company's drug candidate, known as olpasiran, is very effective in treating patients with elevated lipoprotein(a) levels and a history of atherosclerotic cardiovascular disease (ASCVD).  Let's delve into the results of the clinical trial and the ASCVD market to address these questions., Headline: UPDATE 2-Amgen emerges frontrunner in Horizon deal as Sanofi drops bid, source:Yahoo, summary: Amgen Inc is in advanced talks to buy biotech company Horizon Therapeutics Plc, the Wall Street Journal reported on Sunday, while rival bidder French health group Sanofi announced it had dropped its bid.  A deal for Amgen to buy the company could be finalised by Monday assuming the talks don’t fall apart, the Journal report added.  Amgen and Horizon did not immediately respond to Reuters requests for comments., Headline: Amgen in Advanced Talks to Buy Horizon Therapeutics, source:Yahoo, summary: The U.S. biotech company was the last of three suitors standing in an auction for the drugmaker. A deal would likely be valued at well over $20 billion and mark the largest healthcare merger of the year., Headline: Amgen emerges frontrunner in Horizon deal as Sanofi drops bid, source:Reuters, summary: Amgen Inc is in advanced talks to buy biotech company Horizon Therapeutics Plc, the Wall Street Journal reported on Sunday, while rival bidder French health group Sanofi announced it had dropped its bid., Headline: Amgen reportedly in talks to buy Horizon Therapeutics, source:MarketWatch, summary: The U.S. biotechnology company AMGN was the last of three suitors standing in an auction for Horizon, according to sources cited by The Wall Street Journal., Headline: Stocks That Moved Today: Coupa, Weber, Horizon Therapeutics, and More, source:MarketWatch, summary: Shares of Coupa Software soar after the cloud company it announces it will be acquired by private-equity firm Thoma Bravo in an $8 billion all-cash deal.",AMGN
72,2022-12-12,"Headline: Horizon Therapeutics Shares Rally as Amgen Deal Said Near >HZNP, source:MarketWatch, summary: By Colin Kellaher Shares of Horizon Therapeutics PLC jumped more than 10% in premarket trading Monday after The Wall Street Journal reported that Amgen Inc...., Headline: Amgen to Buy Horizon Therapeutics for $27.8 Billion, source:MarketWatch, summary: By Dean Seal Amgen Inc. said Monday that it will acquire drug company Horizon Therapeutics PLC in an all-cash deal valued at $27.8 billion, confirming an..., Headline: Merger Monday Is Back. But It Comes With a Warning., source:MarketWatch, summary: M&A activity can typically be expected to soften in an economic downturn but the flurry of deals emerging Monday doesn’t necessarily signal that the health..., Headline: Coupa stock soars on buyout news: 5 head-turning deal reports, source:Yahoo, summary: Here are the 5 biggest deal dispatches from this past week, as covered first on InvestingPro+., Headline: Wall Street Breakfast December 12: Amgen to Acquire Horizon Therapeutics, $27.8B (Podcast), source:SeekingAlpha, summary: Amgen (AMGN) to acquire Horizon Therapeutics (HZNP) for $27.8B in cash. A recession isn't necessary to bring inflation down - Yellen. Microsoft to acquire 4% stake in London Stock Exchange., Headline: Amgen secures $28.3 billion deal to buy Horizon Therapeutics, source:Yahoo, summary: By Scott Kanowsky, Headline: Amgen set to buy biotech firm Horizon at $26 bln valuation - Bloomberg News, source:Yahoo, summary: Amgen Inc is set to buy biotech firm Horizon Therapeutics Plc at a valuation of about $26 billion in what would be its largest acquisition, Bloomberg News reported on Monday.  The U.S. biotechnology company has offered about $116.5 for each Horizon share, according to the report, citing a person familiar with the matter.  The offer is at about a 20% premium to Horizon's closing price of $97.29 on Friday., Headline: Horizon Therapeutics, Microsoft, Gap rise premarket;  Amgen, Rivian fall, source:Yahoo, summary: By Peter Nurse, Headline: UPDATE 3-Amgen to buy Horizon Therapeutics for $26.40 billion, source:Yahoo, summary: Amgen Inc said on Monday it would buy rare disease drugmaker Horizon Therapeutics Plc for $26.40 billion in its biggest deal yet, giving the biotech company access to blockbuster thyroid eye disease treatment Tepezza.  Amgen will pay $116.50 in cash for each Horizon share held, or a premium of nearly 20% to the stock's last close.  A deal will add several approved drugs to the company's portfolio including Krystexxa used for the treatment of gout that is not controlled by other medicines., Headline: Amgen set to buy biotech firm Horizon at $26 billion valuation - Bloomberg News, source:Reuters, summary: Amgen Inc is set to buy biotech firm Horizon Therapeutics Plc at a valuation of about $26 billion in what would be its largest acquisition, Bloomberg News reported on Monday, after French drugmaker Sanofi dropped its bid., Headline: Stocks Edge Higher, Week Ahead, Microsoft, Boeing, Amgen - Five Things To Know, source:Yahoo, summary: Stock futures edge higher into end-of-year push; Week Ahead: Fed Meeting highlights crucial series of central bank decisions; Boeing shares rise on report of Air India 737 Max deal; Microsoft takes 4% stake in London Stock Exchange Group and Horizon Therapeutics surges on report of $26 billion Amgen takeover., Headline: AMGEN TO HOST WEBCAST INVESTOR CALL FOLLOWING ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS, source:Yahoo, summary: Amgen (NASDAQ:AMGN) will host a webcast call for the investment community following the announced acquisition of Horizon Therapeutics at 8:00 a.m. ET on Monday, December 12, 2022. Robert A. Bradway, chairman and chief executive officer, along with members of the executive team, will participate., Headline: Horizon Therapeutics Stock Surges On $28.5 Billion Amgen Takeover, source:Yahoo, summary: ""The acquisition of Horizon is a compelling opportunity for Amgen and the potential new medicines in Horizon's pipeline strongly complement our own R&D portfolio,"" said Amgen CEO Robert Bradway., Headline: Amgen confirms to acquire Horizon Therapeutics in cash deal valued at about $27.8 billion, source:Yahoo, summary: Amgen Inc. said Monday it has agreed to acquire Horizon Therapeutics Plc in an all-cash deal valued at $27.8 billion, confirming earlier reports and a deal that was first mooted in November. Under the terms of the deal, Amgen will pay $116,50 per each Horizon share owned, equal to a 47.9% premium over the stock's closing price on Nov. 29, the day before the deal was first announced. It's equal to a premium of 19.7% over the stock's closing price Friday at $97.29. Amgen will finance the deal via, Headline: Pfizer: The Best Long-Term Investment Setup Since 2009, source:SeekingAlpha, summary: Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high. Read more on PFE stock here., Headline: Amgen to Buy Horizon Therapeutics for $116.50 a Share or $27.8 Billion, source:Yahoo, summary: Amgen  reached a deal to buy drug company  Horizon Therapeutics  for $116.50 a share in cash.  In a statement, the companies said the deal represents a premium of about 47.9% to Horizon’s closing price of $78.76 a share on Nov. 29, the day before reports of a possible deal surfaced.  Its enterprise value was  put at about $28.3 billion., Headline: Stocks making the biggest moves midday: Horizon Therapeutics, Coupa Software, Weber and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share, source:Yahoo, summary: Amgen Inc (NASDAQ: AMGN) has agreed to buy Horizon Therapeutics plc (NASDAQ: HZNP), implying an enterprise value of approximately $28.3 billion, marking the largest healthcare merger of the year. The Wall Street Journal was the first to report on Sunday that Amgen is in advanced talks to buy Horizon. Horizon confirmed its takeover talks with three large pharma companies in late November. Last week, Johnson & Johnson's (NYSE: JNJ) unit, Janssen, pulled out of the talks. Sunday, Sanofi SA (NASDAQ:, Headline: What Amgen Is Getting Through The Acquisition Of Horizon Therapeutics, source:SeekingAlpha, summary: Amgen will acquire Horizon Therapeutics (HZNP) for $116.50 per share in an all-cash transaction. Check out what AMGN will get through this acquisition., Headline: Take the Zacks Approach to Beat the Market: NVIDIA, Boeing, Amgen in Focus, source:Yahoo, summary: Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months., Headline: These 2 Nasdaq Stocks Are Soaring on Merger News, source:Yahoo, summary: The stock market has gotten locked in a holding pattern lately, and many investors anticipated that would likely continue on Monday.  With the Federal Open Market Committee scheduled to meet on Tuesday and Wednesday to discuss monetary policy and a potential interest rate increase, market participants aren't sure whether the central bank will slow its pace of monetary tightening or double down on its fight against inflation.  Below, you'll learn more about what has Coupa Software (NASDAQ: COUP) and Horizon Therapeutics (NASDAQ: HZNP) leading the Nasdaq higher., Headline: Amgen Agrees to Acquire Horizon Therapeutics for $27.8 Billion, source:Yahoo, summary: The U.S. biotech company’s deal for the drugmaker, which develops medicines to treat autoimmune and inflammatory diseases, is the year’s largest healthcare merger., Headline: Amgen To Buy Rare Diseases Drugmaker Horizon Therapeutics In $28.3 Billion Deal, source:Yahoo, summary: Amgen announced a $28.3 billion plan to acquire Horizon Therapeutics on Monday, leading HZNP stock to soar higher., Headline: Horizon Therapeutics Acquisition: A Good Deal For Amgen Investors, source:SeekingAlpha, summary: Amgen is acquiring Horizon Therapeutics for $27.8 billion, which immediately adds $3.7 billion in annual revenue. Read why I think this deal is good for AMGN., Headline: Amgen to Buy Horizon Therapeutics in $27.8 Billion Deal, source:Yahoo, summary: (Bloomberg) -- Amgen Inc. agreed to buy Horizon Therapeutics Plc for about $27.8 billion in its biggest-ever acquisition, outlasting at least two other suitors for the developer of autoimmune-disease treatments.Most Read from BloombergChina’s Rapid Covid Reversal Sparks Whiplash as Cases SurgeFed’s Message That Rates Will Stay on Hold for ‘Some Time’ Clashes With 2023 Rate-Cut BetsElon Musk Steps Up Attacks on Twitter’s Former Safety HeadChina’s Top Medical Adviser Says Omicron’s Risks Same as F, Headline: Amgen dives deeper into rare disease drugs with $27.8 billion Horizon deal, source:Reuters, summary: Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8 billion, fortifying its rare diseases portfolio amid pressure on its top-selling products and marking the biggest buyout in the sector this year., Headline: Horizon Therapeutics Stock Jumps on Amgen Deal News, source:Yahoo, summary: Shares of Horizon Therapeutics jumped in early Monday trading after Amgen [agreed to acquire the company](https://www.wsj.com/articles/amgen-in-advanced-talks-to-buy-horizon-therapeutics-11670785882), which develops medicines to treat rare autoimmune and severe inflammatory diseases. Horizon's shares were recently up more than 14%. Amgen's were off about 1% as [broader markets edged higher](https://www.wsj.com/articles/global-stocks-markets-dow-update-12-12-2022-11670845873)., Headline: Amgen to buy Horizon Therapeutics, Shein mulls becoming a marketplace, U.S. to announce nuclear breakthrough, source:Yahoo, summary: Notable business headlines include Amgen’s $26.4 billion acquisition of Horizon Therapeutics, Shein considering becoming an online marketplace, and expectations that the U.S. Department of Energy will announce a nuclear fusion breakthrough., Headline: Is the Time Right to Buy Amgen After It Buys Horizon Therapeutics?, source:Yahoo, summary: Horizon Therapeutics  closed on Friday at $97.29, which works out to 20.5 times forward looking earnings.  For Horizon's third quarter, the firm posted GAAP and adjusted EPS that beat Wall Street on about $925M in revenue.  On Monday morning, news broke that Amgen  had agreed to acquire Horizon for $116.50 per share, which is a 20% premium to Friday's closing price., Headline: Busy Week Highlighted by Next Fed Rate Move, source:Yahoo, summary: Consensus is currently for a 50 basis point (bps) hike mid-week, which will bring the Fed funds rate over +4% for the first time in 15 years., Headline: 3 Reasons Amgen Is Buying Horizon — and Why It Wasn’t the Only Company Interested, source:Yahoo, summary: The $27.8 billion deal is by far the largest biotech acquisition of a year that has seen less M&A activity than many investors had anticipated., Headline: Amgen to buy Horizon Therapeutics for $26.4B, source:Yahoo, summary: Amgen Inc. announced on Monday that it will acquire Horizon Therapeutics for $26 billion to further grow the company’s medical legacy. Horizon's best-selling drug is Tepezza., Headline: Wall Street Awaits Key Fed FOMC Decision, source:Yahoo, summary: Wall Street Awaits Key Fed FOMC Decision, Headline: Amgen to buy Horizon Therapeutics for $28 billion cash, source:Yahoo, summary: Horizon built its commercial drug portfolio with the help of two key Bay Area acquisitions. Now Amgen, which has R&D operations in South San Francisco and has been an opportunistic buyer of Bay Area drug developers, has emerged as the winner of a competition to buy Horizon., Headline: Why Horizon Therapeutics Stock Is Soaring Today, source:Yahoo, summary: Shares of Horizon Therapeutics (NASDAQ: HZNP) were soaring 14.8% higher as of 10:51 a.m. ET on Monday.  The nice gain came after the company announced that Amgen (NASDAQ: AMGN) plans to acquire Horizon in a deal that values the smaller drugmaker at $27.8 billion.  Horizon revealed a couple of weeks ago that it was in preliminary discussions with Amgen, Johnson & Johnson, and Sanofi about potentially being acquired., Headline: Amgen’s $28.5 Billion Loan Is Among the Biggest M&A Deals in Two Years, source:Yahoo, summary: (Bloomberg) -- Amgen Inc. secured a $28.5 billion bridge loan to fund its purchase of Horizon Therapeutics Plc, joining ranks with Broadcom Inc. and AT&T Inc. in receiving some of the biggest debt commitments for mergers and acquisitions in nearly two years.Most Read from BloombergChina’s Rapid Covid Reversal Sparks Whiplash as Cases SurgeUS Says Scientists Make Breakthrough in Nuclear Fusion EnergyFed’s Message That Rates Will Stay on Hold for ‘Some Time’ Clashes With 2023 Rate-Cut BetsElon Mus, Headline: Amgen Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slumped 0.67% to $276.78 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Amgen to acquire Horizon Therapeutics for $27.8 billion, source:Yahoo, summary: Yahoo Finance's Anjalee Khemlani explains news of a major biotech merger as Amgen is set to acquire Horizon Therapeutics., Headline: Amgen (AMGN) to Buy Horizon Therapeutics For $27.8 Billion, source:Yahoo, summary: Amgen (AMGN) wins the race to buy Horizon Therapeutics and makes an acquisition offer of $27.8 billion., Headline: First Test for Amgen: Fix Horizon’s Growth Problem, source:Yahoo, summary: Sales of Horizon’s thyroid-eye disease drug Tepezza have plateaued, a challenge its new owner will need to contend with., Headline: The Return of ""Merger Monday"", source:Yahoo, summary: Two major deals in the biotech and software industry were inked this weekend., Headline: Jim Cramer says three key deals helped the market rally on Monday, source:CNBC, summary: Stocks rose on Monday ahead of the monthly consumer price index report set to release Tuesday and the Federal Reserve’s December meeting., Headline: Amgen’s $28 billion deal is a reasonable gamble, source:Reuters, summary: Biotechnology deals are always a gamble, and, on the face of it, Amgen’s $28 billion purchase of Horizon Therapeutics looks both risky and pricey. But large pharmaceutical companies can help catapult smaller drug firms into a new stage of development. Investors in the $150..., Headline: Amgen wins battle for Horizon Therapeutics, bolstering its rare-disease portfolio, source:Yahoo, summary: Amgen Inc. is acquiring Dublin-based Horizon Therapeutics in a roughly $28 billion deal that is the biggest in the healthcare sector in 2022., Headline: Amgen set to acquire Horizon Therapeutics in $26.4 billion deal, source:Yahoo, summary: Amgen will acquire Horizon Therapeutics for more than $26 billion as the company dives deeper into rare disease treatment., Headline: Amgen Hunts for New Revenue in $28 Billion Deal, source:Yahoo, summary: The purchase of Horizon Therapeutics is the biggest this year by a major drugmaker seeking new sources of revenue to offset impending patent expiries., Headline: Mirati Wins FDA Approval For Amgen-Rivaling Cancer Drug As Wild Stock Swing Continues, source:Yahoo, summary: Mirati won FDA approval for its rival to Amgen's lung cancer drug on Monday. The approval comes as MRTX stock continues to experience wild swings., Headline: AMGEN ANNOUNCES 10% INCREASE IN 2023 FIRST QUARTER DIVIDEND, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the first quarter of 2023. The dividend will be paid on March 8, 2023, to all stockholders of record as of the close of business on February 15, 2023. This represents a 10% increase from that paid in each of the previous four quarters., Headline: M&A Could Recover Next Year. These Kinds of Stocks Could Benefit., source:MarketWatch, summary: Global M&A activity as measured by total deal value so far this year has dropped about 36% relative to this time in 2021, according to Refinitiv data., Headline: Amgen announces presentation of results from E1910 randomized Phase 3 trial, source:Thefly.com, summary: No summary, Headline: Amgen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary",AMGN
73,2022-12-13,"Headline: Horizon Therapeutics downgraded to Neutral from Buy at Guggenheim, source:Thefly.com, summary: No summary, Headline: Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo, source:Thefly.com, summary: No summary, Headline: Amgen deal yields nice accretion but large debt position, says Baird, source:Thefly.com, summary: No summary, Headline: Mirati (NASDAQ:MRTX) Stock Jumps as FDA Approves Lung Cancer Drug, source:TipRanks, summary: No summary, Headline: Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Edwards Lifesciences (EW) and Horizon Therapeutics (HZNP), source:TipRanks, summary: No summary, Headline: Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital, source:Thefly.com, summary: No summary, Headline: Eli Lilly dips after issuing underwhelming 2023 guidance, source:Seeking Alpha, summary: No summary, Headline: Amgen: `Winner` For Horizon, source:Seeking Alpha, summary: No summary, Headline: Mirati's lung cancer drug gets an accelerated approval, source:MarketWatch, summary: Shares of Mirati Therapeutics Inc. undefined were up about 3% in premarket trading on Tuesday, the day after the company said it received an accelerated..., Headline: Amgen: 'Winner' For Horizon, source:SeekingAlpha, summary: Amgen has become the ""winner"" in the bidding war for Horizon Therapeutics. Click here to find out why AMGN is a Hold., Headline: Mirati`s lung cancer drug gets an accelerated approval, source:MarketWatch, summary: No summary, Headline: Amgen (AMGN) Receives a Hold from SVB Securities, source:TipRanks, summary: No summary, Headline: AbbVie: Clouds Keep Thickening Due To Lack Of Revolutionary Drugs, source:SeekingAlpha, summary: Humira's international sales were $603 million in Q3 2022, down 25.7% year-over-year. Read more on how AbbVie is facing a lack of revolutionary drugs., Headline: UnitedHealth, Amgen share losses contribute to Dow`s nearly 50-point fall, source:MarketWatch, summary: No summary, Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: Company News for Dec 13, 2022, source:Yahoo, summary: Companies in The News Are: COUP,HZNP,AMGN,RIVN,BA, Headline: 5 Dow Stocks That Helped the Index Minimize Loss in 2022, source:Yahoo, summary: Here we have shortlisted five stocks - CVX, MRK, AMGN, TRV and IBM- that have fared better than the Dow Jones Index this year and have more upside potential for investment consideration., Headline: Amgen to Buy Horizon Therapeutics: ETFs to Bet On, source:Yahoo, summary: Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal., Headline: With Horizon acquisition, Amgen would enter Montgomery County for the first time. Here’s what we know., source:Yahoo, summary: Horizon Therapeutics PLC’s planned $27.8 billion sale to Thousand Oaks, California’s Amgen Inc. would put the West Coast biopharmaceutical giant in Montgomery County for the first time, though it’s not yet clear what the deal would mean for the combined company’s local real estate.  The agreement, announced Monday, comes as Dublin-based Horizon builds a research and development hub in Rockville and roughly two years after it acquired Gaithersburg’s Viela Bio Inc. for $3 billion.  The deal, first reported by the Wall Street Journal, would mark the industry's largest merger this year., Headline: The Bullish Call Eli Lilly Made For Its Next-Gen Obesity Drug, A Rival To Novo, Amgen, source:Yahoo, summary: Eli Lilly said Tuesday it plans to advance its next-generation obesity treatment into final-phase testing, but LLY stock dipped on guidance., Headline: How A Bullish Risk Reversal Option Trade Works On Amgen Stock, source:Yahoo, summary: Risk reversal option trades combine a short out-of-the-money put and a long out-of-the-money call. Here's how it works., Headline: BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL), source:Yahoo, summary: Amgen (NASDAQ: AMGN) today announced the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present results from the E1910 randomized Phase 3 trial. This is the first study to demonstrate superior overall survival (OS) with BLINCYTO added to consolidation chemotherapy over current standard of care (multiagent consolidation chemotherapy) in newly diagnosed adult patients with Philadelphia chromosome-negative B-ALL who were measurable residual disease (MRD)-negative following induction and intensi, Headline: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Amgen (AMGN) closed at $272.26, marking a -1.63% move from the previous day., Headline: Colorado becomes fourth state to ask feds to import drugs from Canada, source:Seeking Alpha, summary: No summary, Headline: How Horizon Therapeutics Will Strengthen Amgen`s Portfolio, source:GuruFocus, summary: No summary, Headline: Mirati draws Hold rating at Needham despite recent selloff, source:Seeking Alpha, summary: No summary, Headline: Amgen Inc. stock falls Wednesday, still outperforms market, source:MarketWatch, summary: No summary",AMGN
74,2022-12-14,"Headline: Cardiff Oncology: Staying The Course, source:SeekingAlpha, summary: Cardiff Oncology's stock is down in recent months due to some strategic changes. Read more to see a full investment analysis of CRDF stock., Headline: BMO Capital Reaffirms Their Hold Rating on Amgen (AMGN), source:TipRanks, summary: No summary, Headline: Finding 20 Dividend Growth Stocks In A Bad Market, source:TalkMarkets, summary: No summary, Headline: Horizon Jumps 15% on $26 Billion Acquisition Deal, source:GuruFocus, summary: No summary, Headline: Fresenius Kabi becomes latest drugmaker to win approval of biosimilar of AbbVie`s Humira, source:Seeking Alpha, summary: No summary, Headline: 15 Biggest Diet/Weight Loss Companies in the World, source:Yahoo, summary: In this article, we will be taking a look at the 15 biggest diet/weight loss companies in the world. To skip our detailed analysis of these companies, you can go directly to see the 5 Biggest Diet/Weight Loss Companies in the World. Over the years, there has been a growth in popularity when it comes to […], Headline: 12 Best Blue Chip Stocks That Outperformed in 2022, source:Yahoo, summary: In this article, we will take a look at 12 best blue chip stocks that outperformed in 2022. If you want to see more best blue chip stocks that outperformed in 2022, go directly to 5 Best Blue Chip Stocks That Outperformed in 2022. 2022 has been a challenging year for the markets as the […], Headline: Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More, source:Yahoo, summary: Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week., Headline: Best Dogs of the Dow Stocks Ranked By Hedge Fund Sentiment, source:Yahoo, summary: In this article, we discuss 10 best Dogs of the Dow stocks ranked by hedge fund sentiment. You can skip our detailed analysis of the Dogs’ performance over the years, and go directly to read 5 Best Dogs of the Dow Stocks Ranked By Hedge Fund Sentiment. ‘Dogs of the Dow’ is an investment strategy […], Headline: GILD vs. AMGN: Two Splendid Dividend Stocks, but One Looks Better, source:TipRanks, summary: No summary, Headline: Amgen Inc. stock falls Thursday, still outperforms market, source:MarketWatch, summary: No summary",AMGN
75,2022-12-15,"Headline: 20 Dividend Growth Stocks For Faster Growth And Profit, source:TalkMarkets, summary: No summary, Headline: The total return for Amgen (NASDAQ:AMGN) investors has risen faster than earnings growth over the last five years, source:Yahoo, summary: Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the..., Headline: 5 Stocks to Watch on Dividend Hikes Before 2022 Wraps Up, source:Yahoo, summary: Investors may keep a tab on LW, NUE, PWRr, TTC, and AMGN which have lately hiked their dividend payments to reward investors., Headline: Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It, source:Yahoo, summary: No summary, Headline: Primecap Odyssey Funds` 2022 Annual Shareholder Letter, source:GuruFocus, summary: No summary, Headline: Amgen Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: No summary, Headline: Gilead: Downgrade To Hold, source:SeekingAlpha, summary: Gilead's return profile has weakened substantially given the valuation risks and fundamental uncertainties. Read why GILD is a Hold.",AMGN
76,2022-12-16,"Headline: Powell Cancels the Santa Rally. Here’s Hoping 2023 Is Better., source:MarketWatch, summary: Despite retail sales falling in November a record season is still forecast, Donald Trump moves into digital trading cards, Covid-19 cases are rising, and..., Headline: Amgen's (NASDAQ:AMGN) Dividend Will Be Increased To $2.13, source:Yahoo, summary: Amgen Inc. ( NASDAQ:AMGN ) will increase its dividend from last year's comparable payment on the 8th of March to $2.13..., Headline: 2 Best Biotech Stocks to Buy Right Now, source:Yahoo, summary: The global population is growing with each passing year.  The pharmaceutical industry has been at the forefront, with the launch of game-changing medicines and vaccines in recent decades.  With the global population expected to rise from around 8 billion now to 9.7 billion by 2050, rising demand for medical treatments is practically built into the business model of big pharma., Headline: Why Atlanta Tops the Hottest 2023 Real Estate Markets, source:MarketWatch, summary: Georgia’s capital leads four other Southern cities in an analysis by the National Association of Realtors. NAR forecasts that the top markets should grow 5%,..., Headline: Deal Making Will Rebound in 2023, source:Yahoo, summary: Economic conditions won’t be ideal next year, but executives will have more confidence in making acquisitions.",AMGN
77,2022-12-17,"Headline: Wall Street Breakfast: What Moved Markets, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify., Headline: Amid Recession Fears, Consider The Low-Risk NPP Strategy, source:SeekingAlpha, summary: The market is going through a period of extraordinary uncertainty. It makes the task of investing and conserving capital hugely challenging. Read more here.",AMGN
78,2022-12-18,"Headline: IBBQ: Healthcare Dashboard For December, source:SeekingAlpha, summary: The pharmaceuticals/biotechnology subsector has good value and quality scores. Click here to read more about IBBQ ETF., Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of December 18, source:SeekingAlpha, summary: Click here to know which companies changed their dividends, companies with upcoming ex-dividend dates and those with upcoming pay dates., Headline: Viridian Therapeutics initiated at buy at Needham on lead asset for thyroid eye disease, source:Seeking Alpha, summary: No summary",AMGN
79,2022-12-19,"Headline: Building A $100,000 Market-Crushing Dividend Portfolio, source:SeekingAlpha, summary: In this article, I start by explaining the theoretical background behind the success of dividend (growth) investing. Read more here., Headline: Amgen Is Making A Smart Move With Horizon Therapeutics, source:SeekingAlpha, summary: Amgen is making a major acquisition of Horizon Therapeutics, one that it can comfortably afford. Click here for more on AMGN acquiring HZNP., Headline: Amgen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. sank 0.64% to $265.70 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: Amgen (AMGN) Stock Moves -0.64%: What You Should Know, source:Yahoo, summary: In the latest trading session, Amgen (AMGN) closed at $265.70, marking a -0.64% move from the previous day.",AMGN
80,2022-12-20,"Headline: Arrowhead receives $25M milestone payment from Amgen for heart disease treatment, source:Seeking Alpha, summary: No summary, Headline: Possible bearish signals as Amgen Inc. (NASDAQ:AMGN) insiders disposed of US$5.2m worth of stock, source:Yahoo, summary: In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have..., Headline: Amgen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. dropped 0.36% to $264.75 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Q4 Earnings Season Update and Analyst Reports for Broadcom, UPS & Amgen, source:Yahoo, summary: Today's Research Daily features update on the Q4 earnings season and new research reports on Broadcom (AVGO), UPS (UPS), Amgen (AMGN) and 16 other stocks.",AMGN
81,2022-12-21,"Headline: Nicholas Ward`s Dividend Growth Portfolio: November 2022 Update, source:Seeking Alpha, summary: No summary, Headline: XBI: Attractive Value In Diversified Biotech Growth, source:SeekingAlpha, summary: Valuations on biotechnology stocks have moderated substantially since the pandemic peak in 2021. Click to read my analysis of the SPDR S&P Biotech ETF (XBI)., Headline: The Zacks Analyst Blog Highlights Broadcom, United Parcel Service, Amgen, America Movil and Manulife Financial, source:Yahoo, summary: Broadcom, United Parcel Service, Amgen, America Movil and Manulife Financial are part of the Zacks top Analyst Blog., Headline: Dow Jones Rallies After Economic Data; Nike Surges 15% On Earnings; Tesla Hits New Low, source:Yahoo, summary: The Dow Jones rallied 375 points Wednesday after consumer and housing data, as Nike stock surged 15% on strong earnings results., Headline: Amgen Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.57% higher to $266.26 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Nicholas Ward's Dividend Growth Portfolio: November 2022 Update, source:SeekingAlpha, summary: My passive income was up by 12.03% during November and my dividends are up by 21.15% year to date. Read more to see an update on my portfolio for Nov 2022.",AMGN
82,2022-12-22,"Headline: 2 No-Brainer Biotech Stocks to Buy Right Now, source:Yahoo, summary: Vertex Therapeutics (NASDAQ: VRTX) and Amgen (NASDAQ: AMGN) have swum against the tide all year, with their shares rising as the S&P 500 has struggled.  While Vertex's pipeline is about to extend well beyond cystic fibrosis (CF), Amgen's combination of emerging drugs, plus the accretive nature of its deal to buy Horizon Therapeutics, could reward investors in the long run., Headline: Dow Jones Dives After GDP, Jobless Data; CarMax Plunges On 'Vehicle Affordability Issues', source:Yahoo, summary: The Dow Jones dived more than 400 points Thursday after first-time jobless claims and GDP. CarMax plunged on ""vehicle affordability issues."", Headline: Amgen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. sank 0.38% to $265.26 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: Amgen inks USD4 billion loan agreements for Horizon acquisition, source:Alliance News, summary: No summary",AMGN
83,2022-12-23,"Headline: LegoChem Biosciences, Amgen in Licensing Agreement, source:MarketWatch, summary: By Chris Wack LegoChem Biosciences Inc. said Friday that it has entered into a research collaboration and license agreement with Amgen Inc. Under the deal,..., Headline: Amgen in $4B term loan credit agreement to finance Horizon Therapeutics acquisition, source:Seeking Alpha, summary: No summary, Headline: Dow Jones Falls On Inflation Data; Tesla Stock Hits New Low Amid Elon Musk Comments, source:Yahoo, summary: The Dow Jones Industrial Average dropped Friday on key inflation data. Tesla stock hit a new low amid Elon Musk's comments on not selling shares., Headline: Amgen Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slumped 0.51% to $263.92 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",AMGN
84,2022-12-24,"Headline: How To Build Wealth: Buy Low And Sell High Consistently, source:SeekingAlpha, summary: What if we could buy low and sell high on a consistent basis? We discuss a systematic and rather conservative strategy to buy low and sell high. Click for more., Headline: HQH: 50 Big-Yield Healthcare Stocks, These 3 Worth Considering, source:SeekingAlpha, summary: We share data on over 50 big-yield healthcare investments, including individual stocks, REITs, closed-end funds (CEFs) and bonds. Learn about our 3 top picks here., Headline: An Intrinsic Calculation For Amgen Inc. (NASDAQ:AMGN) Suggests It's 37% Undervalued, source:Yahoo, summary: Does the December share price for Amgen Inc. ( NASDAQ:AMGN ) reflect what it's really worth? Today, we will estimate..., Headline: The Top 4 Dow Stock Winners of 2022, source:Yahoo, summary: The Dow Jones Industrial Average experienced volatility this year, facing multiple headwinds. Even so, a few stocks listed in the index performed well. Here's a look at four of them., Headline: 2 Market-Beating Stocks to Buy in 2023 and Hold Forever, source:Yahoo, summary: For these companies' shareholders, it may be tempting to take profits right now. But both stocks can keep growing for a while.",AMGN
85,2022-12-25,"Headline: Goldman Sachs highlights key healthcare themes for 2023, source:Seeking Alpha, summary: No summary, Headline: One Company Dominates Wall Street on Oil Frenzy, source:Yahoo, summary: The Dow Jones Industrial Average experienced volatility this year, facing multiple headwinds. Even so, a few stocks listed in the index performed well. Here's a look at four of them.",AMGN
86,2022-12-26,"Headline: Amgen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: No summary",AMGN
87,2022-12-27,"Headline: Amgen in licensing deal with LegoChem for antibody drug conjugates, source:Seeking Alpha, summary: No summary, Headline: Dow Jones Falls After Housing Data As Apple Hits New Low; Tesla Plunges On Reduced Production Schedule In China, source:Yahoo, summary: The Dow Jones Industrial Average turned lower after economic data. Tesla dived on a report that the EV giant will run a reduced production schedule at its Shanghai plant in January., Headline: Jefferies' Michael Yee still likes Amgen in the biotech sector, source:CNBC, summary: Michael Yee, Jefferies biotech analyst, joins 'Closing Bell' to discuss biotech, which is on pace for its worst year since 2016., Headline: Amgen (AMGN) Stock Moves -0.2%: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed the most recent trading day at $263.39, moving -0.2% from the previous trading session., Headline: Dow 30 Stocks List: Ranked By 2022 Hedge Fund Bullishness Index, source:Yahoo, summary: In this article, we discuss the Dow 30 stocks and their rank according to the 2022 hedge fund bullishness index. The Dow Jones Industrial Average, sometimes known as Dow Jones or just the Dow, is an indicator of 30 renowned American firms that are traded on NYSE and NASDAQ. One of the first and most […], Headline: Amgen Inc. stock falls Wednesday, still outperforms market, source:MarketWatch, summary: No summary",AMGN
88,2022-12-28,"Headline: Race is on to develop new generation of weight-loss drugs, source:Yahoo, summary: Surging demand and tight supply for a new class of obesity drugs has sparked a race among several of the world’s largest pharmaceutical companies to develop rival medications for a market projected to be worth $50bn in annual revenues by the end of the decade.  Eli Lilly, Amgen, Pfizer and Regeneron are among the companies aiming to compete with market leader Novo Nordisk in a category which analysts say is rapidly becoming a healthcare priority and could produce several blockbuster obesity treatments this decade.  Mounjaro, a similar medication already marketed by Lilly for treating diabetes but which is expected to get a green light from regulators next year for obesity, is also scarce at least in part because of off-label use by patients with obesity., Headline: The $100,000 Market-Crushing HIGH-Yield Portfolio, source:SeekingAlpha, summary: In this article, I discuss my $100,000 high-yield model portfolio, which comes with both a high yield and high dividend growth., Headline: Amgen Inc. (NASDAQ:AMGN) is a favorite amongst institutional investors who own 82%, source:Yahoo, summary: To get a sense of who is truly in control of Amgen Inc. ( NASDAQ:AMGN ), it is important to understand the ownership..., Headline: Dow Jones Rises After Weak Housing Data; Tesla Stock Hits New Low Amid Historic Plunge, source:Yahoo, summary: The Dow Jones rose Wednesday after key economic data. Tesla stock hit a new low, threatening to add to December's historic plunge., Headline: The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock, source:Yahoo, summary: Investors are closely watching two Eli Lilly battles that will unfold in 2023 as LLY stock continues a fevered streak, tacking on new highs., Headline: 3 Top Performing Blue-Chips of 2022, source:Yahoo, summary: Many investors have flocked to blue-chip stocks in 2022 to shield themselves from volatility. Can the strength of these three stocks spill into 2023?",AMGN
89,2022-12-29,"Headline: 2 Superstar High-Yield Blue-Chip Buys, source:SeekingAlpha, summary: Dividend growth blue-chips are the best-performing asset class in history. See two stocks that one will want to own in 2023 and beyond., Headline: Zacks Investment Ideas feature highlights: Caterpillar, Chevron and Amgen, source:Yahoo, summary: Caterpillar, Chevron and Amgen have been highlighted in this Investment Ideas article., Headline: Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know, source:Yahoo, summary: No summary, Headline: 2 Unstoppable Dividend Growth Stocks to Buy in 2023 and Beyond, source:Yahoo, summary: The beauty of investing for dividend income is that when it's done right, the strategy can provide investors with streams of inflation-topping growth in passive income.  Amgen's (NASDAQ: AMGN) medicines reach millions of patients throughout the world each year, which positions it as one of the largest pharmaceutical companies on the planet.  As you would expect from a big pharma company, its portfolio offering is diversified across a number of therapeutic areas, such as oncology, bone health, and inflammation, to name just a few., Headline: Dow Jones Rallies 300 Points After Jobless Claims; Tesla Stock Surges On Reiterated Buy Rating, source:Yahoo, summary: The Dow Jones rallied Thursday after first-time jobless claims. Tesla stock raced higher on a reiterated overweight rating., Headline: Amgen Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.67% higher to $263.16 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: Amgen (AMGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed at $263.16 in the latest trading session, marking a +0.67% move from the prior day.",AMGN
90,2022-12-30,"Headline: Drugmakers Spent Freely in 2022 to Protect Revenue, source:Yahoo, summary: Pfizer, Amgen and Bristol-Myers Squibb bought makers of proven drugs ahead of potential rising competition from generics., Headline: Dow Jones Beats S&P 500 in 2022: 5 Hot Stocks, source:Yahoo, summary: The Dow Jones fared as the best of the indexes and five stocks -- Chevron (CVX), Merck (MRK), Travelers (TRV), Amgen (AMGN), and Caterpillar (CAT) -- gained in double-digits in 2022., Headline: Dow Jones Falls 275 Points In Final Trading Day; Tesla Stock Set To End 2022 With Record Loss, source:Yahoo, summary: The Dow Jones fell 275 points Friday in the final session of 2022. Tesla stock is set to finish with its worst yearly performance on record., Headline: Amgen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. slipped 0.20% to $262.64 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",AMGN
91,2022-12-31,"Headline: 5 biggest deals of 2022: Musk's Twitter buyout, Microsoft-Activision, source:Yahoo, summary: As we head into 2023, here's a look back at a year that saw dealmaking slow into year-end amid rising interest rates by central banks, with three of the top five deals fraught with regulatory hurdles and controversy. Here are the five biggest merger deals of the year, as covered first on InvestingPro+.",AMGN
92,2023-01-01,"Headline: Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 82% of the company, source:Yahoo, summary: If you want to know who really controls Amgen Inc. ( NASDAQ:AMGN ), then you'll have to look at the makeup of its share..., Headline: 2023 Dividend Growth Portfolio Review And Look Ahead, source:Seeking Alpha, summary: No summary, Headline: The Dow Stock Dogs Performed In 2022, source:SeekingAlpha, summary: Very few investment categories generated a positive return in 2022. One area within equities that outperformed the broader market was stocks that had dividends associated with them.",AMGN
93,2023-01-02,"Headline: BlackRock, Kimberly-Clark Among 13 Companies To Start 2023 With Annual Dividend Increases, source:SeekingAlpha, summary: January will bring double-digit boosts from several companies. Click here to see which companies will announce dividend increases in 2023., Headline: Dow`s nearly 100-point drop led by losses in shares of Chevron, Apple, source:MarketWatch, summary: No summary",AMGN
94,2023-01-03,"Headline: Why The Dogs Of The Dow Strategy Will Likely Succeed In 2023, source:SeekingAlpha, summary: The Dogs of the Dow is a strategy of buying the 10 highest yielding stocks in the Dow (or a subset thereof). Read more to see our recommendations., Headline: Researchers` reanalysis questions mortality data in FOURIER trial, source:Thefly.com, summary: No summary, Headline: Research raises `valid questions` about Amgen`s Repatha, says Barclays, source:Thefly.com, summary: No summary, Headline: Amgen`s Repatha under fire over cardiovascular outcomes data in key trial, source:Seeking Alpha, summary: No summary, Headline: Amgen Becomes Oversold, source:Dividend Channel, summary: No summary, Headline: Amgen's (NASDAQ:AMGN) Upcoming Dividend Will Be Larger Than Last Year's, source:Yahoo, summary: Amgen Inc. ( NASDAQ:AMGN ) has announced that it will be increasing its dividend from last year's comparable payment on..., Headline: Amgen Inc. stock falls Tuesday, still outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. sank 0.38% to $261.65 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Buy 4 January Dogs Of The Dow, Watch 4 More, source:SeekingAlpha, summary: More than half this collection is too pricey and reveals only skinny dividends. Here are 4 January Dogs of the Dow you should buy., Headline: My 26-Stock $349k Portfolio Gets A Nice Petrobras Present To End A Very Difficult 2022, source:SeekingAlpha, summary: My portfolio, built specifically for my retirement, gets a nice end of the year Petrobras dividend to help ease market pain. Learn more about my portfolio here.",AMGN
95,2023-01-04,"Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. rallied 1.05% to $264.39 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: AMGEN TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE, source:Yahoo, summary: Amgen (NASDAQ:AMGN) will present at the 2023 J.P. Morgan Healthcare Conference at 6:45 p.m. ET on Monday, January 9, 2023. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public., Headline: Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed at $264.39 in the latest trading session, marking a +1.05% move from the prior day., Headline: Amgen Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: No summary",AMGN
96,2023-01-05,"Headline: AMGN Crosses Above Average Analyst Target, source:ETF Channel, summary: No summary, Headline: Investors’ Best Friend in 2022: The Dogs of the Dow, source:Yahoo, summary: The 10 stocks with the highest dividend yields of the Dow components at the beginning of last year rose 2.2%., Headline: Healthcare Stocks Had a Strong 2022. It Isn’t Too Late to Buy., source:Yahoo, summary: Profits in the sector tend to be stable even if hard times hurt earnings elsewhere, so the current high inflation and rising rates, represent a chance for the shares to shine., Headline: Tracking Baker Brothers Portfolio - Q3 2022 Update, source:SeekingAlpha, summary: Baker Brothers' 13F portfolio value decreased from $17.63B to $15.27B this quarter. Find out the ongoing analysis of the changes made to the portfolio on a quarterly basis., Headline: The Dow`s Biggest Dividends: Here Are 2023`s Dogs., source:The Online Investor, summary: No summary",AMGN
97,2023-01-06,"Headline: See How Amgen Ranks Among Analysts` Top Dow 30 Picks, source:ETF Channel, summary: No summary, Headline: Video: Dow Analyst Moves: AMGN, source:Market News Video, summary: No summary, Headline: As the U.S. Gets Older, Some ETFs Bet on Aging in Place, source:Yahoo, summary: A number of thematic funds are focused on companies that help seniors who want to stay in their homes as long as possible., Headline: AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE NAMMI THERAPEUTICS TO RECEIVE THE THIRD AMGEN GOLDEN TICKET, source:Yahoo, summary: Amgen (NASDAQ:AMGN) and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticket in Southern California. Nammi Therapeutics will receive one year of lab space at BioLabs LA at The Lundquist Institute (TLI) as well as additional facility benefits and connections to Amgen's scientific and business leaders., Headline: 5 Top Pharma Stocks of 2022 to Buy for the Long Haul, source:Yahoo, summary: Not every stock went down in 2022. Shares in some the biggest pharmaceutical companies rose in price. If you can make it in a market like 2022, imagine what can happen in 2023 for many top pharma stocks. What the best pharma stocks have in common is pricing power, patented medicines, big moats and wide margins. They’re also members of Pharmaceutical Research and Manufacturers of America, the trade group that has fought for decades to keep prices high. Pricing is the key risk for these companies.",AMGN
98,2023-01-07,"Headline: Amgen (NASDAQ:AMGN) Has A Pretty Healthy Balance Sheet, source:Yahoo, summary: The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...",AMGN
99,2023-01-08,"Headline: 15 Most Advanced Countries in Medicine, source:Yahoo, summary: In this article, we take a look at the 15 most advanced countries in medicine. You can skip our detailed analysis of the healthcare industry and go directly to 5 Most Advanced Countries in Medicine. The recent pandemic was the best reflection of the advancements in the field of medicine. Vaccines were developed at a […]",AMGN
100,2023-01-09,"Headline: Amgen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. slid 1.85% to $270.12 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again, source:Yahoo, summary: Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report., Headline: Amgen (AMGN) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed the most recent trading day at $270.12, moving -1.85% from the previous trading session.",AMGN
101,2023-01-10,"Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. advanced 1.39% to $273.88 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: 10 Most Fined Pharmaceutical Companies in the World, source:Yahoo, summary: In this article, we will be taking a look at the 10 most fined pharmaceutical companies in the world. To skip our detailed analysis, you can go directly to see the 5 Most Fined Pharmaceutical Companies in the World. Pharmaceutical companies have often been derided by conspiracy theorists who coined the term “Big Pharma”. The […]",AMGN
102,2023-01-11,"Headline: Ranking The 10 Largest Biotechs By Pipeline, source:SeekingAlpha, summary: The pipeline is the heart of all drug discovery companies, leading to all growth in the future. Here we rank biotechs by pipeline, click to see the list., Headline: Amgen Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slipped 0.35% to $272.91 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: FDRR: Designed For Inflation And Still Unconvincing, source:SeekingAlpha, summary: Fidelity Dividend ETF for Rising Rates ETF invests in dividend stocks that should profit from rising rates. Here's a rundown on FDRR and whether it is right for you.",AMGN
103,2023-01-12,"Headline: IBB: A History Of Outperformance During Recessions, source:SeekingAlpha, summary: iShares Biotechnology has outperformed the S&P 500 during all 3 recessions in the U.S. since inception in early 2001. See why I'm bullish about IBB ETF now., Headline: Will 2023 be the year that pharma M&A makes a comeback?, source:MarketWatch, summary: A handful of acquisitions this week point to a more deal-friendly year for biopharma and biotech companies., Headline: Amgen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. dropped 0.73% to $270.92 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",AMGN
104,2023-01-13,"Headline: FOCUS-Drug companies favor biotech meds over pills, citing new U.S. law, source:Yahoo, summary: Drugmakers are prioritizing complex biotech medicines over treatments that can be given as pills because recent U.S. legislation gives biologics a longer runway before becoming subject to government price limits, top industry executives said this week.  The Inflation Reduction Act (IRA), which Democrats passed last August, for the first time allows the government's Medicare health plan for people age 65 and over to negotiate the prices it is willing to pay for certain medications.  The pharmaceutical industry, whose members gathered in the thousands this week in San Francisco for the annual JP Morgan Healthcare conference, opposed the legislation and has begun implementing strategies to mitigate its impact., Headline: Hoping For A Roaring Bull Run? Think Again!, source:SeekingAlpha, summary: Relying on the high-flyers of tomorrow is a strategy that is rarely successful, emotionally taxing, and not scalable. Check out our strategy - and five picks., Headline: 2023 Market Preview: Value Should Continue To Lead, source:SeekingAlpha, summary: The market's history after negative years is usually positive. What we expect to work in 2023: Industrials and consumer staples. Click for our market preview., Headline: Amgen (AMGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed at $271.73 in the latest trading session, marking a +0.3% move from the prior day.",AMGN
105,2023-01-14,"Headline: Amgen: Dividend Growth Secure But Keep An Eye On Debt, Margins, source:SeekingAlpha, summary: Amgen has been able to grow dividends at a rate of 11% over the past 5 years. Read more to know why AMGN stock is a hold at its current valuation., Headline: Investing in Amgen (NASDAQ:AMGN) five years ago would have delivered you a 66% gain, source:Yahoo, summary: If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can do a lot better..., Headline: A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them., source:Yahoo, summary: Pharmaceutical companies are grappling with the arrival in the U.S. of sweeping new legislation meant to blunt drug prices.  The impact in 2023 may actually be higher drug prices.  President Biden last year signed into law the bill dubbed the Inflation Reduction Act, empowering Medicare, the country’s biggest buyer of prescription drugs, to negotiate how much it pays for certain high-price therapies.",AMGN
106,2023-01-15,"Headline: 25 Biggest California Companies and Stocks, source:Yahoo, summary: In this article, we will be taking a look at the 25 biggest California companies and stocks. To skip our detailed analysis, you can go directly to see the 5 Biggest California Companies and Stocks. California is not just the most populous state in the U.S. with over 39 million residents, but it is also […], Headline: My 2023 Picks For My Portfolio, source:SeekingAlpha, summary: I have started a new investment account with initial funding added around November 15, 2022. Check out my thoughts as to the stocks I will pick for investment.",AMGN
107,2023-01-16,"Headline: How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings, source:Yahoo, summary: Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP., Headline: Amgen Reinforcing Its Portfolio, source:SeekingAlpha, summary: Amgen's newly acquired products bring in almost $1 billion quarterly, all from the U.S. Read what this could mean for AMGN stock in the coming years.",AMGN
108,2023-01-17,"Headline: Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.13, source:Yahoo, summary: Amgen Inc. ( NASDAQ:AMGN ) will increase its dividend from last year's comparable payment on the 8th of March to $2.13..., Headline: Dow Jones Drops After Weak Manufacturing Data; Goldman Sachs Slides On Earnings Miss, source:Yahoo, summary: The Dow Jones dropped Tuesday ahead of more key inflation data due out Wednesday. Goldman Sachs fell on an earnings miss., Headline: Amgen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. sank 0.85% to $269.42 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",AMGN
109,2023-01-18,"Headline: Blue-Chip Stocks And Red Flags - Things To Consider In Your Due Diligence, source:SeekingAlpha, summary: Investing in dividend-paying blue-chip companies is a proven strategy for reliable long-term returns. Read more about the pitfalls with this strategy., Headline: Dow Jones Rises After Cool Inflation Report, Weak Retail Sales; Tesla Extends Gains, source:Yahoo, summary: The Dow Jones Industrial Average rose Wednesday on a cool inflation report and weak retail sales. Tesla stock raced higher, looking to add to Tuesday's surge., Headline: Amgen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slid 1.87% to $264.39 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Nicholas Ward's Dividend Growth Portfolio: December/Full Year 2022 Review, source:SeekingAlpha, summary: My passive income was up by 46.50% on a year-over-year basis during December. For the full-year in 2022, my passive income rose by 23.73%. Click to read more., Headline: Bristol Myers Squibb's New Products Need More Insurance Coverage, But Still A Buy, source:SeekingAlpha, summary: Bristol Myers Squibb touted the launch of 9 new products in the U.S. While these products need more insurance coverage, read why I still rate BMY stock a Buy.",AMGN
110,2023-01-19,"Headline: Dow Jones Falls 225 Points After Jobless Claims; Netflix Earnings Due, source:Yahoo, summary: The Dow Jones Industrial Average fell 225 points Thursday after first-time jobless claims. Netflix earnings are due out after the market close., Headline: Amgen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slipped 0.89% to $262.03 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Amgen (AMGN) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed at $262.03 in the latest trading session, marking a -0.89% move from the prior day.",AMGN
111,2023-01-20,"Headline: Amgen (AMGN) Presents At 41st Annual Healthcare Conference - Slideshow, source:SeekingAlpha, summary: The following slide deck was published by Amgen Inc., Headline: Amgen (AMGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Amgen (AMGN) closed at $263.24, marking a +0.46% move from the previous day.",AMGN
112,2023-01-21,"Headline: Insiders who sold Amgen Inc.'s (NASDAQ:AMGN) earlier this year didn't have to weather this week's 3.1% slide, source:Yahoo, summary: Amgen Inc.'s (NASDAQ:AMGN) value has fallen 3.1% in the last week, but insiders who sold US$5.2m worth of stock over..., Headline: 3 Dividend Stocks You Can Safely Hold for Years, source:Yahoo, summary: Most companies currently paying dividends are equipped to do so for the foreseeable future.  Only a handful of dividend-paying companies, however, are built to continue dishing out dividends into the distant unknown as unforeseen changes arise.  Here's a closer look at three dividend stocks you can safely hold for years.",AMGN
113,2023-01-22,"Headline: 2 Top Passive-Income Stocks to Own in 2023, source:Yahoo, summary: Passive-income stocks are a proven way to cushion your portfolio against market volatility.  What's more, top shelf dividend plays also tend to outperform other asset classes in bull markets.  Not all dividend stocks are cut from the same cloth, however.",AMGN
114,2023-01-23,"Headline: Healthcare Outlook 2023, source:SeekingAlpha, summary: Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. Read more here., Headline: Pluri Inc (Pluristem Therapeutics) Holds No Hope For The Weak, source:SeekingAlpha, summary: Pluri Inc is a biotechnology research company developing medical, pharma, and food products from placenta-based stem cells R&D. Read our outlook on PLUR stock.",AMGN
115,2023-01-24,"Headline: Dogs of the Dow 2023: 5 Dividend Stocks for Income Investors, source:Yahoo, summary: The start of the year is a good time to add to your existing portfolio or start new positions. An excellent source to look for ideas is among the Dogs of the Dow. These stocks are the highest-yielding ones in the Dow Jones Industrial Average (DJIA) at the end of the preceding year. The strategy assumes the stocks are temporarily mispriced, and thus the yields are high. Additionally, the Dogs of the Dow are blue-chip stocks with sustainable growth and excellent reputations. Hence, they make good",AMGN
116,2023-01-25,"Headline: Why Viridian Therapeutics Is One Of My 2023 Top Picks, source:SeekingAlpha, summary: Viridian was one of my top picks in 2022 and it made the 2023 list again. Click here to see our take on VRDN stock., Headline: Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?, source:Yahoo, summary: Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs., Headline: Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline, source:Yahoo, summary: Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",AMGN
117,2023-01-26,"Headline: 2 Top Biotech Stocks to Buy for the Long Haul, source:Yahoo, summary: Equity markets are entirely unpredictable in the short run.  The biotech industry is a great place to look for stocks that can survive down markets and be successful over long periods since the drugs these companies develop are so critical to their customers' lives.  Let's look at two biotech stocks to buy today and hold on to for a while: Amgen (NASDAQ: AMGN) and Moderna (NASDAQ: MRNA)., Headline: Is Amgen Inc. (NASDAQ:AMGN) Trading At A 29% Discount?, source:Yahoo, summary: In this article we are going to estimate the intrinsic value of Amgen Inc. ( NASDAQ:AMGN ) by estimating the company's..., Headline: Warren tells FTC she is ""particularly concerned"" about Amgen and Indivior deals, source:Yahoo, summary: Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals.  In a letter dated Wednesday, Warren said that she was focused on Amgen's plan to buy Horizon Therapeutics , and addiction specialist Indivior's plan to buy Opiant for $145 million, which was announced in mid-November.  ""Given these companies' records of anti-competitive business practices, these acquisitions could cause further price increases on lifesaving drugs and prevent affordable alternatives from entering the market,"" she wrote in the letter to FTC Chair Lina Khan as well as Commissioners Rebecca Slaughter and Alvaro Bedoya, all of whom are Democrats., Headline: UPDATE 2-U.S. Senator Warren 'particularly concerned' about Amgen, Indivior deals, source:Yahoo, summary: Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals.  In a letter dated Wednesday, Warren said that she was focused on Amgen's plan to buy Horizon Therapeutics , and addiction specialist Indivior's plan to buy Opiant for $145 million, which was announced in mid-November.  ""Given these companies' records of anti-competitive business practices, these acquisitions could cause further price increases on lifesaving drugs and prevent affordable alternatives from entering the market,"" she wrote in the letter to FTC Chair Lina Khan as well as Commissioners Rebecca Slaughter and Alvaro Bedoya, all of whom are Democrats., Headline: AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, Jan. 31, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team., Headline: U.S. Senator Warren 'particularly concerned' about Amgen, Indivior deals, source:Reuters, summary: Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals., Headline: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed the most recent trading day at $254.88, moving -0.65% from the previous trading session.",AMGN
118,2023-01-27,"Headline: Bristol Myers Gets CHMP Backing for Sotyktu, Reblozyl >BMY, source:MarketWatch, summary: By Colin Kellaher Bristol Myers Squibb Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended...",AMGN
119,2023-01-30,"Headline: Amgen lays off 300 employees , source:Reuters, summary: Amgen Inc said on Monday that it had let go about 300 employees based in the United States, mainly in its commercial team, citing recent organizational changes to better manage the company against ""industry headwinds"". (Reporting by Bhanvi Satija in Bengaluru; Editing by..., Headline: SCHG Adds Growth In A 2-ETF Package That Beat The S&P 500 Over 10 Years, source:SeekingAlpha, summary: For this article, I decided to take a look at SCHG, an ETF I hadn't previously reviewed. Click here to read what happened after combining this ETF with SCHD.",AMGN
120,2023-01-31,"Headline: First Humira Biosimilar Price Highlights Cost-Saving Challenges, source:MarketWatch, summary: Hopes that competition would bring immediate cost savings was tamped down when Amgen announced a pricing scheme for its generic-style competitor to AbbVie's..., Headline: Amgen launches biosimilar version of AbbVie's Humira, source:Reuters, summary: Amgen Inc said on Tuesday it launched a biosimilar version of AbbVie Inc's big selling arthritis treatment, the first such competition for Humira in the United States., Headline: Amgen 4Q Profit Declines, Revenue Ticks Down Slightly, source:MarketWatch, summary: By Denny Jacob Amgen Inc. on Tuesday reported lower profit and revenue that dipped in the latest quarter. The biotechnology company reported net income of..., Headline: Amgen's Q4 tops views, but 2023 guidance falls on lower end of expectations, source:MarketWatch, summary: Amgen Inc. topped Wall Street expectations for its fourth quarter, but the drug maker's shares fell after hours as its 2023 guidance fell on the lower end of..., Headline: Barron's And Bloomberg 2023 Ideal Dividend Stocks Of The Year, source:SeekingAlpha, summary: Two Barronâs Annual Roundtable, plus one Bloomberg Intelligence, articles published late-January listed 99 intriguing stocks for 2023. Read our analysis., Headline: UPDATE 1-Amgen revenue falls slightly as Lilly COVID deal contributes less, source:Yahoo, summary: Amgen Inc on Tuesday said its fourth-quarter revenue fell slightly as a 4% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co.  Amgen reported revenue of $6.84 billion for the quarter, down from $6.85 billion a year ago, but ahead of analysts' estimates of $6.77 billion, according to Refinitiv data.  Amgen partnered with Lilly in 2020 to increase the supply of its COVID-19 antibody treatments., Headline: Amgen revenue falls slightly as Lilly COVID deal contributes less, source:Reuters, summary: Amgen Inc on Tuesday said its fourth-quarter revenue fell slightly as a 4% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co., Headline: Amgen’s Q4 tops views, but 2023 guidance falls on lower end of expectations, source:Yahoo, summary: Amgen Inc. topped Wall Street expectations for its fourth quarter, but the drug maker's shares fell after hours as its 2023 guidance fell on the lower end of Wall Street's expectations., Headline: Stocks moving in after hours: AMD, Snap, Match Group, Electronic Arts, Amgen, source:Yahoo, summary: Yahoo Finance Live co-host Seana Smith discusses stocks moving in after-hours trading., Headline: Amgen (AMGN) Surpasses Q4 Earnings and Revenue Estimates, source:Yahoo, summary: Amgen (AMGN) delivered earnings and revenue surprises of 1.24% and 1.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?, Headline: Amgen Inc. (AMGN) Q4 2022 Earnings Call Transcript, source:SeekingAlpha, summary: Call Start: 16:30 January 1, 0000 6:00 PM ETAmgen Inc.",AMGN
121,2023-02-01,"Headline: Nasdaq jumps 2% to end at highest since September after Fed raises rate by a quarter-point, Powell signals few more hikes to go, source:MarketWatch, summary: U.S. stocks finish higher on Wednesday, reversing earlier losses after the Federal Reserve raised its policy interest rate by 25 basis points, as widely..., Headline: Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics, source:Yahoo, summary: While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values., Headline: Amgen, Travelers share losses lead Dow's 185-point fall, source:MarketWatch, summary: The Dow Jones Industrial Average is down Wednesday morning with shares of Amgen and Travelers delivering the stiffest headwinds for the blue-chip average...., Headline: Amgen, Travelers share losses lead Dow's 336-point fall, source:MarketWatch, summary: Dragged down by losses for shares of Amgen and Travelers, the Dow Jones Industrial Average is trading down Wednesday morning. The Dow was most recently..., Headline: Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline, source:Yahoo, summary: Amgen Inc's (NASDAQ: AMGN) fourth-quarter revenues were $6.84 billion, beating the consensus of $6.76 billion, largely unchanged from Q4 2021, and benefited from a 4% increase in product sales, offset by lower COVID-19 manufacturing collaboration revenues. Product sales growth was driven by 10% volume growth, partially offset by a 3% lower net selling price and a 2% negative impact from foreign exchange. Excluding the 2% negative impact of foreign exchange on product sales, total revenues increa, Headline: US STOCKS-Futures dip on jitters ahead of ADP report, Fed decision, source:Yahoo, summary: U.S. stock index futures slipped on Wednesday as investors cautiously waited for the Federal Reserve's decision on interest rates later in the day and a reading on private job additions last month.  The Fed is widely seen as raising its target interest rate by a quarter of a percentage point in its first policy meeting of the year, after the rapid increases in 2022 to tame decades-high inflation.  Investors will also likely parse Chair Jerome Powell news conference for clues on the trajectory of future rate hikes., Headline: Amgen Shares Slip 4.1% Following Decline in 4Q Profit, Revenue, source:MarketWatch, summary: By Denny Jacob Amgen Inc. shares slipped 4.1% to $242.17 following lower profit and a dip in revenue in its latest quarter. The biotechnology company on..., Headline: Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13, source:Yahoo, summary: Amgen Inc. ( NASDAQ:AMGN ) will increase its dividend from last year's comparable payment on the 8th of March to $2.13..., Headline: US STOCKS-Wall St set to open lower ahead of Fed decision; AMD rises on outlook, source:Yahoo, summary: U.S. stock indexes were set to open lower on Wednesday as investors cautiously awaited the Federal Reserve's decision on interest rates later in the day, while chipmaker Advanced Micro Devices climbed on an upbeat outlook.  The Fed is widely seen as raising its target interest rate by a quarter of a percentage point in its first policy meeting of the year, after the rapid increases in 2022 to tame decades-high inflation.  ""Consensus is that the Fed is going to talk very hawkish today even though it's only doing 25 basis points,"" said Thomas Hayes, chairman at investment firm Great Hill Capital., Headline: Dow's 235-point drop led by losses in Amgen, Travelers shares, source:MarketWatch, summary: Shares of Amgen and Travelers are trading lower Wednesday afternoon, sending the Dow Jones Industrial Average into negative territory. The Dow was most..., Headline: Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints, source:Yahoo, summary: Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country., Headline: US STOCKS-Wall St dips as Fed decision looms; AMD boosts chipmakers, source:Yahoo, summary: U.S. stock indexes fell on Wednesday ahead of the Federal Reserve's decision on interest rates later in the day, while an upbeat outlook from Advanced Micro Devices lifted chipmakers.  The Fed is widely seen as raising its target interest rate by a quarter of a percentage point in its first policy meeting of the year, after the rapid increases in 2022 to tame decades-high inflation., Headline: Amgen Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slipped 2.37% to $246.41 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: My 26 Stock ~$384k Portfolio Sports Double-Digit Returns To Start The New Year, source:SeekingAlpha, summary: My portfolio, built specifically for my retirement, features growth, dividend, and risk stocks for a happy retirement. Click here to see my strategy., Headline: US STOCKS-Wall St falls as Fed decision looms; AMD boosts chipmakers, source:Yahoo, summary: U.S. stock indexes fell on Wednesday ahead of the Federal Reserve's decision on interest rates later in the day, while an upbeat outlook from Advanced Micro Devices lifted chipmakers.  The Fed is widely seen as raising its target interest rate by a quarter of a percentage point in its first policy meeting of the year, after rapid increases in 2022 to tame decades-high inflation., Headline: FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high, source:Yahoo, summary: U.S. patients will finally get access to cheaper versions of AbbVie Inc’s blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.  Rival drugmaker Amgen Inc on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20-year-old drug, with two tiers of pricing.  One sets a 5% discount to Humira’s monthly price of $6,922., Headline: There's A Key Element Missing From Amgen's 2023 Outlook, Making Comparisons 'Messy', source:Yahoo, summary: Amgen issued an outlook that discounts its looming acquisition of Horizon Therapeutics. In response, Amgen stock skidded Wednesday morning., Headline: Why Amgen Stock Wilted on Wednesday, source:Yahoo, summary: The stock of veteran biotech Amgen (NASDAQ: AMGN) was looking a little tired on Wednesday.  The company's shares fell more than 2% in price, ""thanks"" to fourth-quarter results that didn't put smiles on investors' faces.  In contrast to gloomy Amgen, the S&P 500 index ticked up by slightly more than 1%.",AMGN
122,2023-02-02,"Headline: S&P 500 surges to end at over five-month high, Nasdaq closes up 3.3% as Meta leads rally in tech sector stocks, source:MarketWatch, summary: U.S. stocks ended mostly higher on Thursday after the Nasdaq Composite and the S&P 500 index surged to their highest levels in about five months, buoyed by..., Headline: TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN, source:Yahoo, summary: Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.1 First approved by the FDA in December 2021, TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g., eosinophilic or allergic) or biomarker limitation within its approved label.2-9, Headline: Amgen Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.05% higher to $246.53 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500..., Headline: The 7 Most Undervalued Dow Stocks to Buy in February 2023, source:Yahoo, summary: While investing in the new normal seemingly focused on meme trades and other high-risk ventures, targeting the companies of the Dow Jones is always relevant, particularly if they’re among the most undervalued Dow stocks to buy. Granted, this venerable list doesn’t bring much excitement. However, these stalwarts command well-established businesses, meaning they likely won’t steer you wrong. Before we begin, though, we need to establish some ground rules. First, none of the most undervalued Dow st, Headline: What’s Ailing the Dow This Year? UnitedHealth, Chevron, J&J, Amgen., source:Yahoo, summary: The Dow industrials fell 39 points, or 0.1%, to 34,054, while the  gained 1.5% to 4,179 and the  was up 3.3%.  Several influential stocks in the index are in the red this year, led by  UnitedHealth  Group (ticker: UNH), which is the worst percentage loser, with an 11.1% drop to $470.83.  Other losers in the Dow include  Amgen  (AMGN),  Merck  (MRK),  Johnson & Johnson  (JNJ),  Procter & Gamble  (PG), and  Chevron  (CVX)—which all are down about 6%, Bloomberg data show.",AMGN
123,2023-02-03,"Headline: Amgen Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slumped 0.55% to $245.17 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",AMGN
124,2023-02-05,"Headline: Top 3 Corporate Events To Look For In 2023 (That Aren't Earnings Dates), source:SeekingAlpha, summary: Weâre in the midst of the fourth quarter earnings season and already weâre seeing a cautionary setup for 2023 as corporations find ways to cut back., Headline: AbbVie: The Dreaded Humira Cliff Is Here: Time To Sell?, source:SeekingAlpha, summary: The day has arrived: Biosimilars for AbbVie's blockbuster drug Humira are now being sold in the US. See whether it's not time to sell ABBV?",AMGN
125,2023-02-06,"Headline: Is Amgen (NASDAQ:AMGN) Using Too Much Debt?, source:Yahoo, summary: Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's..., Headline: Amgen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. shed 0.54% to $243.85 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",AMGN
126,2023-02-07,"Headline: Amgen Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.06% higher to $244.00 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",AMGN
127,2023-02-08,"Headline: Beat the Dow Jones With This Unstoppable Dividend Stock, source:Yahoo, summary: The Dow Jones Industrial Average contains 30 of the highest quality businesses in the world.  A $10,000 investment in the stock made 10 years ago would now be worth $37,000 with dividends reinvested.  For context, that is nearly double the $20,000 that the same investment made in the Dow Jones would be worth after 10 years with dividends reinvested., Headline: Amgen Inc. (NASDAQ:AMGN) Q4 2022 Earnings Call Transcript, source:Yahoo, summary: Amgen Inc. (NASDAQ:AMGN) Q4 2022 Earnings Call Transcript January 31, 2023 Amgen Inc. misses on earnings expectations. Reported EPS is $4.09 EPS, expectations were $4.1. Operator: My name is Jason and I will be the conference facilitator today for Amgen’s Fourth Quarter Full Year 2022 Financial Results Conference Call. I would now like to introduce […], Headline: Mirati Therapeutics: Suddenly A Battleground Stock, source:SeekingAlpha, summary: Mirati Therapeutics is focused on developing product candidates to address the genetic and immunological promoters of cancer. Read my analysis of MRTX stock.",AMGN
128,2023-02-09,"Headline: AbbVie`s stock gains on Q4 results, source:MarketWatch, summary: No summary, Headline: AbbVie’s stock gains on Q4 results, source:MarketWatch, summary: Shares of AbbVie Inc. gained 2.4% in premarket trading on Thursday after the company beat earnings expectations for the fourth quarter of 2022. AbbVie had a..., Headline: There's A Lot To Like About Amgen's (NASDAQ:AMGN) Upcoming US$2.13 Dividend, source:Yahoo, summary: It looks like Amgen Inc. ( NASDAQ:AMGN ) is about to go ex-dividend in the next four days. The ex-dividend date is one..., Headline: AbbVie gains after revising estimates for Humira sales erosion, source:Seeking Alpha, summary: No summary, Headline: How To Profit From Amgen Stock's Plunge Using Options, source:Yahoo, summary: Amgen (AMGN) stock has had a difficult few weeks, with the stock dropping from 295 to 240. It is currently the most oversold stock in the Dow Jones Industrial Average. When a quality company has a big drop like this, I like to use a strategy called a diagonal put spread. This option strategy is an advanced strategy because it..., Headline: AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales, source:Yahoo, summary: AbbVie's Q4 earnings (ABBV) beat estimates, while sales miss the same. Full-year 2023 EPS falls short of estimates., Headline: 9 Upcoming Dividend Increases, source:SeekingAlpha, summary: I've tracked 35 dividend increases in 2023 for your consideration. There are nine increases for next week, up from two last week. Click here to read more., Headline: AMGEN TO PRESENT AT THE 2023 SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE, source:Yahoo, summary: Amgen (NASDAQ:AMGN) will present at the 2023 SVB Securities Global Biopharma Conference at 10:40 a.m. ET on Tuesday, February 14, 2023. Susan Sweeney, senior vice president, Global Marketing, Access and Capabilities at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public., Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",AMGN
129,2023-02-10,"Headline: High Yield Stock Watchlist - February 2023, source:SeekingAlpha, summary: The majority of the stocks on my watchlist are undervalued based on dividend yield theory. Click here for a detailed analysis., Headline: Medicare mulls rebates in 2025 for drug prices rising faster than inflation, source:Seeking Alpha, summary: No summary, Headline: Chevron, Amgen share gains contribute to Dow`s 66-point jump, source:MarketWatch, summary: No summary, Headline: BME: Well-Positioned Healthcare CEF For Monthly Income, source:SeekingAlpha, summary: BlackRock Health Sciences Trust is a top healthcare CEF with long tenure that offers monthly distributions and an average yield. See why I'm bullish on BME CEF.",AMGN
130,2023-02-11,"Headline: How This Income Method Could Lead To Financial Freedom, source:SeekingAlpha, summary: We will go over our thesis as to how a diversified income method with low volatility could make you financially independent. Click here for our strategy., Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of February 12, source:SeekingAlpha, summary: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read the update for the week of February 12.",AMGN
131,2023-02-12,"Headline: 12 Most Undervalued Dow Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this article, we will take a look at the 12 most undervalued dow stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Undervalued Dow Stocks To Buy According To Hedge Funds. The stock market bloodbath that started in 2022 has forced investors to shun the so-called […], Headline: OmniAb initiated with a buy at H.C. Wainwright on antibody collaborations, partnerships, source:Seeking Alpha, summary: No summary, Headline: ARK Invest: The 7 Words That Explain Why Wall Street Can`t Stand Cathie Wood, source:InvestorPlace, summary: No summary",AMGN
132,2023-02-13,"Headline: Truist Financial Sticks to Their Hold Rating for Amgen (AMGN), source:TipRanks, summary: No summary, Headline: Amgen price target lowered to $260 from $280 at Truist, source:Thefly.com, summary: No summary, Headline: Don`t Buy Viatris And Organon Just Because Of The Dividends, source:Seeking Alpha, summary: No summary, Headline: Don't Buy Viatris And Organon Just Because Of The Dividends, source:SeekingAlpha, summary: Viatris and Organon are what can currently be described as deep value plays in the pharmaceutical sector. Click for more on OGN and VTRS., Headline: Amgen's (NASDAQ:AMGN) investors will be pleased with their notable 52% return over the last five years, source:Yahoo, summary: While Amgen Inc. ( NASDAQ:AMGN ) shareholders are probably generally happy, the stock hasn't had particularly good run..., Headline: Amgen Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.48% higher to $243.66 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: Tuesday Talk: My Sweet CPI, source:TalkMarkets, summary: No summary",AMGN
133,2023-02-14,"Headline: Amgen Inc. (AMGN) SVB Securities Global Biopharma Conference (Transcript), source:Seeking Alpha, summary: No summary, Headline: Top 5 4th Quarter Trades of Compagnie Lombard Odier SCmA, source:GuruFocus, summary: No summary, Headline: Top Research Reports for Chevron, Novo Nordisk & Amgen, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Novo Nordisk A/S (NVO) and Amgen Inc. (AMGN)., Headline: Health Rounds: Pancreas cancer rising faster among younger U.S. women, source:Yahoo, summary: Pancreas cancer rates are climbing in the U.S., but they’re rising faster in younger women than in their male counterparts, a large study shows.  In other news, a drug that delivers a cancer-killing virus directly into tumors may be an effective new alternative for patients with a hard-to-treat form of breast cancer.  Pancreas cancer rates in the United States are increasing faster in younger women than in their male counterparts, a large study has found., Headline: Amgen plans mega bond deal to help fund $28 billion Horizon Therapeutics acquisition, source:Yahoo, summary: Amgen Inc. plans to finance its acquisition of Horizon Therapeutics in the corporate bond market, underscoring how the Federal Reserve's inflation fight isn't drying up mega deals on Wall Street., Headline: Amgen bond offering to help fund Horizon Therapeutics acquisition, source:Seeking Alpha, summary: No summary, Headline: Palouse Capital Management, Inc. Buys 2, Sells 3 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: FEDERATED HERMES, INC. Buys 1, Sells 4 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: Top Merger Stocks Held By Fund Managers, Mid-Q1 2023, source:SeekingAlpha, summary: Form 13F filings show fund managers' top arbitrage stocks. Find out top M&A stocks of the 28 funds I follow and this quarter's top stock.",AMGN
134,2023-02-15,"Headline: Why Billionaires Paul Tudor Jones and George Soros Bought Up Horizon (HZNP) Stock, source:InvestorPlace, summary: No summary, Headline: Amgen sees about $56 billion in demand for mega bond deal, source:MarketWatch, summary: No summary, Headline: Medicare mulls limiting per month costs for generic drugs at $2, source:Seeking Alpha, summary: No summary, Headline: The Zacks Analyst Blog Highlights Chevron, Novo Nordisk, Amgen, Starbucks and General Dynamics, source:Yahoo, summary: Chevron, Novo Nordisk, Amgen, Starbucks and General Dynamics are part of the Zacks top Analyst Blog., Headline: 5 Stocks In The Dividend Growth Sweet Spot, source:SeekingAlpha, summary: Finding companies with a high initial yield and rapid dividend growth is difficult. Here's my criteria for finding such companies., Headline: Amgen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. shed 0.40% to $240.07 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Amgen to raise $24 billion after seeing about $90 billion in demand for mega bond deal, source:Yahoo, summary: Amgen looks to raise $24 billion on Wednesday, ranking in the top 10 in terms of largest U.S. corporate bond deals ever, according to Informa Global Markets., Headline: Competition Coming For AbbVie's Blockbuster Humira, source:SeekingAlpha, summary: Itâs among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper âbiosimilarâ copycats. Read how price relief is on the way for Humira.",AMGN
135,2023-02-16,"Headline: AMGN Near Buy Point With Strong Fundamentals And Rising Dividend, source:TalkMarkets, summary: No summary, Headline: O`Keefe Stevens Advisory Q4 2022 Update, source:Seeking Alpha, summary: No summary, Headline: Renaissance Technologies Top Trades This Quarter Included Apple, Amazon, Taiwan Semiconductor And More Released Here, source:Fintel, summary: nan, Headline: Dow, Amgen share losses lead Dow`s 225-point fall, source:MarketWatch, summary: No summary, Headline: Amgen Enters Oversold Territory, source:Dividend Channel, summary: No summary, Headline: Dow, Amgen share losses lead Dow's 225-point fall, source:MarketWatch, summary: Behind declines for shares of Dow and Amgen, the Dow Jones Industrial Average is trading down Thursday morning. Shares of Dow and Amgen have contributed to..., Headline: Dow`s 139-point drop led by losses for Microsoft, Amgen stocks, source:MarketWatch, summary: No summary, Headline: Competition Coming For AbbVie`s Blockbuster Humira, source:Seeking Alpha, summary: No summary, Headline: Dow's 139-point drop led by losses for Microsoft, Amgen stocks, source:MarketWatch, summary: Shares of Microsoft and Amgen are trading lower Thursday afternoon, dragging the Dow Jones Industrial Average into negative territory. The Dow was most..., Headline: 2 Market-Beating Dividend Stocks to Buy With $500, source:Yahoo, summary: Dividend-paying corporations can be particularly great picks since the steady and reliable payouts they offer help boost total returns over the long run.  Let's consider two such stocks that you can buy for less than the relatively modest sum of $500: Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK).  Amgen is a biotech leader with a plentiful and diverse lineup of medicines across multiple therapeutic areas., Headline: Amgen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slipped 2.43% to $234.22 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Dow closes more than 100 points higher on Friday, but notches third straight week of losses on rate fears: Live updates, source:CNBC, summary: A week of inflation and retail sales data has put the consumer in sharp focus. Recent comments from Fed officials have also spooked investors., Headline: O'Keefe Stevens Advisory Q4 2022 Update, source:SeekingAlpha, summary: O'Keefe Stevens Advisory recently published its Q4 2022 update. Click here to read the full fund letter., Headline: Dow`s 60-point jump led by gains for Amgen, Merck stocks, source:MarketWatch, summary: No summary, Headline: Catalyst watch: Spotlight on retail earnings, Lucid Group, Silvergate Capital and Radware, source:Seeking Alpha, summary: No summary, Headline: S&P 500, Dow, Nasdaq finish mixed as Fed debate continues, source:Seeking Alpha, summary: No summary, Headline: Amgen After FY22 Earnings: Ambition Is Commendable But Debt Is Problematic, source:Seeking Alpha, summary: No summary",AMGN
136,2023-02-17,"Headline: ‘Biosimilars’ Were Supposed to Tame Costs for Drugs Like Humira. It Isn’t Working., source:Yahoo, summary: AbbVie's arthritis treatment Humira and other complex drugs account for almost half of annual U.S. drug spending—but just 2% of prescriptions., Headline: Early notable gainers among liquid option names on February 17th, source:Thefly.com, summary: No summary, Headline: Dow's 60-point jump led by gains for Amgen, Merck stocks, source:MarketWatch, summary: Shares of Amgen and Merck are trading higher Friday afternoon, sending the Dow Jones Industrial Average into positive territory. Shares of Amgen and Merck..., Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. rallied 2.69% to $240.53 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Best Stocks To Buy Now? 2 Dow Jones Stocks To Watch In 2023, source:StockMarket, summary: Are these the best Dow Jones Industrial Average stocks to buy in 2023?, Headline: Endowments Soared in 2021. The Next Year Was Dramatically Different., source:MarketWatch, summary: University endowments lost 8% in fiscal 20221, slightly better than the S&P 500 but the worst decline since 2009. It was a year of two markets: The first...",AMGN
137,2023-02-19,"Headline: The next big wave of patent cliffs is ahead; expect biopharma M&A to rise ��� report, source:Seeking Alpha, summary: No summary, Headline: 25 Best Countries For A Comfortable Retirement, source:Yahoo, summary: In this article, we take a look at the 25 best countries for a comfortable retirement. You can skip our detailed analysis of the aging demographics and the resulting economic shifts and go directly to 10 Best Countries For A Comfortable Retirement. Retiree Population: By Numbers The UN estimates suggest that there are 703 million […]",AMGN
138,2023-02-20,"Headline: What To Expect From Bristol-Myers Squibb In 2023, source:SeekingAlpha, summary: Bristol-Myers Squibb's primary focus is developing and commercializing innovative products in various therapeutic areas. Click here to read why BMY stock is a Buy., Headline: Amgen: Re-Rating Seems Fair, source:SeekingAlpha, summary: Amgen has seen a near 15% pullback since the Horizon acquisition was announced in December. See why I am still a bit cautious on AMGN stock., Headline: Possible bearish signals as Amgen Inc. (NASDAQ:AMGN) insiders disposed of US$5.2m worth of stock, source:Yahoo, summary: In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have..., Headline: 25 Most Profitable NASDAQ Stocks Today, source:Yahoo, summary: In this article, we will look at the 25 most profitable NASDAQ stocks today. If you want to explore similar stocks, you can also take a look at 10 Most Profitable NASDAQ Stocks Today. 2022 was one of the worst years for the NASDAQ, primarily because it is dominated by tech, and tech stocks crashed as […]",AMGN
139,2023-02-21,"Headline: Top 5 4th Quarter Trades of BERKSHIRE ASSET MANAGEMENT LLC/PA, source:GuruFocus, summary: No summary, Headline: Top 5 4th Quarter Trades of Palouse Capital Management, Inc., source:GuruFocus, summary: No summary, Headline: Unusual Options Activity: BABA, INTC, F and 7 Others, source:Fintel, summary: nan, Headline: Bristol Myers: Looking Good For 2023, source:SeekingAlpha, summary: Bristol Myers has seen a recent pullback in its share price, just like many other big pharma names. Check out why I'm bullish on BMY stock., Headline: Mizuho Securities Remains a Hold on Amgen (AMGN), source:TipRanks, summary: No summary, Headline: Amgen Inc. stock falls Tuesday, still outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slipped 0.95% to $238.24 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...",AMGN
140,2023-02-22,"Headline: Interesting AMGN Put And Call Options For October 20th, source:Stock Options Channel, summary: No summary, Headline: This Recession-Proof Company Has a Best-in-Class Dividend, source:Yahoo, summary: Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group., Headline: AMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced the African American Heart Study, in collaboration with the Association of Black Cardiologists (ABC) and the Morehouse School of Medicine (MSM), which will measure the association between Lipoprotein(a), or Lp(a), and atherosclerotic cardiovascular disease (ASCVD) in 5,000 African American individuals across the United States. ASCVD is defined as the buildup of cholesterol plaque in arteries and includes events such as heart attack and stroke., Headline: Amgen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slumped 0.87% to $236.16 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: 12 Most Profitable Pharmaceutical Stocks Now, source:Yahoo, summary: In this piece, we will take a look at 12 most profitable pharmaceutical stocks now. For more stocks, head on over to 5 Most Profitable Pharmaceutical Stocks Now. The pharmaceutical industry was the center of attention in 2020 and 2021 after the deadly coronavirus pandemic ravaged the globe and disrupted the way of living. As […], Headline: Nicholas Ward`s Dividend Growth Portfolio: January 2023 Review, source:Seeking Alpha, summary: No summary, Headline: Nicholas Ward's Dividend Growth Portfolio: January 2023 Review, source:SeekingAlpha, summary: My dividend income rose by 9.56% on a y/y basis during January. My portfolio's value rose by approximately 6.9%. Here's a review of my portfolio for January 2023.",AMGN
141,2023-02-23,"Headline: Top dividend stocks picked using a UBS machine-learning model, source:Seeking Alpha, summary: No summary, Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.62% higher to $237.62 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: Catalyst watch: Tesla event, Microsoft talks OpenAI, Rivian earnings and Chevron, source:Seeking Alpha, summary: No summary",AMGN
142,2023-02-24,"Headline: Amgen Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slipped 1.67% to $233.66 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Pharmas, medtechs dominate list of innovation leaders thanks to patents, source:Seeking Alpha, summary: No summary",AMGN
143,2023-02-25,"Headline: Regeneron: Innovation And Disruption Done Right, source:SeekingAlpha, summary: Regeneron Pharmaceuticals' collaborative energy is strong and the medium-term looks good. Check out why we rate REGN stock a Hold for now.",AMGN
144,2023-02-26,"Headline: M&A activity in the Americas cooled in 2022 amid ongoing macro uncertainty, source:Seeking Alpha, summary: No summary, Headline: Amgen Inc. (NASDAQ:AMGN) Shares Could Be 37% Below Their Intrinsic Value Estimate, source:Yahoo, summary: Key Insights The projected fair value for Amgen is US$371 based on 2 Stage Free Cash Flow to Equity Current share price...",AMGN
145,2023-02-27,"Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.34% higher to $234.45 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: Top 10 Drug Companies in USA and Their China Reliance, source:Yahoo, summary: In this article, we will be taking a look at the top 10 drug companies in USA and their China reliance. To skip our detailed analysis of the pharmaceutical sector, you can go directly to see the Top 5 Drug Companies in USA and Their China Reliance. The US has long been reliant on China […], Headline: The 20 worst U.S. stocks in February: the biggest loser dropped 35%, source:MarketWatch, summary: No summary",AMGN
146,2023-02-28,"Headline: Stocks most and least liked by hedge funds and mutual funds -  Goldman, source:Seeking Alpha, summary: No summary, Headline: Royalty Pharma: Strong Q4 Results, Reiterating A Buy Rating, source:SeekingAlpha, summary: Royalty Pharma recently reported positive FY 2022 earnings. We like its focus on Lpa class. Read to know why we maintain a buy rating on RPRX stock., Headline: Horizon Therapeutics: Attractive 5.4% Upside To Amgen Offer, source:SeekingAlpha, summary: Horizon Therapeutics is a $25 billion biotech that's being acquired by Amgen Inc. Click for my review of the HZNP deal prospects., Headline: Amgen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. slid 1.19% to $231.66 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index..., Headline: Tracking John Paulson`s Paulson & Company Portfolio - Q4 2022 Update, source:Seeking Alpha, summary: No summary, Headline: Tracking John Paulson's Paulson & Company Portfolio - Q4 2022 Update, source:SeekingAlpha, summary: John Paulsonâs 13F portfolio value decreased from $1.37B to $1.11B this quarter. Read more about Paulson & Company's holdings and trades for Q4 2022.",AMGN
147,2023-03-01,"Headline: Horizon Therapeutics reports Q4  EPS $1.21, consensus  $1.09, source:Thefly.com, summary: No summary, Headline: Amgen to present new Repatha combined data from  Phase 3 FOURIER trials, source:Thefly.com, summary: No summary, Headline: My $394k Portfolio Outperforms The Market Again In A Dreary February, source:SeekingAlpha, summary: My portfolio, built specifically for my retirement ~20+ years from now, features growth, dividends, and risk stocks for a happy retirement. Click to read more., Headline: 3 Value Stocks You'll Regret Not Buying on the Dip, source:Yahoo, summary: Value stocks are poised for a strong decade.  The simple reason is that the Federal Reserve is highly unlikely to spur another growth stock boom by lowering interest rates to the effective floor in the years ahead.  Which value stocks are best positioned to capitalize on this favorable long-term dynamic?, Headline: AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC, source:Yahoo, summary: Amgen (NASDAQ: AMGN) today announced new Repatha® (evolocumab) combined data from the Phase 3 FOURIER and FOURIER Open Label Extension (OLE) studies and the Phase 2 OCEAN(a)-DOSE study of investigational olpasiran, an siRNA that reduces lipoprotein(a) [Lp(a)] by more than 90%. Additional data from Amgen's Center for Observational Research and Amgen funded investigator studies, including YELLOW-III from Mount Sinai will be presented at the American College of Cardiology's 72nd Annual Scientific S, Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. rallied 1.96% to $236.19 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Barclays Sticks to Its Sell Rating for Amgen (AMGN), source:TipRanks, summary: No summary",AMGN
148,2023-03-02,"Headline: Amgen Inc. 2022 Q4 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Amgen Inc., Headline: With 78% institutional ownership, Amgen Inc. (NASDAQ:AMGN) is a favorite amongst the big guns, source:Yahoo, summary: Key Insights Institutions' substantial holdings in Amgen implies that they have significant influence over the..., Headline: Why Is Amgen (AMGN) Down 4.2% Since Last Earnings Report?, source:Yahoo, summary: Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: Amgen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slumped 0.61% to $234.74 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed the most recent trading day at $234.74, moving -0.61% from the previous trading session., Headline: March`s 17 Ideal 2023 Barrons/Bloomberg Dividend Dogs, source:Seeking Alpha, summary: No summary, Headline: Tracking George Soros's Portfolio - Q4 2022 Update, source:SeekingAlpha, summary: George Soros' 13F portfolio value increased from $5.86B to $7.26B this quarter. Click here to read the Q4 2022 Update on Soros Fund Management's portfolio., Headline: March's 17 Ideal 2023 Barrons/Bloomberg Dividend Dogs, source:SeekingAlpha, summary: Ten top 2023 Bar/BI-projected dividend yields ranged from 4.78% to 7.94%. Click here for a detailed analysis.",AMGN
149,2023-03-03,"Headline: Analysts` Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN) and Dexcom (DXCM), source:TipRanks, summary: No summary, Headline: Could This Humira Biosimilar Be a Winner for Amgen?, source:Yahoo, summary: At the end of January, Amgen (NASDAQ: AMGN) celebrated the U.S. launch of its biosimilar Amjevita to AbbVie's (NYSE: ABBV) star immunology drug called Humira.  Amgen's Amjevita received approval from the U.S. Food and Drug Administration (FDA) as a biosimilar in 2016., Headline: 7 Over-$100 Stocks That Are Worth Every Penny, source:Yahoo, summary: If searching out over-$100 stocks to buy seems arbitrary, take a step back and consider this. It’s great to have a mix of stocks in your portfolio. There are all sorts of sizes and flavors of stocks from which to choose, including mega-cap stocks and even small-cap stocks. So it’s understandable that when you’re looking for stocks to buy, you may sometimes miss some obvious well-priced choices that are right in front of you. Some of the best names out there fall into the category of over-$100 st, Headline: Tracking George Soros`s Portfolio - Q4 2022 Update, source:Seeking Alpha, summary: No summary, Headline: 12 Most Profitable Biotech Stocks Today, source:Yahoo, summary: In this article, we will discuss the 12 Most Profitable Biotech Stocks Today. You can skip our industry overview and go directly to the 5 Most Profitable Biotech Stocks Today. The term “biotechnology” refers to the utilization of living organisms or biological systems to create solutions that address various agricultural, industrial, and health-related problems. The most […], Headline: U.S. companies embark on record borrowing spree, despite paying highest rates since 2009, source:MarketWatch, summary: Higher interest rates aren't deterring companies with high credit ratings from borrowing in the U.S. corporate bond market at a record clip in 2023., Headline: Amgen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.03% higher to $234.81 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: AMGEN TO PRESENT AT THE 43RD ANNUAL TD COWEN HEALTHCARE CONFERENCE, source:Yahoo, summary: Amgen (NASDAQ:AMGN) will present at the 2023 TD Cowen Healthcare Conference at 11:10 a.m. ET on Wednesday, March 8, 2023. Murdo Gordon, executive vice president of Global Commercial Operations and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public., Headline: My Dividend Growth Portfolio February Update: Cash Is Not Trash, source:SeekingAlpha, summary: Cash is yielding over 4%, so a dividend growth investor can afford to be patient. Click here to read the February Update on my dividend growth portfolio.",AMGN
150,2023-03-04,"Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of March 5, source:SeekingAlpha, summary: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the companies with upcoming ex-dividend dates.",AMGN
151,2023-03-05,"Headline: Spectrum`s Rolvedon: An Undifferentiated, Small Player In A Vast Market, source:Seeking Alpha, summary: No summary, Headline: Cantor biopharma/biotech analysts to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Spectrum's Rolvedon: An Undifferentiated, Small Player In A Vast Market, source:SeekingAlpha, summary: Spectrum Pharmaceuticals develops and commercializes cancer therapies, including Rolvedon. Read more to see why SPPI stock is a Sell.",AMGN
152,2023-03-06,"Headline: Merck to start phase 3 of oral PCSK9 inhibitor for cholesterol following mid-stage results, source:Seeking Alpha, summary: No summary, Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.13% higher to $235.11 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: Merck's drug boosts exercise capacity in pulmonary hypertension patients, source:Yahoo, summary: Merck & Co Inc said on Monday its experimental therapy, sotatercept, helped increase exercise capacity in patients with a deadly disease that causes high pressure in blood vessels of the heart and lungs in a late-stage study.  A second experimental heart drug, MK-0616, helped reduce levels of low-density lipoprotein (LDL) cholesterol by between 41.2% at a low 6 mg dose to 60.9% at a higher 30 mg dose in a mid-stage study, the drugmaker said.  Sotatercept, which Merck gained through its $11.5 billion buyout of Acceleron Pharma, combined with background therapy helped extend the distance that patients with pulmonary arterial hypertension could walk in six minutes by 40.8 meters., Headline: Amgen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: No summary",AMGN
153,2023-03-07,"Headline: Biden to announce plan to keep Medicare solvent beyond 2050, source:Seeking Alpha, summary: No summary, Headline: Amgen declares $2.13 dividend, source:Seeking Alpha, summary: No summary, Headline: High Yield Stock Watchlist: March 2023, source:SeekingAlpha, summary: There are 17 stocks on my high-yield watchlist for March 2023. Read why the stocks on my watchlist are undervalued based on dividend yield theory., Headline: AMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the second quarter of 2023. The dividend will be paid on June 8, 2023, to all stockholders of record as of the close of business on May 18, 2023., Headline: Noteworthy Wednesday Option Activity: AMGN, MET, LLY, source:Stock Options Channel, summary: No summary, Headline: Amgen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: No summary",AMGN
154,2023-03-08,"Headline: 2 March Dogs Of The Dow To Buy, 4 More To Watch, source:SeekingAlpha, summary: The highest-yield 10 are Marchâs Dogs of the Dow: JNJ, KO, CSCO, AMGN, CVX, DOW, IBM, WBA, MMM, and VZ, averaging a 4.41% annual yield., Headline: A Bull Market Is Coming: 3 Stocks Near Their 52-Week Lows to Buy Now, source:Yahoo, summary: The stock market is struggling, but investors shouldn't bet against it in the long run.  Investing in stocks that are underperforming and that are good long-term investments, before a bull market arrives, can be a way to set yourself up for some great gains down the road.  Three stocks that are trading near 52-week lows that long-term investors should be eyeing right now are Amgen (NASDAQ: AMGN), Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), and Southern Company (NYSE: SO)., Headline: Video: Daily Dividend Report: AMGN,JCI,AMOT,ZBH,FLXS, source:Market News Video, summary: No summary, Headline: Amgen (NASDAQ:AMGN) Has A Pretty Healthy Balance Sheet, source:Yahoo, summary: David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the..., Headline: Amgen Inc. (AMGN) Presents at 43rd Annual TD Cowen Healthcare Conference (Transcript), source:SeekingAlpha, summary: Amgen Inc. (NASDAQ:NASDAQ:AMGN) 43rd Annual TD Cowen Healthcare Conference March 8, 2023 11:10 AM ETCompany ParticipantsPeter Griffith - Executive Vice President and Chief Financial..., Headline: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed the most recent trading day at $228.43, moving -0.13% from the previous trading session., Headline: Amgen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: No summary",AMGN
155,2023-03-09,"Headline: Amgen (AMGN) Declares $2.13 Dividend, source:Fintel, summary: nan, Headline: Cantor biopharma/biotech analysts to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: New Drugs Are Coming to Market at Sky-High Prices, source:Yahoo, summary: A new  Amgen  lung-cancer treatment, Lumakras, carried a hefty price tag when it came out in 2021: $17,900 per patient monthly.  Just over a year later, in December 2022, a second drug for the same type of cancer, Krazati from  Mirati Therapeutics  had an even higher price: $19,750 a month—a 10% premium.  As drugmakers face rising pressure to rein in repeat or annual price hikes on existing drugs, new brand-name medicines are coming to market with ever-higher price tags on day one., Headline: Replimune: A Sell Ahead Of Cutaneous Squamous Cell Carcinoma Data, source:SeekingAlpha, summary: Replimune's RP1 results are promising, but caution is warranted due to the limitations of the study. Learn why REPL stock is a 'Sell' & 'Short.', Headline: New Drugs for Cancer, Rare Disease Can Now Cost More Than $20,000 a Month, source:Yahoo, summary: As drugmakers face pressure to rein in price hikes on existing drugs, new medicines arrive with ever-higher prices on day one, contributing to rising costs for patients and stretched budgets for insurers., Headline: AMGEN TO PRESENT AT THE 33rd ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE, source:Yahoo, summary: Amgen (NASDAQ:AMGN) will present at the 2023 Oppenheimer Healthcare Conference at 2:00 p.m. ET on Monday, March 13, 2023. Susan Sweeney, senior vice president, Global Marketing, Access and Capabilities at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public., Headline: Mizuho Securities Sticks to Its Hold Rating for Amgen (AMGN), source:TipRanks, summary: No summary",AMGN
156,2023-03-10,"Headline: Assuming No-Growth, Gilead Is The Safest Choice Among The Large Biotechs, source:SeekingAlpha, summary: Gilead has a strong credit profile and a low cost of equity. Find out why for an investor seeking relative safety, GILD stock is worth a look., Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.92% higher to $227.87 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",AMGN
157,2023-03-11,"Headline: The Near-Perfect Portfolio: Sleep Well During Turbulent Times, source:SeekingAlpha, summary: With the economy going through the boom and bust cycles more frequently, the extreme ups and downs of the market are inevitable. Read more here., Headline: Amgen's (NASDAQ:AMGN) Shareholders Will Receive A Bigger Dividend Than Last Year, source:Yahoo, summary: Amgen Inc. ( NASDAQ:AMGN ) has announced that it will be increasing its dividend from last year's comparable payment on...",AMGN
158,2023-03-13,"Headline: Amgen upgraded to Overweight from Equal Weight at Wells Fargo, source:Thefly.com, summary: No summary, Headline: Wells Fargo upgrades Amgen to Overweight, lowers target to $265, source:Thefly.com, summary: No summary, Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: Amgen, Procter & Gamble share gains lead the way, but Dow flat, source:MarketWatch, summary: The Dow Jones Industrial Average is flat Monday morning with shares of Amgen and Procter & Gamble seeing positive momentum for the price-weighted average...., Headline: Amgen, Procter & Gamble share gains lead Dow`s 90-point climb, source:MarketWatch, summary: No summary, Headline: Amgen, Procter & Gamble share gains lead Dow's 90-point climb, source:MarketWatch, summary: Shares of Amgen and Procter & Gamble are trading higher Monday morning, sending the Dow Jones Industrial Average into positive territory. The Dow is trading..., Headline: Amgen upgraded at Wells Fargo citing a post-Horizon deal opportunity, source:Seeking Alpha, summary: No summary, Headline: Amgen facing class action suit over owing more than $10B in back taxes and penalties, source:Seeking Alpha, summary: No summary, Headline: Dow jumps nearly 200 points on gains for Amgen, Microsoft stocks, source:MarketWatch, summary: Behind positive momentum for shares of Amgen and Microsoft, the Dow Jones Industrial Average is up Monday morning. The Dow was most recently trading 197..., Headline: Amgen, Microsoft share gains contribute to Dow`s nearly 100-point climb, source:MarketWatch, summary: No summary, Headline: Amgen, Microsoft share gains contribute to Dow's nearly 100-point climb, source:MarketWatch, summary: The Dow Jones Industrial Average is up Monday afternoon with shares of Amgen and Microsoft seeing positive momentum for the price-weighted average. Shares of..., Headline: Microsoft, Amgen share gains lead the way, but Dow flat, source:MarketWatch, summary: The Dow Jones Industrial Average is flat Monday afternoon with shares of Microsoft and Amgen seeing positive growth for the price-weighted average. The Dow..., Headline: Amgen Inc. (AMGN) Oppenheimer 33rd Annual Healthcare Conference (Transcript), source:SeekingAlpha, summary: Amgen Inc. (NASDAQ:NASDAQ:AMGN) Oppenheimer 33rd Annual Healthcare Conference March 13, 2023 2:00 PM ETCompany ParticipantsArvind Sood - Vice President, Investor RelationsSusan Sweeney -..., Headline: 15 Biggest Retirement Mistakes You Will Regret Forever, source:Yahoo, summary: In this article, we take a look at the 15 biggest retirement mistakes you will regret forever. For more such retirement mistakes, go to 5 Biggest Retirement Mistakes You Will Regret Forever. Retirement is an inevitable stage in every individual’s life. After working for several years, people eventually reach a point where they want to […], Headline: Wells Fargo Upgrades Amgen (AMGN), source:Fintel, summary: nan",AMGN
159,2023-03-14,"Headline: Wall Street Breakfast Podcast: Report: Another Auction Of SVB, source:SeekingAlpha, summary: FDIC is reportedly planning another auction of Silicon Valley Bank. Credit Suisse discloses 'material weakness' in reporting procedures. CPI watch: All eyes on inflation data., Headline: Video: Dow Movers: AMGN, CRM, source:Market News Video, summary: No summary, Headline: 2 Stocks to Buy Near Their 52-Week Lows That Could Help You Beat The Market, source:Yahoo, summary: Digging deeper, though, reveals that Amgen and Match Group both have excellent prospects.  Amgen has been dealing with declining sales of some of its key products, causing the company's revenue to grow, if at all, at a pretty modest pace., Headline: Amgen is sued for concealing $10.7 billion tax bill from investors, source:Reuters, summary: Amgen Inc has been sued in a proposed class action accusing the drugmaker of waiting too long to tell investors it might owe the Internal Revenue Service $10.7 billion in taxes and penalties., Headline: Amgen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. shed 1.12% to $230.58 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index..., Headline: Amgen Faces Lawsuit For Hiding Its Stupendous Tax Bill Of $10B, source:Yahoo, summary: In a complaint filed in Manhattan federal court, a Detroit-based pension fund said Amgen Inc (NASDAQ: AMGN) concealed the dispute over its international tax strategy between July 2020 and April 2022 and had its investors wait for too long on disclosing taxes and penalties bill of $10.7 billion. The Internal Revenue Service (IRS) accused Amgen of underreporting taxes from 2010 to 2015 by inappropriately attributing its U.S. profits to a Puerto Rico subsidiary. Though Puerto Rico is a U.S. territo, Headline: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed at $230.58 in the latest trading session, marking a -1.12% move from the prior day., Headline: 25 Biggest Pharmaceutical Companies in the World, source:Yahoo, summary: In this article, we will be taking a look at the 25 biggest pharmaceutical companies in the world. To skip our detailed analysis, you can go directly to see the 10 biggest pharmaceutical companies in the world. There is no need to emphasize the value of the pharmaceutical industry after the Covid-19 pandemic. Without the […]",AMGN
160,2023-03-15,"Headline: 2 Top Biotech Stocks to Buy Right Now, source:Yahoo, summary: A high dividend yield and powerful growth prospects are a rare combination for any single stock to offer.  On one hand, a high yield often comes with the trade-off of an elevated dividend payout ratio and lower resulting growth potential.  On the other hand, a company with adequate growth opportunities will generally have a lower payout ratio to retain the capital needed for growth., Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. advanced 1.87% to $234.90 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: Amgen (AMGN) Gains As Market Dips: What You Should Know, source:Yahoo, summary: In the latest trading session, Amgen (AMGN) closed at $234.90, marking a +1.87% move from the previous day.",AMGN
161,2023-03-16,"Headline: PBE: Healthcare Dashboard For March, source:SeekingAlpha, summary: Healthcare equipment is the less attractive subsector regarding both valuation and quality. Click here to find out why PBE is a Hold., Headline: Visa, Merck share losses lead Dow`s nearly 250-point drop, source:MarketWatch, summary: No summary, Headline: Is It Time to Buy the Dow Jones' 3 Worst-Performing February (and Now March) Stocks?, source:Yahoo, summary: If you're a fan of buying beaten-up blue chip stocks, there's certainly no shortage of them now.  The Dow Jones Industrial Average (DJINDICES: ^DJI) is down nearly 8% from last month's high -- a sell-off that actually got going in mid-February.  Roughly half of the Dow's components are doing worse than the average -- and that can pose a tricky temptation for investors., Headline: Buy And Hold Coffee Can Portfolio For The Next 15 Years, source:SeekingAlpha, summary: This article covers topics from Christopher Mayer's book , Headline: Amgen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. shed 0.14% to $234.57 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index..., Headline: BRIEF-Amgen Announces Workforce Reduction By About 450 Jobs, source:Reuters, summary: * AMGEN - ANNOUNCED CHANGES THAT WILL RESULT IN A REDUCTION OF OUR WORKFORCE BY APPROXIMATELY 450 JOBS, REPRESENTING LESS THAN 2% OF OUR TOTAL WORKFORCE, Headline: UPDATE 2-Amgen to cut 450 jobs in second round of layoffs this year, source:Yahoo, summary: Amgen Inc said on Thursday it would cut 450 jobs, or less than 2% of its workforce, making it the company's second round of layoffs this year amid intensifying pressure on drug prices and high inflation.  ""We made these changes to realign our expense base in the face of intensifying pressure on drug prices and high levels of inflation,"" a company spokeswoman said in a statement to Reuters.  The company had about 25,200 staff members in more than 50 countries as of Dec. 31, 2022, according to its latest annual regulatory filing with the U.S. Securities and Exchange Commission., Headline: Amgen to cut 450 jobs in second round of layoffs this year, source:Yahoo, summary: ""We made these changes to realign our expense base in the face of intensifying pressure on drug prices and high levels of inflation,"" a company spokeswoman said in a statement to Reuters.  The company had about 25,200 staff members in more than 50 countries as of Dec. 31, 2022, according to its latest annual regulatory filing with the U.S. Securities and Exchange Commission.  Amgen's decision to downsize its workforce underscores the impact of rapidly increasing interest rates on the healthcare industry., Headline: Amgen to cut about 450 jobs in second round of layoffs this year, source:Yahoo, summary: Amgen Inc. on Thursday said it would lay off about 450 employees, or less than 2% of its workforce, as it faces increasing pressure from drug prices and high inflation., Headline: Amgen (NASDAQ:AMGN) to Slash More Jobs in Second Round of Layoffs, source:TipRanks, summary: No summary, Headline: More U.S. companies layoffs as Amgen deepens job cuts amid pressure on drug prices and inflations woes, source:Seeking Alpha, summary: No summary",AMGN
162,2023-03-17,"Headline: More U.S. companies layoff as Amgen deepens job cuts amid pressure on drug prices and inflation woes, source:Seeking Alpha, summary: No summary, Headline: Analysts Conflicted on These Healthcare Names: Amgen (AMGN) and Acurx Pharmaceuticals (ACXP), source:TipRanks, summary: No summary, Headline: Amgen Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slipped 2.04% to $229.79 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...",AMGN
163,2023-03-19,"Headline: The Tao Of The Dow, Simple Self-Indexing Strategy, source:Seeking Alpha, summary: No summary, Headline: Mirati`s Krazati: A Strong Competitor In The KRAS G12C-Mutated NSCLC Market, source:Seeking Alpha, summary: No summary, Headline: Mirati's Krazati: A Strong Competitor In The KRAS G12C-Mutated NSCLC Market, source:SeekingAlpha, summary: Mirati Therapeutics's Krazati could capture a significant share of the 2L KRAS G12C-mutated NSCLC market. Click here to read why MRTX stock is a Buy.",AMGN
164,2023-03-20,"Headline: 3 Dow Stocks Near 52-Week Lows That Look Like Bargains Now, source:Yahoo, summary: The past 15 months have been disastrous for the major stock market indexes, but one has fared better than its peers.  The Dow Jones Industrial Average has fallen around 12% since the end of 2021.  While traditionally filled with industrial and financial stocks, there aren't any specific rules that determine which companies become one of the Dow's 30 components., Headline: 3 Dow Jones Stocks To Watch Today, source:StockMarket, summary: Here are three Dow Jones stocks to keep on watch in the stock market now., Headline: Amgen Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. rose 2.15% to $234.72 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index..., Headline: Top Analyst Reports for Alphabet, Tesla & Amgen, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Tesla, Inc. (TSLA) and Amgen Inc. (AMGN)., Headline: Amgen Announces More Layoffs - Why I`d Buy This Dip, source:Seeking Alpha, summary: No summary, Headline: Altimmune leads obesity drug developers lower after data for lead asset, source:Seeking Alpha, summary: No summary",AMGN
165,2023-03-21,"Headline: Nvidia unveils language models, generative AI service to help Life Sciences R&D, source:Thefly.com, summary: No summary, Headline: The Zacks Analyst Blog Highlights Alphabet, Tesla, Amgen, FedEx and Capital One Financial, source:Yahoo, summary: Alphabet, Tesla, Amgen, FedEx and Capital One Financial are part of the Zacks top Analyst Blog., Headline: Amgen Announces More Layoffs - Why I'd Buy This Dip, source:SeekingAlpha, summary: Amgen expects to lay off 3% of its entire workforce before 1H 2023 - around 750 staff. Read why, despite the dour news, AMGN stock may be a buy at current levels., Headline: Horizon Therapeutics: Attractive 7.16% Upside To Amgen Deal, source:SeekingAlpha, summary: Horizon Therapeutics Public Limited Company is a $25 billion biotech Amgen Inc. is acquiring. Click here to read our view of the HZNP-AMGN deal., Headline: Amgen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slumped 0.75% to $232.95 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Amgen (AMGN) closed at $232.95, marking a -0.75% move from the previous day.",AMGN
166,2023-03-22,"Headline: Here's What is Driving Amgen (AMGN) Stock's Outperformance, source:Yahoo, summary: Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. It is also rapidly advancing its robust pipeline., Headline: Those who invested in Amgen (NASDAQ:AMGN) five years ago are up 59%, source:Yahoo, summary: While Amgen Inc. ( NASDAQ:AMGN ) shareholders are probably generally happy, the stock hasn't had particularly good run..., Headline: Amgen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. slipped 1.34% to $229.83 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Amgen (AMGN) Stock Moves -1.34%: What You Should Know, source:Yahoo, summary: In the latest trading session, Amgen (AMGN) closed at $229.83, marking a -1.34% move from the previous day.",AMGN
167,2023-03-23,"Headline: Interesting AMGN Put And Call Options For May 5th, source:Stock Options Channel, summary: No summary, Headline: See How Amgen Ranks Among Analysts` Top Dow 30 Picks, source:ETF Channel, summary: No summary, Headline: Video: Dow Analyst Moves: AMGN, source:Market News Video, summary: No summary, Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. advanced 1.42% to $233.10 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: Amgen, Procter & Gamble share gains contribute to Dow`s 100-point jump, source:MarketWatch, summary: No summary",AMGN
168,2023-03-24,"Headline: Amgen: Questioning The Horizon Therapeutics Acquisition, source:Seeking Alpha, summary: No summary, Headline: Amgen: Revenue Growth Potentials And Financial Performance, source:Seeking Alpha, summary: No summary, Headline: Mizuho Securities Keeps Their Hold Rating on Amgen (AMGN), source:TipRanks, summary: No summary, Headline: FDA draft guidance impacts companies using accelerated approval for oncology drugs, source:Seeking Alpha, summary: No summary, Headline: Amgen, Procter & Gamble share gains lead the way, but Dow flat, source:MarketWatch, summary: Shares of Amgen and Procter & Gamble are seeing positive growth Friday afternoon, though the Dow Jones Industrial Average remains roughly flat. The Dow is..., Headline: Amgen, Procter & Gamble share gains contribute to Dow's 100-point jump, source:MarketWatch, summary: Powered by strong returns for shares of Amgen and Procter & Gamble, the Dow Jones Industrial Average is climbing Friday afternoon. Shares of Amgen and..., Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. rose 2.11% to $238.03 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index..., Headline: Final Trades: AMGN, FHN, MLPX & WMT, source:CNBC, summary: The final trades of the week. With CNBC's Melissa Lee and the Fast Money traders, Steve Grasso, Courtney Garcia, Tim Seymour and Guy Adami.",AMGN
169,2023-03-27,"Headline: Amgen bid to revive cholesterol drug patents comes to U.S. Supreme Court, source:Yahoo, summary: The U.S. Supreme Court on Monday is set to hear a bid by Amgen Inc to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a ""blatant attempt"" to squeeze competitors out of the market.  Amgen is appealing a lower court's ruling that invalidated two of its patents on Repatha, a drug that can reduce risk of heart attack and stroke in people with heart disease, after a legal fight with French drugmaker Sanofi and its partner Regeneron Pharmaceuticals Inc., Headline: Supreme Court hears arguments in Amgen Repatha patent case against Sanofi, source:Seeking Alpha, summary: No summary, Headline: UPDATE 1-U.S. Supreme Court hears Amgen bid to revive cholesterol drug patents, source:Yahoo, summary: The U.S. Supreme Court on Monday began hearing a bid by Amgen Inc to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a ""blatant attempt"" to squeeze competitors out of the market.  Amgen is appealing a lower court's ruling that invalidated two of its patents on Repatha, a drug that can reduce risk of heart attack and stroke in people with heart disease, after a legal fight with French drugmaker Sanofi and its partner Regeneron Pharmaceuticals Inc., Headline: U.S. Supreme Court mulls Amgen bid to revive cholesterol drug patents, source:Reuters, summary: U.S. Supreme Court justices on Monday weighed a bid by Amgen Inc to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a ""blatant attempt"" to squeeze competitors out of the market., Headline: Amgen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. shed 0.53% to $236.76 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index..., Headline: Amgen-Sanofi patent case divides makers of antibody drugs, source:Reuters, summary: Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines.",AMGN
170,2023-03-28,"Headline: Amgen (AMGN) Receives a Hold from SVB Securities, source:TipRanks, summary: No summary, Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.73% higher to $238.48 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: Amgen (AMGN) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed at $238.48 in the latest trading session, marking a +0.73% move from the prior day., Headline: Viridian Therapeutics initiated with a Buy at Stifel, source:Thefly.com, summary: No summary",AMGN
171,2023-03-29,"Headline: Amgen, AstraZeneca`s asthma therapy Tezspire gets UK`s NICE backing, source:Seeking Alpha, summary: No summary, Headline: WHO to weigh adding obesity therapies to `essential` medicines list ��� Reuters, source:Seeking Alpha, summary: No summary, Headline: Selling US$5.2m worth of stock earlier this year was a lucrative decision for Amgen Inc. (NASDAQ:AMGN) insiders, source:Yahoo, summary: Even though Amgen Inc. ( NASDAQ:AMGN ) stock gained 3.8% last week, insiders who sold US$5.2m worth of stock over the..., Headline: Amgen Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. rallied 1.07% to $241.03 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",AMGN
172,2023-03-30,"Headline: This Blue Chip Dividend Stock Should Return to Form When the Risk Premium Flips, source:Yahoo, summary: T-bills may be the flavor of the month, but history has shown this top biotech stock is a far better long-term investment., Headline: Why Investors Need to Take Advantage of These 2 Medical Stocks Now, source:Yahoo, summary: Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP., Headline: Amgen Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.19% higher to $241.50 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",AMGN
173,2023-03-31,"Headline: Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Eledon Pharmaceuticals (ELDN), source:TipRanks, summary: No summary, Headline: 1 Dividend Growth Stock to Buy Hand Over Fist, source:Yahoo, summary: Investing in dividend stocks, particularly those that raise their payouts regularly, can pay off massively in time., Headline: My Top 10 High Dividend Yield Stocks To Invest In April 2023, source:SeekingAlpha, summary: In todayâs article, I will present you with my top 10 high Dividend Yield stocks to invest in for April 2023. Read more here., Headline: Amgen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.10% higher to $241.75 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: Amgen (AMGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed the most recent trading day at $241.75, moving +0.1% from the previous trading session.",AMGN
174,2023-04-02,"Headline: Seagen/Pfizer deal spread becoming increasingly attractive, analyst says, source:Seeking Alpha, summary: No summary",AMGN
175,2023-04-03,"Headline: A March ~6% Gain In My 25 Stock $417k Portfolio Beats The Market For The Third Time In 2023, source:SeekingAlpha, summary: My portfolio, built specifically for my retirement ~20 years from now, features growth, dividends, and risk stocks for a happy retirement. Click here for a detailed analysis., Headline: 3 Dow Stocks With Above-Average Dividends Yields to Buy in April, source:Yahoo, summary: Income-seeking investors are going to love the annual payout raises and yields of 2.9% or better that these legendary dividend payers offer right now., Headline: High Yield Stock Watchlist: April 2023, source:SeekingAlpha, summary: Click to see 19 stocks on my high-yield watchlist for April 2023. The majority of the stocks on my watchlist are undervalued based on dividend yield theory., Headline: Amgen Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. rallied 1.11% to $244.44 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Dogs Of The Dow Stumble In First Quarter, source:SeekingAlpha, summary: The Dogs of the Dow strategy has the sole focus of investing in the highest dividend-yielding stocks in the Dow Jones Industrial Average Index.",AMGN
176,2023-04-04,"Headline: Analysts Are Bullish on These Healthcare Stocks: Amgen (AMGN), OncoCyte (OCX), source:TipRanks, summary: No summary, Headline: Why Investors Need to Take Advantage of These 2 Medical Stocks Now, source:Yahoo, summary: Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP., Headline: Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?, source:Yahoo, summary: Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report., Headline: Amgen Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. rallied 1.26% to $247.53 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index..., Headline: April Dogs Of The Dow: 2 Buy, 3 Watch, source:SeekingAlpha, summary: The highest-yield 10 stocks are Aprilâs Dogs of the Dow: CSCO, GS, JPM, AMGN, CVX, IBM, DOW, WBA, MMM, VZ, averaging a 4.44% annual yield. Click here for our lists., Headline: Tracking Baker Brothers Portfolio - Q4 2022 Update, source:SeekingAlpha, summary: Baker Brothersâ 13F portfolio value increased from $15.27B to $16.65B this quarter. Click here to see the Q4 2022 update on the portfolio.",AMGN
177,2023-04-05,"Headline: Early notable gainers among liquid option names on April 5th, source:Thefly.com, summary: No summary, Headline: Dow up nearly 100 points on gains for Johnson & Johnson, Amgen stocks, source:MarketWatch, summary: The Dow Jones Industrial Average is climbing Wednesday morning with shares of Johnson & Johnson and Amgen leading the way for the index. Shares of Johnson &..., Headline: Amgen's (NASDAQ:AMGN) Upcoming Dividend Will Be Larger Than Last Year's, source:Yahoo, summary: Amgen Inc. ( NASDAQ:AMGN ) has announced that it will be increasing its dividend from last year's comparable payment on..., Headline: InflaRx upgraded to Buy at Guggenheim after Gohibic gets COVID EUA, source:Thefly.com, summary: No summary, Headline: AMGN Makes Bullish Cross Above Critical Moving Average, source:Dividend Channel, summary: No summary, Headline: AbbVie downgraded to hold at Argus on Humira competition in US, source:Seeking Alpha, summary: No summary, Headline: 3 Must-Buy Dow Stocks for Your April Buy List, source:Yahoo, summary: The Dow is short for the Dow Jones Industrial Average, a stock index that tracks the largest highly-traded public companies. It is one of the most watched indicators of overall stock market direction and includes 30 of the largest publicly traded firms. Thus, Dow stocks tend to get their fair share of attention from investors, due to their size and importance to the economy. The Dow represents the most significant industrial components of the U.S. economy. Thus, this index is often viewed as a w, Headline: Amgen Inc. stock underperforms Wednesday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Amgen Inc. advanced 2.36% to $253.37 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",AMGN
178,2023-04-06,"Headline: 7 Very Undervalued Penny Stocks to Buy in April 2023, source:InvestorPlace, summary: No summary, Headline: Income Investors: These 2 Stocks Have Quadrupled Their Dividend Payouts Over the Past 10 Years, source:Yahoo, summary: While there are thousands of publicly traded companies available, not all are worth putting your hard-earned money into.  One of the more objective measures of quality in investing is a track record of outsized dividend growth.  Here are two dividend payers in the healthcare sector that have achieved huge payout growth in the past 10 years., Headline: Morgan Stanley cuts Comcast, adds Becton Dickinson to its model portfolio, source:Seeking Alpha, summary: No summary, Headline: FDA forces pre-term birth drug off the market after 12 years, source:Seeking Alpha, summary: No summary, Headline: Nicholas Ward`s Dividend Growth Portfolio: Special Fixed Income Edition, source:Seeking Alpha, summary: No summary, Headline: Amgen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. sank 0.02% to $253.32 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed at $253.35 in the latest trading session, marking a -0.01% move from the prior day., Headline: Nicholas Ward's Dividend Growth Portfolio: Special Fixed Income Edition, source:SeekingAlpha, summary: My passive income stream grew by 22.63% in February and by 46.87% in March. Read more as I review my February and March results in this piece., Headline: Catalyst Watch: Eyes on inflation data, big bank earnings, source:Seeking Alpha, summary: No summary",AMGN
179,2023-04-07,"Headline: Mizuho Securities Keeps Their Hold Rating on Amgen (AMGN), source:TipRanks, summary: No summary, Headline: Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Amgen (AMGN) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal, source:TalkMarkets, summary: No summary",AMGN
180,2023-04-09,"Headline: Love Dividends? These 3 Stocks Are Smart Buys Right Now, source:Yahoo, summary: Receiving cash payments every three months is one obvious attraction.  If you're looking for businesses that can make and raise dividend payments regardless of an uncooperative economic environment, it's hard to do better than the healthcare sector.  While you're most likely familiar with CVS Health's (NYSE: CVS) chain of retail pharmacies, most don't realize that retail is a small part of this company's overall business., Headline: Premier cancer research event, AACR is starting this week; Here is what to expect, source:Seeking Alpha, summary: No summary, Headline: Diving Into the Smead Value Fund`s Top Holdings as Value Conference Approaches, source:GuruFocus, summary: No summary",AMGN
181,2023-04-10,"Headline: Horizon posts positive Phase 4 data for thyroid eye disease therapy Tepezza, source:Seeking Alpha, summary: No summary, Headline: Amgen Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slumped 0.96% to $250.90 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: Barclays Keeps Their Sell Rating on Amgen (AMGN), source:TipRanks, summary: No summary",AMGN
182,2023-04-11,"Headline: Stable growth companies aren't priced in to this market: Goldman's David Kostin, source:CNBC, summary: David Kostin, Goldman Sachs Chief U.S. Equity Strategist, joins 'Squawk on the Street' to give his thoughts on the upcoming earnings season, where the surprises will be, and more., Headline: Amgen Inc. (NASDAQ:AMGN) is a favorite amongst institutional investors who own 78%, source:Yahoo, summary: Key Insights Given the large stake in the stock by institutions, Amgen's stock price might be vulnerable to their..., Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.21% higher to $251.43 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500..., Headline: DivHut Portfolio Update: March 2023, source:SeekingAlpha, summary: The system is clearly broken, and has been for a while; however, I could find comfort in one thing, my dividends. Four figures in a month is a win in my book., Headline: Why Healthcare Stocks Are A Prescription For Investors In Q2 2023, source:SeekingAlpha, summary: The recent drop in biopharma stocks presents a buying opportunity for investors. Find out why XLV seems like the best fit.",AMGN
183,2023-04-12,"Headline: Amgen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. shed 0.77% to $249.50 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Medical research has driven 'the last 200 years of economic expansion': Michael Milken, source:Yahoo, summary: Health investment and innovation has been on a roller coaster as a result of the pandemic. But the momentum needs to continue, according to Michael Milken.",AMGN
184,2023-04-13,"Headline: Editas Medicine appoints Reeve as Chair of Board, Levy as new director, source:Thefly.com, summary: No summary, Headline: How Horizon Therapeutics sold to Amgen for $27.8 billion without ever licensing a drug of its own, source:Yahoo, summary: Horizon grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices., Headline: Amgen Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.78% higher to $251.44 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: Amgen (AMGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed the most recent trading day at $251.44, moving +0.78% from the previous trading session., Headline: Amgen (AMGN) Receives a Sell from Barclays, source:TipRanks, summary: No summary",AMGN
185,2023-04-14,"Headline: Amgen price target lowered to $227 from $230 at Barclays, source:Thefly.com, summary: No summary, Headline: Ghana 1st in world to approve new malaria vaccine by Oxford, source:Seeking Alpha, summary: No summary, Headline: Amgen (AMGN) Receives a Hold from Mizuho Securities, source:TipRanks, summary: No summary, Headline: Horizon announces FDA label update for thyroid eye disease therapy, source:Seeking Alpha, summary: No summary, Headline: Amgen Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slid 0.57% to $250.00 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Barclays Maintains Amgen (AMGN) Underweight Recommendation, source:Fintel, summary: nan",AMGN
186,2023-04-16,"Headline: Better Buy For Retiring With Dividends: VYM Or SCHD?, source:SeekingAlpha, summary: VYM and SCHD provide an all-in-one solution by offering attractive and growing dividend income streams. Check out which is the better buy at the moment., Headline: Is Arrowhead Pharmaceuticals a Buy Now?, source:Yahoo, summary: The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts., Headline: 7 Dividend Stocks to Buy That Are Backed by Strong Cash Flows, source:Yahoo, summary: Many investors have heard the phrase “cash is king” relative to the current banking crisis. But it also has significance for dividend investors. A company’s cash flow, and particularly its free cash flow, is an important indicator for investors trying to determine how safe a dividend payout is. This article highlights seven dividend stocks with strong cash flows. And I’ve put an emphasis on free cash flow. Free cash flow is simply the money a company has left (or free to use) after it has paid o, Headline: Merck to Acquire Prometheus Biosciences, source:Yahoo, summary: Merck  & Co. said it agreed to acquire  Prometheus Biosciences  for $10.8 billion, a push into the lucrative market for immune-disease treatments.  Merck said Sunday it would acquire Prometheus at $200 a share, a roughly 75% premium to where shares closed on Friday, at $114.01.  The Wall Street Journal reported earlier Sunday that Merck was in late-stage talks with Prometheus for an acquisition.",AMGN
187,2023-04-17,"Headline: Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development, source:PR Newswire, summary: No summary, Headline: Amgen Has Long-Term Staying Power, source:SeekingAlpha, summary: nan, Headline: 15 Cheapest Countries for Retirement, source:Yahoo, summary: In this article, we will explore the 15 cheapest countries for retirement. You can skip our detailed analysis and go directly to 5 Cheapest Countries for Retirement. The Costs of Living in Retirement On average, a comfortable retirement in the USA costs an estimated $1 million. With Americans spending $50,220 annually post-retirement, 25% have already […], Headline: Johnson & Johnson: 4 Key Areas Of Focus Ahead Of Q1 Earnings, source:SeekingAlpha, summary: nan, Headline: Amgen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. dropped 0.77% to $248.07 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",AMGN
188,2023-04-18,"Headline: Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Resmed (RMD) and Travere Therapeutics (TVTX), source:TipRanks, summary: No summary, Headline: These 4 Measures Indicate That Amgen (NASDAQ:AMGN) Is Using Debt Reasonably Well, source:Yahoo, summary: Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that..., Headline: Amgen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. slid 0.80% to $246.09 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index..., Headline: Amgen wins appeals court ruling in patent dispute over psoriasis drug Otezla, source:Seeking Alpha, summary: No summary, Headline: Amgen wins patent appeal on Otezla, source:Thefly.com, summary: No summary",AMGN
189,2023-04-19,"Headline: Amgen Inc. stock underperforms Wednesday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.05% higher to $246.21 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500..., Headline: Amgen wins appeal in US patent case over generic psoriasis drugs, source:Reuters, summary: Amgen Inc convinced a U.S. appeals court on Wednesday to uphold patents that barred generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis' Sandoz Inc., Headline: AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST), source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the District of New Jersey in a patent infringement lawsuit against Sandoz Inc. (""Sandoz"") and Zydus Pharmaceuticals (USA), Inc. (""Zydus""). Today's decision affirms the permanent injunction entered by the district court prohibiting Sandoz and Zydus from making, using, selling, offering to sell, or importing each of their generic versions of Otezla un, Headline: UPDATE 1-US Amgen ruling keeps generic psoriasis drug off market until 2028, source:Yahoo, summary: Amgen Inc convinced a U.S. appeals court on Wednesday to uphold patents that bar generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis AG's Sandoz Inc until 2028.  The U.S. Court of Appeals for the Federal Circuit affirmed a New Jersey federal court's ruling that Amgen patents covering the drug were valid and that the proposed generics would infringe them.  The Federal Circuit also upheld a decision to invalidate one of Amgen's patents that Sandoz said would have barred its generics until 2034., Headline: Amgen (AMGN) Gains As Market Dips: What You Should Know, source:Yahoo, summary: In the latest trading session, Amgen (AMGN) closed at $246.21, marking a +0.05% move from the previous day., Headline: Amgen (AMGN) Receives a Sell from Barclays, source:TipRanks, summary: No summary",AMGN
190,2023-04-20,"Headline: Amgen (NASDAQ:AMGN) Wins Patent Appeal on Key Psoriasis Drug, source:TipRanks, summary: No summary, Headline: See Which Of The Latest 13F Filers Holds Amgen, source:Preferred Stock Channel, summary: No summary, Headline: Amgen (AMGN) Wins Patent Appeal for Blockbuster Psoriasis Drug, source:Yahoo, summary: The Appeal Court's decision upholding the patents for Amgen's (AMGN) blockbuster psoriasis drug Otezla will prevent drug-makers from selling a generic version till February 2028., Headline: Amgen (AMGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?, source:Yahoo, summary: Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Amgen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. shed 1.12% to $243.46 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: VMware/Broadcom deal spread widens amid notice of FTC closed door meetings, source:Seeking Alpha, summary: No summary",AMGN
191,2023-04-21,"Headline: Amgen (AMGN) Receives a Hold from Mizuho Securities, source:TipRanks, summary: No summary, Headline: XBI: Uncorrelated Growth Capitalizing On The M&A Tidal Wave In Pharma, source:SeekingAlpha, summary: nan, Headline: 12 Best Pharma Dividend Stocks To Buy in 2023, source:Yahoo, summary: In this article, we discuss 12 best pharma dividend stocks to buy in 2023. You can skip our detailed analysis of the pharmaceutical sector and its outlook this year, and go directly to read 5 Best Pharma Dividend Stocks To Buy in 2023. The pharmaceutical industry in the US is one of the largest in […], Headline: Amgen Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.16% higher to $243.86 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: 11 Best Fast Money Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this article, we will discuss the 11 best Fast Money stocks to buy now according to hedge funds. If you want to explore similar stocks, you can also take a look at 5 Best Fast Money Stocks To Buy According To Hedge Funds. “Trendlines Over Headlines” On April 12 Piper Sandler’s chief market technician, […], Headline: AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 27, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team., Headline: China’s Consumer-Led Growth Looks More Like a Bounce, Not a Recovery, source:Yahoo, summary: China’s first-quarter GDP grew faster than expected after a Covid-racked 2022. But some strategists question whether it has the strength to drive a sustainable recovery.",AMGN
192,2023-04-22,"Headline: ClearBridge SMID Cap Growth Strategy Q1 2023 Portfolio Manager Commentary, source:SeekingAlpha, summary: nan",AMGN
193,2023-04-23,"Headline: Nautilus Biotechnology: The Rubber Will Soon Meet The Road, source:SeekingAlpha, summary: nan, Headline: Investing in Amgen (NASDAQ:AMGN) five years ago would have delivered you a 59% gain, source:Yahoo, summary: If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see...",AMGN
194,2023-04-24,"Headline: 4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates, source:Yahoo, summary: We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter., Headline: Oppenheimer Maintains AMGEN (AMGN) Outperform Recommendation, source:Fintel, summary: nan, Headline: Can Amgen (AMGN) Keep the Earnings Streak Alive in Q1?, source:Yahoo, summary: Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others is expected to have been partially offset by biosimilar/generic competition for mature drugs., Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.24% higher to $244.45 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: Top Biotech Stocks For Q2 2023: First Gem Is BioNTech, source:SeekingAlpha, summary: nan",AMGN
195,2023-04-25,"Headline: Is Amgen A Buy Ahead Of The Q1 Results?, source:SeekingAlpha, summary: Amgen will publish its Q1 results in a couple of days, followed by an earnings call post-market hours. Click here to read a detailed analysis of AMGN stock., Headline: Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Bluebird Bio (BLUE) and InMode (INMD), source:TipRanks, summary: No summary, Headline: Amgen Inc. stock underperforms Tuesday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.17% higher to $244.87 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500..., Headline: Dow`s 182-point fall led by losses in Merck, Honeywell shares, source:MarketWatch, summary: No summary, Headline: Will Amgen`s streak of EPS beats continue in Q1?, source:Seeking Alpha, summary: No summary",AMGN
196,2023-04-26,"Headline: 14 Best Income Stocks To Invest In, source:Yahoo, summary: In this article, we discuss 14 best income stocks to invest in. You can skip our detailed analysis of income stocks and the performance of dividend stocks over the years, and go directly to read 5 Best Income Stocks To Invest In. Income stocks are picking up steam this year because they offer a relatively […], Headline: EU publishes proposed reforms for pharma industry, source:Seeking Alpha, summary: No summary, Headline: Will Humira competition impact AbbVie Q1 results?, source:Seeking Alpha, summary: No summary, Headline: Democratic senators introduce bill to enhance CMS drug price negotiations, source:Seeking Alpha, summary: No summary, Headline: These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar, source:Yahoo, summary: The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now., Headline: Amgen Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slipped 2.48% to $238.80 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index..., Headline: GLOBAL BRIEFING: Samsung posts weakest profit in 14 years in Q1, source:Alliance News, summary: No summary, Headline: Notable companies reporting after market close, source:Thefly.com, summary: No summary, Headline: Noteworthy Thursday Option Activity: AMGN, COOP, OXY, source:Stock Options Channel, summary: No summary, Headline: Amgen reports Q1 adjusted EPS $3.98, consensus $3.85, source:Thefly.com, summary: No summary, Headline: Amgen raises FY23 adjusted EPS view to $17.60-$18.70 from $17.40-$18.60, source:Thefly.com, summary: No summary, Headline: Amgen Non-GAAP EPS of $3.98 in-line, revenue of $6.1B misses by $140M, source:Seeking Alpha, summary: No summary, Headline: Amgen 2023 revenue, earnings outlook include consensus estimates, source:Seeking Alpha, summary: No summary",AMGN
197,2023-04-27,"Headline: Mizuho Securities Sticks to Their Hold Rating for Amgen (AMGN), source:TipRanks, summary: No summary, Headline: Fly Intel: After-Hours Movers, source:Thefly.com, summary: No summary, Headline: Lilly obesity therapy shows ~16% weight loss in Phase 3 trial, source:Seeking Alpha, summary: No summary, Headline: Revenue Headwinds Pull Amgen Into Neutral, source:SeekingAlpha, summary: Amgen is a large biotechnology constituent of the Dow Jones Industrial Average index. Learn why AMGN is no longer a Buy., Headline: Time To Sound The Warning Bells For AbbVie?, source:SeekingAlpha, summary: AbbVie reported Q1 results that investors found underwhelming. Read more to know why I rate ABBV stock as a hold., Headline: Amgen 1Q Net Income Surges Despite 2% Dip in Revenue, source:MarketWatch, summary: By Denny Jacob Amgen Inc. net income surged in the latest quarter even as revenue declined slightly. The biotechnology company logged net income of $2.84..., Headline: Amgen: Q1 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Amgen Raises 2023 Revenue, EPS Outlook, source:MarketWatch, summary: By Denny Jacob Amgen Inc. on Thursday raised its 2023 outlook after volume grew in the latest quarter. The biotechnology company guided for revenue between..., Headline: Amgen sales drop due to lower Covid-19 manufacturing collaboration, source:Alliance News, summary: No summary, Headline: Stocks making the biggest moves after hours: Amazon, Intel, Snap, Pinterest and more, source:CNBC, summary: These are the stocks posting the largest moves in extended trading., Headline: AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2023., Headline: Amgen 1st quarter profit falls as costs rise, sales flatten, source:Yahoo, summary: Amgen Inc on Thursday reported lower first-quarter profit as expenses rose and a 2% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co.  Product sales by volume grew 14% from a year earlier, but was partially offset by a 5% decline in net selling prices due to unfavorable foreign exchange and sales deductions, such as rebates.  Amgen reported revenue of $6.1 billion for the quarter, down 2% from a year earlier, but in line with analysts' estimates of $6.13 billion, according to Refinitiv data., Headline: UPDATE 1-Amgen 1st quarter profit falls as costs rise, sales flatten, source:Yahoo, summary: Amgen Inc on Thursday reported lower first-quarter profit as expenses rose and a 2% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co.  Product sales by volume grew 14% from a year earlier, but net selling prices fell 5%, while foreign exchange rates and other factors also limited sales revenue gains, Amgen said.  Amgen is seeing prescription trends return to prepandemic levels and ""demand for medicines is resilient despite current macroeconomic challenges,"" Amgen Chief Executive Robert Bradway said on a conference call with investors., Headline: Amgen Inc. (AMGN) Q1 2023 Earnings Call Transcript, source:SeekingAlpha, summary: Amgen Inc. (NASDAQ:NASDAQ:AMGN) Q1 2023 Earnings Conference Call April 27, 2023 4:30 PM ETCompany ParticipantsArvind Sood - Vice President of Investor RelationsBob Bradway - Chairman and..., Headline: Amgen (AMGN) Q1 Earnings Beat Estimates, source:Yahoo, summary: Amgen (AMGN) delivered earnings and revenue surprises of 3.65% and 0.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?, Headline: Amgen 1st quarter profit falls as costs rise, sales up 2%, source:Reuters, summary: Amgen Inc on Thursday reported lower first-quarter profit as expenses rose and a 2% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co., Headline: GLOBAL BRIEFING: BoJ leaves rates unchanged; Intel swings to loss, source:Alliance News, summary: No summary, Headline: Catalyst watch: FOMC, Apple earnings, Kenvue IPO and jobs report are on tap, source:Seeking Alpha, summary: No summary, Headline: Goldman Sachs Reaffirms Their Buy Rating on Amgen (AMGN), source:TipRanks, summary: No summary",AMGN
198,2023-04-28,"Headline: Analysts` Top Healthcare Picks: Amgen (AMGN), Dexcom (DXCM), source:TipRanks, summary: No summary, Headline: Amgen price target lowered to $288 from $293 at Piper Sandler, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Dexcom (DXCM) and Merck & Company (MRK), source:TipRanks, summary: No summary, Headline: Video: Dow Movers: AMGN, INTC, source:Market News Video, summary: No summary, Headline: Weight loss drug market is just beginning to take off, says Mizuho's Jared Holz, source:CNBC, summary: Jared Holz, Mizuho healthcare equity strategist, joins 'The Exchange' to discuss new weight loss drugs coming to market, forecasts for market expansion in weight loss drugs, and key players in the weight loss drug sector., Headline: Why Amgen Shares Are Trading Lower Today, source:Yahoo, summary: Amgen Inc (NASDAQ: AMGN) reported Q1 FY23 sales of $6.11 billion, down 2% Y/Y, resulting from lower revenue from COVID-19 manufacturing collaboration, partially offset by a 2% increase in product sales. The consensus estimate stood at $6.17 billion. Product sales growth was driven by 14% volume growth, partially offset by 5% lower net selling price, 3% unfavorable changes to estimated sales deductions, 2% lower inventory levels, and 2% negative impact from foreign exchange. Excluding the 2% nega, Headline: Amgen (AMGN) Q1 Earnings Beat Estimates, 2023 View Raised, source:Yahoo, summary: Amgen (AMGN) beats estimates for earnings but misses the same for sales. It raises its earnings and sales guidance for 2023., Headline: Amgen Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. shed 0.25% to $239.74 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index..., Headline: What To Expect After The Failed AbbVie Drug Sales, source:SeekingAlpha, summary: AbbVie's revenue amounted to $12,225 million in the first three months of 2023, 9.7% less than the previous year. Find out my recent analysis of ABBV stock., Headline: Piper Sandler Maintains AMGEN (AMGN) Overweight Recommendation, source:Fintel, summary: nan",AMGN
199,2023-04-29,"Headline: Possible bearish signals as Amgen Inc. (NASDAQ:AMGN) insiders disposed of US$5.2m worth of stock, source:Yahoo, summary: Many Amgen Inc. ( NASDAQ:AMGN ) insiders ditched their stock over the past year, which may be of interest to the..., Headline: 27 Largest Biotech Companies in the US, source:Yahoo, summary: In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US have a total market cap of $88 trillion. Latest Developments in […]",AMGN
200,2023-05-01,"Headline: Amgen price target lowered to $225 from $227 at Barclays, source:Thefly.com, summary: No summary, Headline: Amgen (AMGN) Gets a Sell from Barclays, source:TipRanks, summary: No summary, Headline: Galera Therapeutics expands commercial leadership team, source:Thefly.com, summary: No summary, Headline: Coherus Biosciences initiated with a Buy at Truist, source:Thefly.com, summary: No summary, Headline: RBC Capital Keeps Their Hold Rating on Amgen (AMGN), source:TipRanks, summary: No summary, Headline: Coherus spikes as Truist starts at Buy on biosimilar business, source:Seeking Alpha, summary: No summary, Headline: Robert W. Baird Remains a Sell on Amgen (AMGN), source:TipRanks, summary: No summary, Headline: SVB Securities Remains a Hold on Amgen (AMGN), source:TipRanks, summary: No summary, Headline: Amgen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. dropped 0.35% to $238.90 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: Barclays Maintains AMGEN (AMGN) Underweight Recommendation, source:Fintel, summary: nan, Headline: Healthcare And Facebook Help Propel My 25 Stock ~$424K Portfolio To New Highs In April, source:SeekingAlpha, summary: My portfolio, built specifically for my retirement ~20 years from now, features growth, dividends and risk stocks for. See how it performed in April 2023., Headline: Market Briefing For Tuesday, May 2 `23, source:TalkMarkets, summary: No summary",AMGN
201,2023-05-02,"Headline: Upcoming Dividend Run For AMGN?, source:Dividend Channel, summary: No summary, Headline: 2 Incredibly Cheap Dividend Stocks to Buy in May, source:Yahoo, summary: While the impact of an economic downturn on stocks is hard to predict, high-quality dividend stocks have a proven track record of delivering above market gains during turbulent periods.  Here are two dividend-paying pharmaceutical stocks that ought to hold up well in a recessionary environment, are proven passive income vehicles, and trade at extremely attractive valuations.  Amgen (NASDAQ: AMGN) is a global biotechnology company., Headline: Amgen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slid 1.23% to $235.97 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Amgen sues Novartis to block generic osteoporosis, bone cancer drugs, source:Reuters, summary: Amgen Inc sued Novartis AG's Sandoz in New Jersey federal court Monday, accusing Sandoz's proposed versions of its multibillion-dollar bone-strengthening drugs Prolia and Xgeva of infringing several patents., Headline: Walgreens Boots, Amgen share losses lead Dow`s 85-point fall, source:MarketWatch, summary: No summary",AMGN
202,2023-05-03,"Headline: Amgen price target raised to $214 from $208 at Mizuho, source:Thefly.com, summary: No summary, Headline: Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents, source:Yahoo, summary: Amgen Inc (NASDAQ: AMGN) has reportedly sued Novartis AG's (NYSE: NVS) Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several patents. Amgen said the proposed biosimilars infringe 21 patents covering Prolia and Xgeva. Also Read: Amgen Faces Lawsuit For Hiding Its Stupendous Tax Bill Of $10B. Prolia is indicated for a high risk of bone fracture in certain settings, for example, osteoporosis. XGEVA is prescribed to prevent, Headline: Walgreens Boots, Amgen share losses lead Dow's 85-point fall, source:MarketWatch, summary: Dragged down by declines for shares of Walgreens Boots and Amgen, the Dow Jones Industrial Average is falling Wednesday afternoon. The Dow was most recently..., Headline: Amgen Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. shed 2.82% to $229.31 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: AMGEN TO PRESENT AT THE 2023 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE, source:Yahoo, summary: Amgen (NASDAQ:AMGN) will present at the 2023 Bank of America Merrill Lynch Global Healthcare Conference at 11:00 a.m. ET on Tuesday, May 9, 2023. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public., Headline: Dow Jones Today: Index Falls Following Rate Hike, source:Yahoo, summary: The Dow dropped 250 points with Walgreens taking the index lower after rival CVS cut its profit outlook., Headline: Why Amgen Stock Was Sickly Today, source:Yahoo, summary: What happened Investors are often encouraged when one of their companies bulks up by acquiring a peer. But that sentiment can turn sour if the takeover target stumbles. This was the impetus behind Amgen's (NASDAQ: AMGN) nearly 3% decline on the stock market Wednesday., Headline: Weight-Loss Drugs Will Be Blockbusters. Here’s the Stock to Buy., source:MarketWatch, summary: Everyone is talking about Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic. Now, the drugs are poised to go from conversation starters to profit makers.",AMGN
203,2023-05-04,"Headline: Assertio Holdings: A Little More Risk, A Lot Higher Reward, source:SeekingAlpha, summary: Assertio acquired a future blockbuster which may likely generate sales by itself are more than half the current market cap. Read why ASRT stock is a strong buy., Headline: Amgen Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. rose 1.13% to $231.89 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: 7 Blue-Chip Stocks to Buy in May 2023, source:Yahoo, summary: While large-capitalization enterprises don’t offer much excitement, current circumstances may call for the best blue-chip stocks to buy. Frankly, it’s getting a little bit toasty on Wall Street, which is why stability may come at a premium. Naturally, the failure of First Republic – the third such collapse of a banking enterprise this year – generated plenty of jitters. Despite JPMorgan Chase (NYSE:JPM) CEO Jamie Dimon’s encouraging words that the FRC takeover averted a crisis, circumstances sti",AMGN
204,2023-05-05,"Headline: High Yield Stock Watchlist: May 2023, source:SeekingAlpha, summary: The majority of the stocks on my watchlist are undervalued based on dividend yield theory. Click here for a detailed analysis., Headline: 2 Magnificent Dividend Stocks to Buy Before the Next Recession, source:Yahoo, summary: Let's look at two great dividend stocks to consider buying before the economy worsens: Gilead Sciences (NASDAQ: GILD) and Amgen (NASDAQ: AMGN).  Gilead Sciences is a biotech company with a particular focus on developing HIV medicines.  It has helped Gilead Sciences' revenue stay afloat as the company failed to earn approval for important candidates., Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. rose 2.00% to $236.53 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...",AMGN
205,2023-05-06,"Headline: 2 Best Biotech Stocks to Buy Right Now, source:Yahoo, summary: Buying pharmaceutical companies with all-around drug portfolios and pipelines is the key to success as an investor.",AMGN
206,2023-05-07,"Headline: Amgen, Entera end research collaboration, source:Seeking Alpha, summary: No summary",AMGN
207,2023-05-08,"Headline: DICE Therapeutics: Worth A Roll At The Right Price, source:SeekingAlpha, summary: DICE Therapeutics recently posted encouraging Phase 1c data from its lead candidate, psoriasis therapy DC-806. Check out my recommendation on DICE stock., Headline: Amgen investors given opportunity to lead securities fraud class action, source:Thefly.com, summary: No summary, Headline: Amgen highlights benefit of Prolia over Fosamax in fracture risk, source:Seeking Alpha, summary: No summary, Headline: Amgen osteoporosis drug Prolia outperforms commonly used therapy, source:Seeking Alpha, summary: No summary, Headline: Walgreens Boots, Amgen share losses lead Dow`s 84-point fall, source:MarketWatch, summary: No summary, Headline: Walgreens Boots, Amgen share losses lead Dow's 84-point fall, source:MarketWatch, summary: The Dow Jones Industrial Average is down Monday morning with shares of Walgreens Boots and Amgen seeing the biggest declines for the blue-chip average...., Headline: Video: Dow Movers: AMGN, DIS, source:Market News Video, summary: No summary, Headline: NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia® (denosumab) injection reduced fracture risk in patients versus oral alendronate, a frequently prescribed bisphosphonate treatment. Treatment with Prolia was also associated with greater reductions in fracture risk over time. The data were presented during an oral presentation at the World Congress on Osteoporosis, Ost, Headline: WTV: A Shareholder Yield ETF With Great Valuation, source:SeekingAlpha, summary: WisdomTree U.S. Value Fund ETF is an actively managed fund focused on dividends, buybacks and quality. Click for my review of the WTV ETF., Headline: Amgen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slipped 0.81% to $234.62 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",AMGN
208,2023-05-09,"Headline: Amgen and TScan Therapeutics partner for Crohn`s Disease target identification, source:Thefly.com, summary: No summary, Headline: Amgen, TScan Therapeutics announce collaboration to identify targets in Crohn`s, source:Thefly.com, summary: No summary, Headline: TScan Therapeutics stock soars after Amgen collaboration on Crohn`s disease treatment that could bring in more than $500 million, source:MarketWatch, summary: No summary, Headline: AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE, source:PR Newswire, summary: No summary, Headline: TScan jumps 102% after deal with Amgen for Crohn`s disease, source:Seeking Alpha, summary: No summary, Headline: TScan Therapeutics stock soars after Amgen collaboration on Crohn’s disease treatment that could bring in more than $500 million, source:MarketWatch, summary: Shares of TScan Therapeutics Inc. powered up 43.1% in premarket trading Tuesday, after the biopharmaceutical company announced a collaboration with Amgen..., Headline: Amgen, TScan Therapeutics Set Crohn's Disease Collaboration, source:MarketWatch, summary: By Colin Kellaher Amgen on Tuesday said it has signed onto a multi-year collaboration with clinical-stage biopharmaceutical company TScan Therapeutics..., Headline: TScan Therapeutics Shares Take Flight on Amgen Pact >TCRX, source:MarketWatch, summary: By Colin Kellaher TScan Therapeutics shares surged on Tuesday after the clinical-stage biopharmaceutical company said it entered a collaboration potentially..., Headline: TScan Therapeutics More than Doubles Following Deal with Amgen, source:TipRanks, summary: No summary, Headline: O`Keefe Stevens Advisory Q1 2023 Update, source:Seeking Alpha, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Axsome Therapeutics (AXSM) and Shockwave Medical (SWAV), source:TipRanks, summary: No summary, Headline: Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease, source:Yahoo, summary: Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan’s proprietary target discovery, Headline: Amgen Inc. (NASDAQ:AMGN) Shares Could Be 42% Below Their Intrinsic Value Estimate, source:Yahoo, summary: Key Insights Amgen's estimated fair value is US$405 based on 2 Stage Free Cash Flow to Equity Amgen's US$235 share..., Headline: RBC Capital Reiterates AMGEN (AMGN) Sector Perform Recommendation, source:Fintel, summary: nan, Headline: Amgen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. sank 0.08% to $234.43 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Why Are TScan Therapeutics Shares Are Shooting Higher Today, source:Yahoo, summary: Amgen Inc (NASDAQ: AMGN) and TScan Therapeutics Inc (NASDAQ: TCRX) announced a multi-year collaboration to use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30 million upfront payment and is eligible to earn over $500 million in milestones and tiered single-digit royalty payments. Amgen will evaluate a variety of modalities to create therapeutics b, Headline: 15 Biggest Immunotherapy Companies in the World, source:Yahoo, summary: In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power […], Headline: O'Keefe Stevens Advisory Q1 2023 Update, source:SeekingAlpha, summary: O'Keefe Stevens Advisory released its Q1 2023 update recently. Click here to read the full fund letter. ",AMGN
209,2023-05-10,"Headline: Dow`s 100-point fall led by losses for shares of Travelers, Chevron, source:MarketWatch, summary: No summary, Headline: Amgen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slipped 0.14% to $234.11 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500..., Headline: May Dogs Of The Dow: Buy 2, Watch 4, source:SeekingAlpha, summary: The Dow adds a stock if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Click for our lists., Headline: Novartis CEO criticizes US, EU efforts to curb drug company power, source:Yahoo, summary: Novartis CEO pushes back against government attempts to direct pharma RD, Headline: Walt Disney, Intel share losses contribute to Dow`s 234-point drop, source:MarketWatch, summary: No summary",AMGN
210,2023-05-11,"Headline: GOP law cut Big Pharma tax rates by 40%, Senate report says, source:CNBC, summary: Senate Finance Committee Democrats said the Republican bill resulted in billion of dollars in tax savings for pharmaceutical companies. , Headline: Amgen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slid 0.78% to $232.29 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Horizon Therapeutics ticks higher amid report FTC meeting unrelated to Amgen deal, source:Seeking Alpha, summary: No summary",AMGN
211,2023-05-12,"Headline: Amgen Inc. (NASDAQ:AMGN) Pays A US$2.13 Dividend In Just Four Days, source:Yahoo, summary: Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Amgen Inc..., Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.28% higher to $232.95 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",AMGN
212,2023-05-13,"Headline: How To Invest $100,000 Today: The Near-Perfect Portfolio Strategy, source:SeekingAlpha, summary: With the economy going through boom and bust cycles more frequently, extreme market ups and downs are inevitable. Click here for more., Headline: Amgen Inc. (AMGN) Presents at BofA Securities 2023 Health Care Conference (Transcript), source:SeekingAlpha, summary: Amgen Inc. (NASDAQ:NASDAQ:AMGN) BofA Securities 2023 Health Care Conference May 9, 2023 11:00 AM ETCompany ParticipantsPeter Griffith - CFODave Reese - EVP, R&DConference Call..., Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of May 14, source:SeekingAlpha, summary: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the companies with upcoming ex-dividend dates.",AMGN
213,2023-05-15,"Headline: BridgeBio Pharma: A Lot Of Paths To Potential Success, source:SeekingAlpha, summary: BridgeBio has had some positive recent trial developments and executed a needed capital raise in March. Find out a full investment analysis of BBIO stock., Headline: FTC looks to blow Horizon Therapeutics acquisition by Amgen, Capitol Forum says, source:Thefly.com, summary: No summary, Headline: FTC looks to block Horizon Therapeutics deal with Amgen, Capitol Forum says, source:Thefly.com, summary: No summary, Headline: Ex-Dividend Reminder: Amgen, Select Medical Holdings and Laboratory Corporation of America Holdings, source:Dividend Channel, summary: No summary, Headline: Amgen Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.25% higher to $233.53 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: Lightning Round: 'I don't like companies that pick fights with the SEC', says Jim Cramer on Coinbase, source:CNBC, summary: 'Mad Money' host Jim Cramer weighs in on stocks including: Chewy, Enterprise Products, Coinbase, Triple Flag Precious Metals, Amgen, GSK, IONQ, Southern Co., and Snowflake., Headline: Cramer's Lightning Round: I am not a believer in Coinbase, source:CNBC, summary: ""Mad Money"" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed., Headline: Horizon shares sink on report that FTC will sue to block takeover by Amgen, source:MarketWatch, summary: Shares of Horizon Therapeutics Inc. plunged 15% in extended trading Monday after Bloomberg News reported the FTC is expected to file a lawsuit to block Amgen..., Headline: FTC suit against Horizon deal may have chilling effect on biotech M&A, source:Seeking Alpha, summary: No summary, Headline: FTC Surprise Challenge Of Amgen`s Acquisition Of Horizon Therapeutics, source:Seeking Alpha, summary: No summary, Headline: UPDATE 2-FTC to block Amgen's $27.8 billion deal for Horizon Therapeutics - source, source:Yahoo, summary: The U.S. Federal Trade Commission is expected to file a lawsuit as early as Tuesday to block Amgen Inc's $27.8 billion deal to buy Horizon Therapeutics PLC, a person familiar with the matter told Reuters.  Amgen struck a deal last year to buy Horizon to strengthen its rare diseases drugs portfolio.  Amgen said on Monday it wasn't aware of any decision made by the agency., Headline: Pfizer bond offering to fund Seagen deal said to among largest on record, source:Seeking Alpha, summary: No summary, Headline: Pfizer bond offering to fund Seagen deal said to be among largest on record, source:Seeking Alpha, summary: No summary, Headline: Dow falls, Nasdaq edges up with U.S. debt-ceiling talks in focus, source:MarketWatch, summary: No summary, Headline: FTC to block Amgen's $27.8 billion deal for Horizon Therapeutics - source, source:Reuters, summary: The U.S. Federal Trade Commission is expected to file a lawsuit as early as Tuesday to block Amgen Inc's $27.8 billion deal to buy Horizon Therapeutics PLC, a person familiar with the matter told Reuters.",AMGN
214,2023-05-16,"Headline: FTC will sue to block Horizon Therapeutics takeover by Amgen, Bloomberg says, source:Thefly.com, summary: No summary, Headline: Amgen’s $28 Billion Horizon Buy Will Be Challenged by FTC, source:Yahoo, summary: (Bloomberg) -- Amgen Inc.’s $27.8 billion deal to buy Horizon Therapeutics Plc, the largest in the biotechnology company’s history, will be challenged by federal regulators who argue the tie-up would hamper innovation and slow the pace of drug development, according to a person familiar with the matter.Most Read from BloombergTurkey Latest: Erdogan Says Unclear If Vote Will Go to RunoffMichael Burry Doubles Alibaba Stake in Big Bet on China TechTurkey Set for Runoff as Erdogan Falls Just Short o, Headline: Capital One stock rallies and Home Depot shares dips, and other companies on the move, source:MarketWatch, summary: No summary, Headline: Seagen, impacted by FTC Amgen/Horizon suit, closes down 6%, source:Seeking Alpha, summary: No summary, Headline: Amgen-Horizon Deal: A Major Roadblock in Sight, source:TipRanks, summary: No summary, Headline: Horizon Shares Slide Premarket on Report That FTC to Fight Amgen Deal, source:MarketWatch, summary: By Colin Kellaher Horizon Therapeutics tumbled in premarket trading Tuesday following a published report that U.S. regulators will move to block the $27.8..., Headline: Home Depot`s stock selloff would cut nearly 80 points off the Dow`s price, source:MarketWatch, summary: No summary, Headline: Capital One stock rallies and Home Depot shares dip, and other companies on the move, source:MarketWatch, summary: No summary, Headline: Jefferies thinks Amgen-Horizon deal still gets done after `speed bump`, source:Thefly.com, summary: No summary, Headline: Home Depot’s stock selloff would cut nearly 80 points off the Dow’s price, source:MarketWatch, summary: Shares of Home Depot Inc. took a 4.0% dive, to pace the Dow Jones Industrial Average’s premarket decliners, after the home improvement retailer missed fiscal..., Headline: Wall Street Breakfast Podcast: 13F Filings: Berkshire Takes New Stakes In COF, DEO, source:SeekingAlpha, summary: Warren Buffett's Berkshire takes new stakes in COF, Diageo, exits RH. Daniel Loeb's Third Point amasses new stakes in Alphabet, Micron, AMD, Alibaba. Rumble buys Callin., Headline: Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Compugen (CGEN) and Eli Lilly & Co (LLY), source:TipRanks, summary: No summary, Headline: What You Missed On Wall Street On Tuesday, source:Thefly.com, summary: No summary, Headline: Seagen, Prometheus Biosciences fall amid news of FTC planned block of Horizon/Amgen deal, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca to exit leading U.S. drug industry group PhRMA, source:Seeking Alpha, summary: No summary, Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: No summary, Headline: HZNP Stock Alert: Why Is Horizon Therapeutics Plunging Today, source:InvestorPlace, summary: No summary, Headline: FTC files suit to block Amgen acquisition of Horizon Therapeutics, source:Thefly.com, summary: No summary, Headline: FTC sues to block Amgen, Horizon Therapeutics deal on monopoly concerns, source:Thefly.com, summary: No summary, Headline: Amgen responds to FTC action on proposed acquisition of Horizon Therapeutics, source:Thefly.com, summary: No summary, Headline: Amgen `disappointed` in FTC`s decision to block Horizon Therapeutics deal, source:Thefly.com, summary: No summary, Headline: Amgen remains committed to closing Horizon Therapeutics deal by mid-December, source:Thefly.com, summary: No summary, Headline: Amgen: Horizon Therapeutics deal poses `no legitimate competitive issues`, source:Thefly.com, summary: No summary, Headline: Horizon Therapeutics responds to FTC`s action to block acquisition by Amgen, source:Thefly.com, summary: No summary, Headline: FTC sues to block Amgen acquisition of Horizon Therapeutics, source:CNBC, summary: The Federal Trade Commission on Tuesday said it has sued to block Amgen's $27.8 billion acquisition of Horizon Therapeutics. CNBC's David Faber reports., Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: FTC sues to block Amgen`s acquisition of Horizon Therapeutics, source:MarketWatch, summary: No summary, Headline: Tracking George Soros`s Portfolio - Q1 2023 Update, source:Seeking Alpha, summary: No summary, Headline: AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS, source:PR Newswire, summary: No summary, Headline: Prometheus, Seagen slip after FTC sues to block Horizon acquisition, source:Thefly.com, summary: No summary, Headline: Monopoly concerns push FTC to sue to block Amgen's more than $26B deal for Horizon, source:Associated Press, The, summary: No summary, Headline: Hot Stocks: SE and IQ slip after earnings; HZNP down on FTC lawsuit; VOD fall on job cuts; AMD and VKTX gain, source:Seeking Alpha, summary: No summary, Headline: Seagen likely to stay `distanced` from deal price after FTC action, says Stifel, source:Thefly.com, summary: No summary, Headline: Stocks making the biggest moves midday: Horizon Therapeutics, Capital One, RH, Home Depot and more , source:CNBC, summary: These are the stocks posting the largest moves midday., Headline: Trade commission fights Amgen's $28B purchase of Horizon Therapeutics, source:United Press International, summary: No summary, Headline: US STOCKS-Wall St falls as Home Depot, retail sales data weigh , source:Reuters, summary: U.S. stocks fell on Tuesday after a dour forecast from Home Depot and April retail sales data pointed to consumers feeling the pinch from rising prices and interest rates, ahead of crucial debt limit talks., Headline: Wall St falls as Home Depot, retail sales data weigh, source:Reuters, summary: U.S. stocks fell on Tuesday after a dour forecast from Home Depot and April retail sales data pointed to consumers feeling the pinch from rising prices and interest rates, ahead of crucial debt limit talks., Headline: FTC Surprise Challenge Of Amgen's Acquisition Of Horizon Therapeutics, source:SeekingAlpha, summary: Amgen is facing a suit from the FTC to block its acquisition of Horizon Therapeutics. Check out my key takeaways for AMGN and HZNP investors., Headline: Jefferies' Michael Yee expects Amgen's Horizon Therapeutics deal will go through despite FTC block, source:CNBC, summary: Michael Yee, Jefferies managing director, joins 'Power Lunch' to discuss the FTC's move to block Amgen's $27.8 billion deal for Horizon Therapeutics., Headline: FTC Commissioners yet to meet on Amgen-Horizon deal - CNBC, source:Reuters, summary: Commissioners at the U.S. Federal Trade Commission (FTC) have not yet met to discuss Amgen's acquisition of Horizon Therapeutics, CNBC reported on Tuesday., Headline: FTC sues to block Amgen's $27.8 bln deal for Horizon Therapeutics -statement, source:Reuters, summary: The U.S. Federal Trade Commission said on Tuesday that it would sue to stop Amgen Inc's $27.8 billion deal to buy Horizon Therapeutics Plc ., Headline: US sues to block USD28 billion Amgen biopharma acquisition, source:Alliance News, summary: No summary, Headline: Factbox-Amgen-Horizon deal joins mega mergers facing regulatory heat, source:Reuters, summary: A U.S. antitrust regulator said on Tuesday it will sue to stop Amgen's $27.8 billion deal for Horizon Therapeutics Plc, as it would give Amgen ""monopoly positions"" in treatments for thyroid eye disease and chronic refractory gout., Headline: US FTC sues to block Amgen's $27.8 billion deal for Horizon Therapeutics, source:Reuters, summary: The U.S. Federal Trade Commission said on Tuesday it would sue to stop Amgen Inc's $27.8 billion acquisition of Horizon Therapeutics Plc in a rare move to block a large pharmaceutical deal., Headline: Why These 2 Large-Cap Stocks Dropped 10%-Plus on Tuesday, source:Yahoo, summary: Although the Nasdaq Composite managed to post modest gains, the Dow Jones Industrial Average and S&P 500 were both lower.  Sea Limited (NYSE: SE) raised some concerns about the strength of consumers in the Asia-Pacific region, while shareholders in Horizon Therapeutics (NASDAQ: HZNP) had to deal with a threat that could bring hopes for a lucrative acquisition to a grinding halt.  Shares of Sea Limited dropped 15% on Tuesday morning following the release of the Southeast Asian e-commerce and video game specialist's latest financial results., Headline: Amgen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slipped 2.42% to $227.88 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index..., Headline: FTC Sues to Block Amgen’s $27.8 Billion Acquisition of Horizon Therapeutics, source:Yahoo, summary: Amgen reached an agreement to buy Horizon in December, and at the time said it expected the deal to be completed in the first half of 2023., Headline: US STOCKS-Dow, S&P 500 fall as Home Depot, retail sales data weigh, source:Reuters, summary: The Dow and the S&P 500 fell on Tuesday after a dour forecast from Home Depot and April retail sales data pointed to consumers feeling the pinch from rising prices and interest rates, ahead of crucial debt limit talks., Headline: FTC Sues to Block Amgen’s Acquisition of Horizon Therapeutics, source:Yahoo, summary: The Federal Trade Commission is suing to block Amgen Inc.'s $28 billion acquisition of Horizon Therapeutics to prevent a monopoly in the market for d.rugs that treat critical ailments, Headline: Horizon Therapeutics Stock Plunges as FTC Plans to Block Amgen Deal, source:Yahoo, summary: Amgen’s nearly $28 billion cash deal to buy Horizon Therapeutics is in jeopardy.  Horizon shares were recently down around 15% on the news that the Federal Trade Commission is planning a lawsuit to [block the deal](https://www.wsj.com/articles/ftc-poised-to-block-amgens-27-8-billion-deal-for-horizon-therapeutics-a9c1b499).  Horizon closed Monday at $112.25 a share, which is a less than 4% discount to the planned acquisition price., Headline: US STOCKS-S&P 500, Dow fall, dragged by Home Depot outlook, US retail sales, source:Reuters, summary: The Dow and the S&P 500 retreated on Tuesday after a disappointing forecast from Home Depot and U.S. retail sales data for April pointed to softer consumer spending, while uncertainty about interest rates and debt limit negotiations weighed on sentiment., Headline: FTC May Reportedly Block Amgen's (AMGN) $28B Horizon Buyout, source:Yahoo, summary: Unconfirmed reports suggest that the FTC may challenge the $28-billion buyout of Horizon Therapeutics (HZNP) by Amgen., Headline: UPDATE 5-US FTC sues to block Amgen's $27.8 bln deal for Horizon Therapeutics, source:Yahoo, summary: The U.S. Federal Trade Commission said on Tuesday it has filed a lawsuit to stop Amgen Inc's $27.8 billion acquisition of Horizon Therapeutics Plc in a rare move to block a large pharmaceutical deal.  The FTC said it opposed the deal because of concern that Amgen would leverage its big selling drugs to pressure insurance companies and pharmacy benefit managers to give favorable terms for Horizon's two key products - the fast-growing thyroid eye disease treatment Tepezza and gout drug Krystexxa.  The FTC decision to stop this acquisition marks a change., Headline: FTC sues to block Amgen's $27.8 billion deal to acquire Horizon Therapeutics, source:Yahoo, summary: Yahoo Finance healthcare reporter Anjalee Khemlani joins the Live Show to discuss details surrounding the FTC suing biopharmaceutical giant Amgen Inc and its plan to block Amgen's $27.8 billion deal to acquire Horizon Therapeutics., Headline: FTC sues to stop Amgen’s $27.8B deal for Horizon Therapeutics, source:Yahoo, summary: The FTC said in its complaint that Amgen would be able to leverage its position with insurance companies and pharmacy benefit managers wanting access to its blockbuster drugs., Headline: US STOCKS-Wall Street declines after Home Depot outlook, US retail sales, source:Reuters, summary: U.S. stock indexes closed lower on Tuesday after a disappointing forecast from Home Depot and U.S. retail sales data for April pointed to softer consumer spending, while uncertainty about interest rates and debt limit negotiations weighed on sentiment., Headline: Horizon Tumbles — Taking Seagen, Prometheus With It — As FTC Blocks Amgen Takeover, source:Yahoo, summary: The FTC plans to block Amgen's takeover of Horizon. The move reverberated across biotechs, with an HZNP stock crash leading the way., Headline: CORRECTED-US STOCKS-Wall Street closes lower after Home Depot outlook, US retail sales, source:Yahoo, summary: U.S. stock indexes closed lower on Tuesday after a disappointing forecast from Home Depot and U.S. retail sales data for April pointed to softer consumer spending, while uncertainty about interest rates and debt limit negotiations weighed on sentiment.  Home Depot declined 2.15% as one of the biggest drag on both the Dow Industrials and S&P 500 after the home improvement retailer cut its annual sales forecast and projected a steeper-than-expected decline in profit., Headline: Lowe's, Horizon Therapeutics, AMD: Stocks moving ahead of the close, source:Yahoo, summary: The Yahoo Finance Live team discusses stocks to watch at the closing bell, including Lowe's, Horizon Therapeutics, AMD, and Nvidia., Headline: Markets Fall on Home Depot Warning, Debt Talks, source:Yahoo, summary: U.S. equities fell on Tuesday, May 16, 2023 as Home Depot’s revenue warning raised concerns about economic growth, and as President Biden met with congressional leaders on the debt ceiling to avoid a government default., Headline: Dow Jones Today: Index Falls on Retail Sales Slump, source:Yahoo, summary: The Dow Jones Industrial Average fell 1%, or 336 points, on a day of disappointing earnings and macroeconomic reports. Nike lost the most, while Microsoft led a small pack of gainers., Headline: Pfizer Sells $31 Billion of Bonds in Fourth-Largest Deal Ever, source:Yahoo, summary: (Bloomberg) -- Pfizer Inc. sold $31 billion of debt in the fourth-largest US bond sale ever, according to a person with knowledge of the matter.Most Read from BloombergA 32-Year-Old Nears Billionaire Status by Using AI to Broker Japan MergersHere’s How Much Wealth You Need to Join the Richest 1% GloballyDebt-Limit Talks to Intensify as Biden Set to Depart for JapanGoldman Banker Wins Promotion, Then Leaves for Rival Two Weeks LaterGoogle Billionaire Sergey Brin Gifts $600 Million in Surging Shar, Headline: Home Depot, FTC blocks Amgen deal, Comcast's Hulu stake: Tuesday's top headlines, source:Yahoo, summary: The Yahoo Finance Live team breaks down Tuesday's biggest stories, including Home Depot earnings report, the FTC suing to block Amgen's deal to buy Horizon Therapeutics, and Comcast's talks to sell its Hulu stake to Disney., Headline: FTC Sues Over Amgen’s $28 Billion Horizon Therapeutics Deal, source:Yahoo, summary: (Bloomberg) -- The Federal Trade Commission sued to block Amgen Inc.’s $27.8 billion deal to buy Horizon Therapeutics Plc Tuesday, arguing the tie-up would stifle competition for the development of treatments for serious illnesses. Most Read from BloombergA 32-Year-Old Nears Billionaire Status by Using AI to Broker Japan MergersHere’s How Much Wealth You Need to Join the Richest 1% GloballyDebt-Limit Talks to Intensify as Biden Set to Depart for JapanGoldman Banker Wins Promotion, Then Leaves fo, Headline: FTC Moves to Block Amgen’s $27.8 Billion Deal for Horizon Therapeutics, source:Yahoo, summary: The FTC hasn’t often challenged mergers involving drugmakers, but under Chair Lina Khan it has taken a stricter stance on deals., Headline: The FTC Wants to Block the $28 Billion Amgen-Horizon Therapeutics Deal, source:Yahoo, summary: Big Pharma needs an antitrust antidote. The Federal Trade Commission and its hard-nosed chair Lina Khan have struck again, this time filing a..., Headline: Tracking George Soros's Portfolio - Q1 2023 Update, source:SeekingAlpha, summary: Soros' 13F portfolio value decreased from $7.26B to $6.49B this quarter. Click here to see an update on the portfolio's trades for Q1 2023., Headline: Wall Street closes lower after Home Depot outlook, US retail sales, source:Reuters, summary: U.S. stock indexes closed lower on Tuesday after a disappointing forecast from Home Depot and U.S. retail sales data for April pointed to softer consumer spending, while uncertainty about interest rates and debt limit negotiations weighed on sentiment., Headline: Amgen-Horizon Deal Stumbles on FTC`s Lawsuit, source:TipRanks, summary: No summary, Headline: U.S. stocks are falling after Home Depot report, weak retail sales, source:Investing.com, summary: No summary, Headline: Midday movers: Home Depot, Capital One Financial, Tesla and more, source:Investing.com, summary: No summary, Headline: Regeneron CEO backs regulators attempt to block Amgen deal, FT reports, source:Thefly.com, summary: No summary",AMGN
215,2023-05-17,"Headline: Regeneron boss backs attempt to block $28bn Amgen acquisition, source:Yahoo, summary: The Regeneron chief executive has backed an attempt by US regulators to block Amgen’s $28bn acquisition of Horizon Therapeutics as he accused some pharmaceutical companies of abusing their market power to prevent competition.  Leonard Schleifer said he supported the US Federal Trade Commission’s decision to tackle a “new area” after the agency made its first attempt to block a pharma deal in over a decade by filing a novel lawsuit against the Amgen transaction.  Drugmakers pay rebates to ensure their treatment is placed on the lists of drugs covered by insurance companies., Headline: US sues to block drug merger, source:Yahoo, summary: This is an audio transcript of the FT News Briefing podcast episode: ‘US sues to block drug merger’Marc Filippino Good morning from the Financial Times. Today is Wednesday, May 17th, and this is your FT News Briefing., Headline: Analysts Conflicted on These Healthcare Names: Amgen (AMGN) and ReShape Lifesciences (RSLS), source:TipRanks, summary: No summary, Headline: Wall Street Breakfast: Retail On The Radar, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify., Headline: Is This Dow Jones Stock a Buy for Income Investors?, source:Yahoo, summary: Replacing Pfizer (NYSE: PFE) as a component of the Dow Jones Industrial Average nearly three years ago, the pharmaceutical company Amgen (NASDAQ: AMGN) is among the best dividend payers in its industry.  Let's dig into Amgen's fundamentals and valuation to get an answer to this question.  With around 24,000 employees in total, Amgen is a major drugmaker with a $124 billion market capitalization., Headline: FTC Seeks to Block Amgen's Acquisition of Horizon Therapeutics: What's Next for Both Stocks?, source:Yahoo, summary: Deal or no deal? That's now the big question for investors concerning Amgen's (NASDAQ: AMGN) pending $28 billion acquisition of Horizon Therapeutics (NASDAQ: HZNP). The Federal Trade Commission (FTC) announced on Tuesday that it has filed a lawsuit to prevent this buyout from happening., Headline: Analysis-Amgen's antitrust woes spur wider pharmaceutical deal fears, source:Yahoo, summary: Investors are scrambling to assess the fallout of a U.S. regulatory challenge against Amgen Inc's proposed $27.8 billion acquisition of Horizon Therapeutics Plc, with some fearing a spillover to other big deals in the drug sector.  While investors are accustomed to regulators under U.S. President Joe Biden citing potential harm to consumers in objecting to many large mergers, the U.S. Federal Trade Commission's (FTC) lawsuit filed on Tuesday surprised those who had brushed off the antitrust risk in Amgen's deal because of its limited business overlap with Horizon., Headline: Applied Materials, Lowe`s added to Jefferies franchise picks list, source:Seeking Alpha, summary: No summary, Headline: Debt Ceiling Negotiations Turn a Corner. Why The Risk Isn’t Over Yet., source:Yahoo, summary: Still no debt-ceiling deal as Biden shortens G-7 trip, UBS takes $35 billion gain from Credit Suisse takeover, Musk hints at two new vehicles and starts advertising campaign, and other news to start your day., Headline: Amgen deal for Horizon likely to go through despite FTC objection: Guggenheim, source:Seeking Alpha, summary: No summary, Headline: Video: Dow Movers: AMGN, BA, source:Market News Video, summary: No summary, Headline: Amgen Becomes Oversold, source:Dividend Channel, summary: No summary, Headline: Noteworthy Wednesday Option Activity: AMGN, LKQ, LYV, source:Stock Options Channel, summary: No summary, Headline: Pfizer to raise $31 billion in debt offering to fund Seagen acquisition, SEC filing shows, source:CNBC, summary: The debt offering by Pfizer to buy cancer drug maker Seagen comes as Apple, Merck and T-Mobile tap the U.S. bond market ahead of the debt ceiling standoff. , Headline: Pfizer, Amgen, and 7 More Cheap Healthcare Stocks for Investors to Consider, source:MarketWatch, summary: The stocks our screen found are cheap, relative to highfliers like Eli Lilly, and many are cheap for a reason., Headline: Pfizer (PFE) to Raise $31B in Debt to Fund Seagen (SGEN) Deal, source:Yahoo, summary: Pfizer (PFE) offers bonds worth $31 billion to fund its pending acquisition of cancer drugmaker, Seagen (SGEN)., Headline: Amgen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. sank 0.32% to $225.02 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: Amgen/FTC: deal bar ignores realities of pharma food chain, source:Yahoo, summary: No deal is fully inoculated against regulatory intervention.  In December, biopharmaceutical firm Amgen announced the acquisition of biotech star Horizon Therapeutics for $116.50 per share or $28bn in aggregate.  On Tuesday, the US Federal Trade Commission sued to block the deal., Headline: FTC Challenges Amgen's (AMGN) $28B Acquisition of Horizon, source:Yahoo, summary: Per the FTC, Amgen's (AMGN) acquisition of Horizon (HZNP) would entrench the monopoly positions for the latter's medications for thyroid eye disease and chronic refractory gout., Headline: M&A crackdown a ‘disaster’ for pharma sector, Pfizer executive warns, source:Yahoo, summary: A senior Pfizer executive has warned that a crackdown on mergers and acquisitions by antitrust regulators would be a “disaster” for the system of innovation that underpins the pharmaceutical industry.  William Pao, Pfizer’s chief development officer, said M&A is an important part of the funding ecosystem that supports the development of innovative therapies by scientists.  “If you can’t get those M&A [deals] and then get those molecules distributed across the globe, it stifles innovation for sure,” said Pao, who heads the Pfizer arm responsible for clinical development of drugs and ensuring a pipeline of new therapies., Headline: Fed, labor market concerns showing 'some dents in the armor of the consumer': Strategist, source:Yahoo, summary: Hennion & Walsh CIO Kevin Mahn joins Yahoo Finance Live to discuss the state of the consumer amid retail earnings, Target Q1 earnings, Walmart earnings preview, Fed rate hikes, inflation, and the impact on consumer spending., Headline: Dow Jones Today: Index Jumps on Debt Talk Hopes, source:Yahoo, summary: Home Depot and Boeing help lead the Dow more than 400 points higher, while Intel continued its losing streak, Headline: Unusual Put Option Trade in AMGEN (AMGN)  Worth $9,481.50K, source:Fintel, summary: nan, Headline: Unusual Put Option Trade in AMGEN (AMGN)  Worth $6,563.75K, source:Fintel, summary: nan, Headline: Top 5 1st Quarter Trades of INTERNATIONAL BIOTECHNOLOGY TRUST PLC, source:GuruFocus, summary: No summary, Headline: The FTC, Amgen, And Horizon: A New Hurdle For Biotech Deal Making Or Regulatory Overreach?, source:TalkMarkets, summary: No summary",AMGN
216,2023-05-18,"Headline: Supreme Court upholds Sanofi patent victory over Amgen, source:Thefly.com, summary: No summary, Headline: Supreme Court upholds Sanofi PCSK9 drug patent victory over Amgen, source:Thefly.com, summary: No summary, Headline: Anticompetitive Behavior At United Therapeutics, Regeneron, And The FTC, source:SeekingAlpha, summary: Much of what the FTC attacks isnât anticompetitive, itâs competitive. Click here to find out more on HZNP and LQDA., Headline: Supreme Court rules against Amgen in Rapatha patent dispute with Sanofi/ Regeneron, source:Seeking Alpha, summary: No summary, Headline: Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron, source:Seeking Alpha, summary: No summary, Headline: Horizon Therapeutics says Amgen deal could close earlier than planned if FTC fails to block it, source:CNBC, summary: The new timeline is earlier than what Amgen, Horizon Therapeutics and Wall Street analysts were initially expecting after the FTC sued to block the deal. , Headline: Regeneron `applauds` Supreme Court`s striking down Amgen`s patent claims, source:Thefly.com, summary: No summary, Headline: Sanofi `pleased` with Supreme Court`s ruling on Amgen`s asserted patent claims, source:Thefly.com, summary: No summary, Headline: Regeneron Says Supreme Court Ruling Ends Patent Dispute With Amgen, source:MarketWatch, summary: By Denny Jacob Regeneron Pharmaceuticals on Thursday said a U.S. Supreme Court opinion affirms a lower court opinion that held Amgen's asserted U.S. PCSK9..., Headline: Amgen`s Horizon Deal Won`t Close before September, source:TipRanks, summary: No summary, Headline: U.S. court issues temporary restraining order on $27.8 bln Amgen-Horizon deal, source:Reuters, summary: A U.S. district court has issued a temporary restraining order on Amgen Inc's $27.8 billion acquisition of Horizon Therapeutics following a submission for it by the two companies and the U.S. Federal Trade Commission, Amgen said on Wednesday., Headline: UPDATE 1-Amgen agrees not to seek quick close to Horizon acquisition, source:Yahoo, summary: Amgen Inc has agreed not to quickly close on its $27.8 billion acquisition of Horizon Therapeutics after the U.S. Federal Trade Commission (FTC) filed suit to block the deal.  A U.S. district court judge issued a temporary restraining order late on Wednesday after the two companies and the FTC reached an agreement that both sides said in a joint filing would permit a full briefing and ""less-compressed consideration"" by the court of the FTC request.  Absent an agreement, Amgen could have sought to close the deal as early as Monday., Headline: UPDATE 1-U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents, source:Yahoo, summary: The U.S. Supreme Court on Thursday ruled against Amgen Inc in its bid to revive patents on its cholesterol-lowering drug Repatha over a legal challenge by French rival Sanofi SA.  The nine justices unanimously upheld a lower court's ruling that had invalidated Amgen's patents on the grounds that the Thousand Oaks, California-based drugmaker had failed to provide a roadmap for recreating the full scope of its claimed innovation.  Amgen has waged a years-long court battle to restore two of its patents on Repatha, a drug that can reduce the risk of heart attack and stroke in people with heart disease, stemming from a legal fight with Sanofi and its partner Regeneron Pharmaceuticals Inc., Headline: Amgen agrees not to seek quick close to Horizon acquisition, source:Reuters, summary: Amgen Inc has agreed not to quickly close on its $27.8 billion acquisition of Horizon Therapeutics after the U.S. Federal Trade Commission (FTC) filed suit to block the deal., Headline: FTC effort to stop Amgen's Horizon takeover faces uphill fight, source:Reuters, summary: The Federal Trade Commission (FTC) faces an uphill battle in its fight against Amgen Inc's $27.8 billion acquisition of Horizon Therapeutics with an untested argument before a Trump-appointed judge, three antitrust experts said., Headline: Amgen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slid 0.35% to $224.23 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index..., Headline: Sanofi Wins Supreme Court Patent Dispute With Amgen, source:Yahoo, summary: The court said Amgen patents relating to its cholesterol drug Repatha shouldn’t have been granted by the patent office, handing a victory to rival pharmaceutical firm Sanofi., Headline: U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents, source:Reuters, summary: The U.S. Supreme Court on Thursday ruled against Amgen Inc in its bid to revive patents on its cholesterol-lowering drug Repatha in a legal clash with French rival Sanofi SA., Headline: 5 High Yield Stocks With Steady Dividend Growth And An Attractive Valuation, source:SeekingAlpha, summary: I consider companies that combine a relatively high Dividend Yield and Dividend Growth Rate to be particularly attractive for dividend income investors. Read more here., Headline: Blocking the Horizon-Amgen deal will be worse for pharma than for biotech, says Mizuho's Jared Holz, source:CNBC, summary: Jared Holz, Mizuho healthcare sector strategist, joins 'Fast Money' to discuss merger and acquisition crackdowns in the biotech space, government regulation in the space, and more., Headline: Why Viking Therapeutics Stock Is Buckling Today, source:Yahoo, summary: Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics (NASDAQ: VKTX) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon.  Small- and mid-cap biotech stocks are under pressure today following the Federal Trade Commission's (FTC) decision to sue over the proposed merger between Amgen and Horizon Therapeutics earlier this week.  Before investors get too concerned, however, it's important to understand what's actually driving this takeover speculation., Headline: Oppenheimer Reiterates AMGEN (AMGN) Outperform Recommendation, source:Fintel, summary: nan, Headline: GLOBAL BRIEFING: Japanese inflation hits 3.4%; new sanctions on Russia, source:Alliance News, summary: No summary, Headline: Amgen (NASDAQ:AMGN) Loses Patent Battle to Sanofi, Regeneron, source:TipRanks, summary: No summary",AMGN
217,2023-05-19,"Headline: 3 Safe Dividend Stocks to Beat Inflation, source:Yahoo, summary: Inflation rates may finally be cooling down from last year's unnerving levels.  Plenty of dividend-paying companies are dishing out -- and growing -- their dividend payments generously enough to outpace inflation's impact.  Here's a closer look at three such dividend stocks to consider adding to the income-paying portion of your portfolio., Headline: 5 Things to Know Before Markets Open, source:Yahoo, summary: President Biden said he was confident that negotiators would reach a deal on the debt ceiling and Fed Chair Jerome Powell is set to speak on monetary policy. Here’s what investors need to know today., Headline: Amgen Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. dropped 0.36% to $223.42 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: A global antitrust alliance battles Microsoft and Amgen, source:Yahoo, summary: As the EU approved Microsoft’s $75bn bid to buy Activision Blizzard, the US Federal Trade Commission sued to block Amgen’s $28.3bn deal to acquire Horizon Therapeutics and warned of “rampant consolidation” in pharmaceuticals.  Margrethe Vestager, EU competition commissioner, is known as the nemesis of Big Tech but others are taking her place.  The Amgen suit epitomises the tough approach adopted by Lina Khan, chair of the FTC, and Khan has a new ally: Sarah Cardell, chief executive of the UK Competition and Markets Authority., Headline: Washington Is Coming Down Hard on Deal Making. What It Means for Stocks., source:Yahoo, summary: FTC Chair Khan now seems less interested in ensuring competition than in blocking all linkups on principle. And that includes acquisitions that wouldn’t have earned more than a passing look under previous regimes, Headline: Walmart, Tesla, Micron: Stocks That Defined the Week, source:Yahoo, summary: Retail giant  Walmart  posted stronger-than-expected profit and revenue and raised its full-year profit outlook, as the company’s stores attract price-sensitive customers who have curtailed spending elsewhere.  Walmart said it continued to gain grocery market share, including among higher-income shoppers.  Walmart shares rose 1.3% Thursday.",AMGN
218,2023-05-20,"Headline: We Think Amgen (NASDAQ:AMGN) Can Stay On Top Of Its Debt, source:Yahoo, summary: Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...",AMGN
219,2023-05-21,"Headline: Viridian Therapeutics Has Promise, source:SeekingAlpha, summary: Shares of Viridian Therapeutics are off some 40% since setting an all-time high in January following a positive readout on VRDN-001. Click for more on VRDN., Headline: 4 big deal reports: Amgen-Horizon merger on the ropes, source:Yahoo, summary: Here is your Pro Recap of 4 head-turning deal dispatches you may have missed this week: potential block of Horizon/Amgen transaction, merger deals at Magellan Midstream/Oneok and Urstadt Biddle/Regency Centers, and New Relic’s potential $5B acquisition.  InvestingPro subscribers got this news before anyone else.  Horizon Therapeutics (NASDAQ:HZNP) shares plunged more than 14% on Tuesday after the report that the U.S. Federal Trade Commission (FTC) is expected to introduce a lawsuit to block the proposed $27.8 billion merger with Amgen (NASDAQ:AMGN)., Headline: Billions of dollars at stake as FDA shortcut allows half-proven drugs - report, source:Seeking Alpha, summary: No summary",AMGN
220,2023-05-22,"Headline: 10 Health Care Stocks Whale Activity In Today's Session, source:Benzinga, summary: No summary, Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.26% higher to $223.99 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500..., Headline: Check Out What Whales Are Doing With AMGN, source:Benzinga, summary: No summary, Headline: Amgen, J&J settle lawsuit over Stelara biosimilar, source:Seeking Alpha, summary: No summary, Headline: Amgen Takes Over #60 Spot From Union Pacific, source:The Online Investor, summary: No summary",AMGN
221,2023-05-23,"Headline: SGEN, ACAD & BMEA Drove Baker Brothers Advisors' Q1 Returns as ASND and HZNP Were Culled, source:Fintel, summary: nan, Headline: Amgen, J&J settle patent lawsuit over Stelara biosimilar, Reuters reports, source:Thefly.com, summary: No summary, Headline: Bayer, Amgen looked at Iveric before agreeing to Astellas sale - report, source:Seeking Alpha, summary: No summary, Headline: 10 Health Care Stocks Whale Activity In Today's Session, source:Benzinga, summary: No summary, Headline: Amgen settles J&J patent lawsuit over drug similar to blockbuster Stelara, source:Reuters, summary: Johnson & Johnson's Janssen Biotech Inc has settled its lawsuit against Amgen Inc over Amgen's proposed similar version of J&J's top-selling drug Stelara, according to a filing Monday in Delaware federal court., Headline: UPDATE 2-Amgen settles patent lawsuit over biosimilar of J&J's  big-selling Stelara, source:Yahoo, summary: Johnson & Johnson has settled its lawsuit over Amgen Inc's proposed biosimilar version of J&J's top-selling treatment Stelara for psoriasis and other autoimmune conditions,  according to a filing in Delaware federal court.  Amgen said in a statement on Tuesday that the settlement terms are confidential, but it will allow the company to sell its biosimilar of Stelara ""no later than January 1st, 2025."", Headline: Amgen settles patent lawsuit over biosimilar of J&J's  big-selling Stelara, source:Reuters, summary: Johnson & Johnson has settled its lawsuit over Amgen Inc's proposed biosimilar version of J&J's top-selling treatment Stelara for psoriasis and other autoimmune conditions, according to a filing in Delaware federal court., Headline: UPDATE 1-US judge hearing fight over Amgen deal for Horizon eyes September trial, source:Yahoo, summary: The judge who will decide if Amgen can go forward with its $27.8 billion purchase of Horizon Therapeutics on Tuesday said he was considering an evidentiary hearing on the matter in September.  Judge John Kness said he would likely take about four weeks after the hearing ends to make a ruling.  The case is being heard in federal court in Chicago., Headline: US judge hearing fight over Amgen deal for Horizon eyes September trial, source:Reuters, summary: The judge who will decide if Amgen can go forward with its $27.8 billion purchase of Horizon Therapeutics on Tuesday said he was considering an evidentiary hearing on the matter in September., Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.20% higher to $224.44 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: Noteworthy Wednesday Option Activity: AMGN, GPRE, RETA, source:Stock Options Channel, summary: No summary",AMGN
222,2023-05-24,"Headline: FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?, source:Yahoo, summary: The Federal Trade Commission (FTC) has been taking a much more adversarial approach to mergers and acquisitions lately.  For instance, it recently said it plans to block the pending deal between pharmaceutical companies Horizon Therapeutics (NASDAQ: HZNP) and Amgen (NASDAQ: AMGN).  Does the FTC's recent tough stance on big deals increase the chances that Pfizer's (NYSE: PFE) acquisition of Seagen (NASDAQ: SGEN) will also run into problems?, Headline: Elizabeth Warren and the FTC Are the Least of Amgen’s Problems, source:Yahoo, summary: The Internal Revenue Service has gone after the biotech for billions of dollars in back taxes.  Lina Khan’s Federal Trade Commission is seeking to block its $27.8 billion acquisition of  Horizon Therapeutics  (a move some insiders think was at least partly prompted by a blistering letter from Sen. Elizabeth Warren)., Headline: 14 Best Healthcare Dividend Stocks to Buy, source:Yahoo, summary: In this article, we will take a look at 14 best healthcare dividend stocks to buy. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks to Buy. The healthcare sector in the US encompasses a wide range of providers, facilities, and […], Headline: Amgen Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slid 1.39% to $221.32 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Dow's 90-point fall led by losses for shares of Intel, Walgreens Boots, source:MarketWatch, summary: No summary",AMGN
223,2023-05-25,"Headline: Novartis' Sandoz gets EMA review for biosimilar to Amgen's Prolia, Xgeva, source:Seeking Alpha, summary: No summary, Headline: 14 Best Biotech Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […], Headline: Dow drops 175 points on losses in Intel, Walgreens Boots shares, source:MarketWatch, summary: No summary, Headline: Intel, Verizon share losses lead Dow's nearly 100-point drop, source:MarketWatch, summary: No summary, Headline: 3 Dogs of the Dow for High-Yield Investors, source:Yahoo, summary: The “Dogs of the Dow” strategy consists of investing in the 10 highest-yielding stocks in the Dow Jones Industrial Average. Purchasing the Dogs of the Dow creates higher dividend income by focusing on high-yielding stocks. This is a simple strategy for value investors looking to purchase high-yield dividend stocks with reasonable valuations. The following three stocks are part of the 10 Dogs of the Dow. They have high dividend yields and strong business models and should maintain their dividends, Headline: Amgen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slipped 1.74% to $217.46 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",AMGN
224,2023-05-26,"Headline: A Challenger to J&J's Top Blockbuster Is on the Way. Here's What You Need to Know., source:Yahoo, summary: When you think of Johnson & Johnson (NYSE: JNJ), you may think of shampoo and Band-Aids.  In fact, J&J is in the process of spinning off that business into an entity called Kenvue.  What is J&J's top revenue driver?, Headline: Nvidia Pops 25% on Super Guidance, source:GuruFocus, summary: No summary, Headline: Is the Options Market Predicting a Spike in Amgen (AMGN) Stock?, source:Yahoo, summary: Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately., Headline: Amgen Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. dropped 0.24% to $216.93 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: AMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT, source:Yahoo, summary: Amgen (NASDAQ: AMGN) will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. ET on Wednesday, May 31, 2023. David M. Reese, M.D., executive vice president of Research and Development at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",AMGN
225,2023-05-29,"Headline: Top-Ranked Dividend Stocks: A Smarter Way To Boost Your Retirement Income, source:TalkMarkets, summary: No summary, Headline: Amgen: Appeal Becomes Visible Despite Uncertainty On The 'Horizon', source:SeekingAlpha, summary: Amgen's stock has seen a further pullback since it announced acquisition of Horizon Therapeutics in December. Check out my thoughts on AMGN stock., Headline: Amgen's (NASDAQ:AMGN) underlying earnings growth outpaced the notable return generated for shareholders over the past five years, source:Yahoo, summary: When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd..., Headline: Quant Ratings Updated on 107 Stocks, source:InvestorPlace, summary: No summary",AMGN
226,2023-05-30,"Headline: Amgen: Now At A Record High Yield, source:SeekingAlpha, summary: Amgen (AMGN) stock is trading near its 52-week low, presenting a potential opportunity for long-term investors., Headline: LABU: 2 Requirements For Making Money In This Leveraged Biotech Fund, source:SeekingAlpha, summary: LABU is 3X leveraged fund that has disappointed the biotech bulls. It can work for medium term returns if two requirements are met. See more on this ETF here., Headline: Viridian an outperform at RBC on thyroid eye disease candidate, source:Seeking Alpha, summary: No summary, Headline: Top Merger Stocks Held By Fund Managers, Mid-Q2 2023, source:SeekingAlpha, summary: Merger arbitrage in mid-2023 faces regulatory hurdles, with agencies attempting to block deals across industries. Read more here., Headline: Iveric bio, Still A 5+% Opportunity, source:SeekingAlpha, summary: Iveric bio, focused on developing treatments for retinal diseases, has announced its acquisition by Astellas Pharma Inc. Find out our thoughts on ISEE stock., Headline: Amgen Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.74% higher to $218.53 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500..., Headline: AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced new research examining the use of Otezla® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC study and an exploratory analysis of cardiometabolic risk factors, which are commonly elevated in patients with psoriatic disease. The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), taking place May 31-June 3 in Milan, Italy.",AMGN
227,2023-05-31,"Headline: Amgen Inc. (AMGN) 4th Annual Oncology Innovation Summit: Insights for ASCO & EHA (Transcript), source:SeekingAlpha, summary: Amgen Inc. (NASDAQ:NASDAQ:AMGN) 4th Annual Oncology Innovation Summit: Insights for ASCO & EHA May 31, 2023 11:00 AM ETCompany ParticipantsDavid Reese - Executive Vice President of..., Headline: Amgen Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.97% higher to $220.65 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500..., Headline: 2 Large Cap Biotech Stocks To Watch Right Now, source:StockMarket, summary: Large-cap biotech stocks to check out in the stock market today., Headline: Amgen (AMGN) Shares Cross 4% Yield Mark, source:Dividend Channel, summary: No summary",AMGN
228,2023-06-01,"Headline: Tracking Baker Brothers Portfolio - Q1 2023 Update, source:SeekingAlpha, summary: Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B. Click here to read the portfolio's full Q1 2023 update., Headline: Mark Cuban online pharmacy to offer AbbVie Humira biosimilar, source:Seeking Alpha, summary: No summary, Headline: Salesforce, Amgen share losses contribute to Dow's nearly 150-point fall, source:MarketWatch, summary: Shares of Salesforce and Amgen are trading lower Thursday morning, dragging the Dow Jones Industrial Average into negative territory. Shares of Salesforce..., Headline: Wells says Coherus' Humira biosimilar pricing 'actually good news' for AbbVie, source:Thefly.com, summary: No summary, Headline: AMGN July 14th Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: House Committee starts probe into FTC Chair Lina Khan, source:Seeking Alpha, summary: No summary, Headline: Notable Thursday Option Activity: AMGN, ABBV, RCL, source:Stock Options Channel, summary: No summary, Headline: AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago. More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CR, Headline: Is Amgen a Good Dividend Stock?, source:Yahoo, summary: Biotech pioneer Amgen (NASDAQ: AMGN) has several key elements of a good dividend stock.  Amgen is also a component of the Dow Jones Industrial Average and Nasdaq-100 index, making its shares highly liquid.  Amgen is moving into a highly uncertain period, characterized by high levels of competition from biosimilars (generic biologics) for many of its aging blockbusters, pushback from the Federal Trade Commission over its proposed takeover of Horizon Therapeutics (NASDAQ: HZNP), and serious question marks surrounding the rationale of this $28 billion buyout., Headline: Amgen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slid 2.89% to $214.27 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Why AbbVie and Amgen Are Moving Lower Today, source:Yahoo, summary: Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday.  The big loss came after Coherus Biosciences announced a partnership with billionaire Mark Cuban's pharmaceuticals start-up -- known as the Mark Cuban Cost Plus Drug Company -- to sell a biosimilar (a generic biologic) version of AbbVie's flagship anti-inflammatory medication, Humira, at an 85% discount.  Coherus' biosimilar will be branded as Yusimry., Headline: Dow Jones Today: Debt Vote Drives Index Higher, source:Yahoo, summary: The Dow Jones Industrial Average moved higher by more than 0.5%, or 153 points, as investors celebrated the House of Representatives passage of the debt-ceiling bill, which now goes to the Senate.",AMGN
229,2023-06-02,"Headline: Possible Bearish Signals With Amgen Insiders Disposing Stock \, source:Yahoo, summary: Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have..., Headline: High Yield Stock Watchlist: June 2023, source:SeekingAlpha, summary: There are 20 stocks on my high yield watchlist for June 2023. The majority of the stocks on my watchlist are undervalued based on dividend yield theory. Read more here., Headline: 3 Undervalued Biotech Stocks to Buy Before They Blast Off, source:Yahoo, summary: When investors hear the words “undervalued biotech stocks to buy,” they frequently think of companies in the clinical trial stage. That’s understandable. If you can buy a company’s stock before it releases a game-changing drug or therapeutic into the market, you can make a fortune. That line of thinking was displayed in 2020 when many biotech companies raced to produce a Covid-19 vaccine. But every investor also knows that many of those moonshots never pan out. That’s not the kind of uncertainty, Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. advanced 1.77% to $218.07 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree, source:Yahoo, summary: Big Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here's where things stand.",AMGN
230,2023-06-03,"Headline: Analysts Conflicted on These Healthcare Names: Amgen (AMGN) and Natera (NTRA), source:TipRanks, summary: No summary, Headline: How To Build Wealth: Buy Low And Sell High Consistently, source:SeekingAlpha, summary: The strategy discussed is about buying or selling small quantities of shares when certain thresholds are met. Click here to read more about that strategy., Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of June 4, source:SeekingAlpha, summary: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Click here to read the complete list.",AMGN
231,2023-06-04,"Headline: Amgen presents new LUMAKRAS CodeBreaK 200 CNS data at ASCO, source:Thefly.com, summary: No summary, Headline: AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development program in patients with KRAS G12C-mutated cancers, at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago. The research presented reinforces the efficacy of LUMAKRAS®/LUMYKRAS® (sotorasib) in advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC). Additionally, data from SCA, Headline: Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays., source:MarketWatch, summary: No summary",AMGN
232,2023-06-05,"Headline: Analysis-Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast, source:Yahoo, summary: Johnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the  drug a larger contributor to J&J’s 2024 and 2025 sales than Wall Street is forecasting.  Stelara, introduced in 2009, has been J&J’s top-selling drug since 2019, with sales reaching $9.7 billion in 2022.  Its patents begin to expire this year, opening the door to a cheaper biosimilar entering the market, and raising expectations that the company would need to lower the $13,000 per month price of Stelara., Headline: Even Mark Cuban Can’t Fix This Broken Drug System, source:Yahoo, summary: Coherus BioSciences’ partnership to offer deeply discounted biosimilar Humira can go only so far in reducing overall prices., Headline: Here's How Much $1000 Invested In Amgen 15 Years Ago Would Be Worth Today, source:Benzinga, summary: No summary, Headline: Iveric Bio gains after holder vote on Astellas takeover set for July 6, source:Seeking Alpha, summary: No summary, Headline: Stocks making the biggest moves midday: Palo Alto Networks, 3M, Amedisys, Target and more, source:CNBC, summary: These are among the stocks posting the largest moves in midday trading Monday. , Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. advanced 1.75% to $221.88 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Dow Jones Today: Apple Headset Can’t Lift Index, source:Yahoo, summary: The Dow Jones Industrial Average fell 0.6%, or about 200 points, as markets cooled off from Friday's blistering rally. Amgen rose more than any other stock, but Intel led the index lower.",AMGN
233,2023-06-06,"Headline: Lina Khan Is Upending One of Wall Street’s Favorite Trades, source:Yahoo, summary: (Bloomberg) -- Lina Khan is the most aggressive trustbuster the US has had in decades. Roughly two years into her tenure, Wall Street is still learning the hard way just how far she’ll take her fight against some of America’s most powerful businesses.Most Read from BloombergUkraine Dam Blast Blamed on Russia Tips War Into New PhasePGA Tour Bows to Saudi Rival in Shock Combination With LIV GolfSEC’s Coinbase Lawsuit Heralds Deepening US Crypto CrackdownApple Headset Looks Sleek in Person But Batt, Headline: U.S. Wide-Moat Stocks On Sale - The June 2023 Heat Map, source:SeekingAlpha, summary: Our 3-step process focuses on wide-moat stocks (as per Morningstarâs rating). Click here to see the heat map of the most investable candidates for June 2023., Headline: Are You a Value Investor? This 1 Stock Could Be the Perfect Pick, source:Yahoo, summary: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage., Headline: Amgen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. shed 0.30% to $221.22 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Buy 3 June Dogs Of The Dow, Watch 4, source:SeekingAlpha, summary: Analyst one-year targets showed ten highest-yield Dow stocks producing 13.64% more gain from $5k invested in the lowest-priced five. Learn more about our stock lists.",AMGN
234,2023-06-07,"Headline: Video: Dow Analyst Moves: AMGN, source:Market News Video, summary: No summary, Headline: See How Amgen Ranks Among Analysts' Top Dow 30 Picks, source:ETF Channel, summary: No summary, Headline: Amgen Inc. stock underperforms Wednesday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.01% higher to $221.25 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow..., Headline: Amgen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: No summary",AMGN
235,2023-06-08,"Headline: The 3 Best Long-Term Dividend Stocks to Buy in June, source:InvestorPlace, summary: No summary, Headline: DJD: Attractive Valuation, Average Quality And Return, source:SeekingAlpha, summary: DJD holds 27 stocks of the Dow Jones paying a dividend. Valuation and dividend growth look attractive, but quality and historical return are average. Read more here., Headline: July 28th Options Now Available For Amgen (AMGN), source:Stock Options Channel, summary: No summary, Headline: Is AbbVie or Amgen the Better Bargain Buy Right Now?, source:Yahoo, summary: Due to the highly competitive nature of the pharmaceutical industry, it is no easy task to replace the aging stars in a drug portfolio.  Teva Pharmaceutical (NYSE: TEVA) illustrates this point nicely.  In the middle of the last decade, Teva lost exclusivity for its multiple sclerosis medication Copaxone., Headline: Ideaya Biosciences: Lots Of 'Shots On Goal' And Upcoming Potential Catalysts, source:SeekingAlpha, summary: Ideaya Biosciences is moving forward a large pipeline of drug candidates based on its focus on synthetic lethality. Click here to read more on IDYA stock., Headline: Amgen: Big Yield And Dividend Growth On Sale Now, source:SeekingAlpha, summary: Amgen's products are inelastic and should grow with the population over time. Click here to see why AMGN stock is a Buy., Headline: Seagen gains as antitrust deadline for Pfizer purchase nears on Monday, source:Seeking Alpha, summary: No summary, Headline: Amgen Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: No summary",AMGN
236,2023-06-09,"Headline: Amgen Inc. (NASDAQ:AMGN) Shares Could Be 44% Below Their Intrinsic Value Estimate, source:Yahoo, summary: Key Insights Amgen's estimated fair value is US$394 based on 2 Stage Free Cash Flow to Equity Current share price of..., Headline: AMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE, source:Yahoo, summary: Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 44th Annual Global Healthcare Conference at 2:20 p.m. ET on Wednesday, June 14, 2023. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors, and the general public., Headline: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed at $218.82 in the latest trading session, marking a -0.88% move from the prior day.",AMGN
237,2023-06-12,"Headline: Big Pharma dealmaking recovers with $85bn M&A splurge, source:Yahoo, summary: Pharmaceutical and biotech companies spent $85bn on acquisitions in the first five months of the year, marking a dramatic recovery in dealmaking as they seek to replenish their drug pipelines.  The surge in M&A, compared to just $35.6bn in deals in the same period of 2022 and $49.1bn the year before, according to Stifel, an investment bank, is being fuelled by large cash reserves amassed by Big Pharma during the coronavirus pandemic and investor concerns about future growth prospects.  At the start of year, the world’s largest pharmaceutical companies held more than $1.4tn in dealmaking firepower, according to an analysis by EY., Headline: Teva, Alvotech in pact with Johnson & Johnson over Stelara knockoff, source:Seeking Alpha, summary: No summary, Headline: Video: Dow Movers: AMGN, CRM, source:Market News Video, summary: No summary, Headline: 5 Stocks to Buy With Explosive 500% Potential, source:InvestorPlace, summary: No summary, Headline: Pharma: M&A strategy gets dose of bitter medicine, source:Yahoo, summary: Medicines price gouger Martin Shkreli was one of a kind.  Illumina bought cancer test developer Grail for $8bn in 2021, even though US and EU authorities complained the US gene sequencer could deny crucial inputs to Grail’s rivals.  On Monday, its boss Francis deSouza resigned after a proxy fight with activist investor Carl Icahn over Illumina’s decision to proceed., Headline: Amgen Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. dropped 0.64% to $217.36 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: Deep Value Moments, source:GuruFocus, summary: No summary",AMGN
238,2023-06-13,"Headline: Nicholas Ward's Dividend Growth Portfolio: April And May Review, source:SeekingAlpha, summary: My passive income stream increased by 25.59% YoY in April 2023 and 40.02% YoY in May 2023, with a YTD growth of 29.99%. See the full April & May update here., Headline: Top 20 Most Profitable Pharmaceutical Companies In The World, source:Yahoo, summary: In this article, we will be covering the top 20 most profitable pharmaceutical companies in the world. If you wish to see the top ones, head straight to the Top 5 Most Profitable Pharmaceutical Companies In The World. Undoubtedly, the pharmaceutical industry stands as one of the most financially rewarding and essential sectors worldwide, leading […], Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. rallied 2.13% to $221.99 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: Dow Jones Today: Inflation Down, Index Up, source:Yahoo, summary: The Dow Jones Industrial Average rose 0.4%, or about 145 points, after May’s inflation report encouraged investors the Federal Reserve will keep interest rates steady at least until July.",AMGN
239,2023-06-14,"Headline: BTIG starts Virdian at buy, cites market potential for thyroid eye drug, source:Seeking Alpha, summary: No summary, Headline: Amgen reportedly hires Moderna chief medical officer as new CMO, source:Seeking Alpha, summary: No summary, Headline: Medifast: A Revamp Is Necessary, An Embrace Of GLP-1s Can Help, source:SeekingAlpha, summary: Medifast is currently deploying positive cash flow dollars to maintenance of over 8% yielding dividend and to share repurchases. Find out why MED stock is a Strong Buy., Headline: Amgen Inc. (AMGN) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript), source:SeekingAlpha, summary: Amgen Inc. (NASDAQ:NASDAQ:AMGN) Goldman Sachs 44th Annual Global Healthcare Conference June 14, 2023 2:20 PM ETCompany ParticipantsRobert Bradway - Chairman and Chief Executive..., Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.13% higher to $222.28 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...",AMGN
240,2023-06-15,"Headline: Microsoft, Amgen share gains lead Dow's nearly 450-point rally, source:MarketWatch, summary: Led by strong returns for shares of Microsoft and Amgen, the Dow Jones Industrial Average is rallying Thursday afternoon. The Dow is trading 445 points..., Headline: Amgen Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. rose 2.77% to $228.44 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Dow Jones Today: Microsoft Leads Index Higher, source:Yahoo, summary: The Dow Jones Industrial Average rose 1.3%, or about 430 points, after retail sales data showed Americans are still upping their spending, a sign of resilience amid slowing inflation., Headline: How Amgen Makes Money, source:Yahoo, summary: Amgen produces drugs to treat several conditions and markets them worldwide. Learn its revenue-earning structure and how it makes money., Headline: Noteworthy Friday Option Activity: AMGN, WW, SCHW, source:Stock Options Channel, summary: No summary",AMGN
241,2023-06-16,"Headline: AbbVie's (ABBV) Skyrizi Meets Ulcerative Colitis Study Goals, source:Yahoo, summary: AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remission in a late-stage study as a maintenance treatment for ulcerative colitis., Headline: This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy?, source:Yahoo, summary: Assuming it does, it's not going to be stealing a fry from the corner of AbbVie's plate -- it's going for a big-mouth chomp of the cheeseburger with all the fixings.  AbbVie shareholders are doubtless bracing themselves.  Coherus develops new oncology drugs with a combination of in-licensing candidates and its own research and development (R&D) activities, but it also currently sells biosimilar drugs that are copies of medicines developed by other companies., Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.53% higher to $229.66 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: Amgen (AMGN) Gains As Market Dips: What You Should Know, source:Yahoo, summary: In the latest trading session, Amgen (AMGN) closed at $229.66, marking a +0.53% move from the previous day.",AMGN
242,2023-06-17,"Headline: Verizon: Fear, Greed, Top Dividend Dog Of The Dow, source:SeekingAlpha, summary: Verizon shares offer a well-covered 7.2% dividend yield and currently trade at an attractive price relative to the value. Click here to read more on VZ stock., Headline: A great week that adds to Amgen Inc.'s (NASDAQ:AMGN) one-year returns, institutional investors who own 77% must be happy, source:Yahoo, summary: Key Insights Institutions' substantial holdings in Amgen implies that they have significant influence over the...",AMGN
243,2023-06-18,"Headline: How to Retire Rich: Biotech Stocks Edition, source:Yahoo, summary: Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector – which falls under the broad healthcare industry – is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement",AMGN
244,2023-06-19,"Headline: Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half, source:SeekingAlpha, summary: Tech stocks have staged a massive comeback in 2023, but value investors should consider looking into currently unloved sectors like healthcare. See my top picks.",AMGN
245,2023-06-20,"Headline: Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court , source:CNBC, summary: The lawsuits are the opening salvo in a historic and potentially decisive battle over Medicare's efforts to bring rising drug prices under control. , Headline: Cantor Fitzgerald biotech/biopharma to hold a luncheon meeting, source:Thefly.com, summary: No summary, Headline: Cantor Fitzgerald biotech/biopharma to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Amgen Inc. stock falls Tuesday, still outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slid 0.47% to $228.59 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Tracking John Paulson's Paulson & Company Portfolio - Q1 2023 Update, source:SeekingAlpha, summary: John Paulson's 13F portfolio value increased by around 8% from approximately $1.11B to $1.20B in Q1 2023. Read more on stake increases and decreases here.",AMGN
246,2023-06-21,"Headline: Amgen's Blincyto granted full approval for leukemia by FDA, source:Thefly.com, summary: No summary, Headline: Amgen wins full approval for leukemia therapy Blincyto, source:Seeking Alpha, summary: No summary, Headline: Amgen Gets FDA Approval for Blincyto Supplemental Biologics License Application, source:MarketWatch, summary: By Chris Wack Amgen said Wednesday that the U.S. Food and Drug Administration has approved its supplemental biologics license application for Blincyto, a..., Headline: Top pharma lobby sues U.S. govt. over Medicare drug pricing negotiations, source:Seeking Alpha, summary: No summary, Headline: IN BRIEF: Amgen jubilant as FDA approves Blincyto leukemia drug, source:Alliance News, summary: No summary, Headline: If You Invested $1000 In This Stock 15 Years Ago, You Would Have $4,900 Today, source:Benzinga, summary: No summary, Headline: FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) for the treatment of adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%, based on additional data from two Phase 3 studies that were submitted. The approval conver, Headline: Amgen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. dropped 0.68% to $227.04 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500..., Headline: Leveraging AI in Drug Discovery: Elizabeth Schwarzbach of BigHat Biosciences, Live from NYSE, source:Yahoo, summary: IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with Elizabeth Schwarzbach, Chief Business Officer of BigHat Biosciences. She spoke to IPO Edge Editor-in-Chief […]",AMGN
247,2023-06-22,"Headline: August 4th Options Now Available For Amgen (AMGN), source:Stock Options Channel, summary: No summary, Headline: Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia, source:Yahoo, summary: Amgen (AMGN) announces full approval of its sBLA for Blincyto as an immune-oncology therapy for treating adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia., Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. rallied 1.15% to $229.66 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index..., Headline: Spectrum's Rolvedon A Differentiator In A $3B/Yr Market, source:SeekingAlpha, summary: Spectrum and Assertio's merger would lead to a diversified product portfolio and a combination of two unique marketing strategies. Click here to read more., Headline: California, other states join FTC bid to block Amgen deal, source:Yahoo, summary: The states of California, New York, Illinois, Minnesota,  Washington and Wisconsin have joined a Federal Trade Commission (FTC) lawsuit to stop Amgen's $27.8 billion deal to buy Horizon Therapeutics, according to a court filing on Thursday.  Washington Attorney General Bob Ferguson said his state had joined the lawsuit because ""monopolies harm consumers"" and the merger could allow Amgen to ""dominate"" prescription drug markets.  The group of six states filed an amended complaint Thursday, joining the FTC which last month filed suit opposing the deal because it would give Amgen ""monopoly positions"" for medicines used to treat thyroid eye disease and chronic refractory gout., Headline: UPDATE 1-California, other states join FTC bid to block Amgen deal, source:Yahoo, summary: The states of California, New York, Illinois, Minnesota,  Washington and Wisconsin have joined a Federal Trade Commission (FTC) lawsuit to stop Amgen's $27.8 billion deal to buy Horizon Therapeutics, according to a court filing on Thursday.  Washington Attorney General Bob Ferguson said his state had joined the lawsuit because ""monopolies harm consumers"" and the merger could allow Amgen to ""dominate"" prescription drug markets.  The group of six states filed an amended complaint Thursday, joining the FTC which last month filed suit opposing the deal because it would give Amgen ""monopoly positions"" for medicines used to treat thyroid eye disease and chronic refractory gout., Headline: What You Missed On Wall Street On Friday, source:Thefly.com, summary: No summary",AMGN
248,2023-06-23,"Headline: California, others join FTC challenge of Amgen deal to buy Horizon Therapeutics, source:Thefly.com, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: UnitedHealth unit to add Boehringer's Humira biosimilar to reimbursement list, source:Yahoo, summary: Boehringer Ingelheim's biosimilar of AbbVie Inc's blockbuster arthritis drug Humira will be included in the reimbursement list of UnitedHealth Group Inc's OptumRx unit, the German drugmaker said on Friday.  It will be offered on OptumRx's commercial formulary as a preferred brand, Boehringer said., Headline: Amgen Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slipped 1.11% to $227.11 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Amgen (AMGN) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed the most recent trading day at $227.11, moving -1.11% from the previous trading session.",AMGN
249,2023-06-24,"Headline: 4 Stocks That Can Turn $100,000 Into $500,000 by the Time You Retire, source:Yahoo, summary: Buy 'em and then just get out of the way. Time and these companies' long-term strength will take care of the rest.",AMGN
250,2023-06-25,"Headline: Russian Insurrection Crushed: 5 Stocks That Continue To Have Exposure To The Country, source:Benzinga, summary: No summary, Headline: What is behind big pharma's underperformance?, source:Seeking Alpha, summary: No summary, Headline: Cantor biotech/biopharma analysts hold analyst/industry conference call, source:Thefly.com, summary: No summary",AMGN
251,2023-06-26,"Headline: 7 Analysts Have This to Say About Amgen, source:Benzinga, summary: No summary, Headline: Amgen price target lowered to $260 from $270 at Argus, source:Thefly.com, summary: No summary, Headline: Video: Dow Movers: AMGN, NKE, source:Market News Video, summary: No summary, Headline: Dow falls 109 points on losses for Amgen, Johnson & Johnson shares, source:MarketWatch, summary: Behind losses for shares of Amgen and Johnson & Johnson, the Dow Jones Industrial Average is down Monday morning. The Dow was most recently trading 109..., Headline: A Look Into Amgen Inc's Price Over Earnings, source:Benzinga, summary: No summary, Headline: Amgen Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slid 1.05% to $224.73 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Why Amgen Stock Slumped on Monday, source:Yahoo, summary: Amgen (NASDAQ: AMGN) stock came under renewed pressure on Monday, several days after more regulators piled on to block a major acquisition announced by the company.  As a result, Amgen's share price sank by slightly over 1%, which was more than double the percentage-rate decline of the S&P 500 index on the day.  The person taking the scissors to his Amgen price target was Argus Research's David Toung., Headline: Notable Tuesday Option Activity: AMGN, GIS, AMKR, source:Stock Options Channel, summary: No summary, Headline: Eli Lilly (NYSE:LLY) Touts Superior Results of Weight Loss Shot, source:TipRanks, summary: No summary",AMGN
252,2023-06-27,"Headline: Next-Gen Weight-Loss Drugs Set To Up The Game From Ozempic  And Mounjaro: WSJ, source:Benzinga, summary: No summary, Headline: Pharmaceutical companies are developing drugs to surpass Ozempic, WSJ reports, source:Thefly.com, summary: No summary, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY) and Amgen (AMGN), source:TipRanks, summary: No summary, Headline: Does Amgen (NASDAQ:AMGN) Have A Healthy Balance Sheet?, source:Yahoo, summary: Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of..., Headline: Amgen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. sank 0.94% to $222.61 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index..., Headline: Argus Research Maintains AMGEN (AMGN) Buy Recommendation, source:Fintel, summary: nan, Headline: Dow Jones Today: Index Ends 6-Day Losing Streak, source:Yahoo, summary: Tech and retail stocks helped lift the Dow Jones, while Walgreens plummeted after lowering its earnings outlook, Headline: How Is The Market Feeling About Amgen?, source:Benzinga, summary: No summary",AMGN
253,2023-06-28,"Headline: Cantor Fitzgerald biotech/biopharma to hold a luncheon meeting, source:Thefly.com, summary: No summary, Headline: Cantor Fitzgerald biotech/biopharma to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Cantor biotech/biopharma analysts hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Avantor: Promising Long-Term Buy With Potential For Opportunistic Entry, source:SeekingAlpha, summary: Avantor faces near-term challenges amid macro headwinds and revenue growth uncertainties due to continuing COVID roll-off. Read my analysis of AVTR stock here., Headline: Amgen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slid 0.58% to $221.31 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index..., Headline: The New M&A Rules That Would Delay Million-Dollar Deals, source:Yahoo, summary: (Bloomberg) -- The US antitrust agencies are requiring firms to turn over much more information about their transactions than before in an overhaul to merger rules that could delay deals by months. Most Read from BloombergPutin Claims He’s Back in Control. Russia’s Elite Isn’t SureSwitzerland Blocks Sale of Leopard 1 Tanks Bound for UkraineQatar Group Now Confident of Winning Manchester United RaceSweden Police Give Permit to Koran Burning Near Stockholm MosqueUBS Preparing to Cut Over Half of C, Headline: Pfizer sees second request as likely in FTC's review of Seagen deal - analyst, source:Seeking Alpha, summary: No summary",AMGN
254,2023-06-29,"Headline: Morgan Stanley shakes up its global dividend portfolio, source:Seeking Alpha, summary: No summary, Headline: Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck, source:Benzinga, summary: No summary, Headline: 10 Health Care Stocks Whale Activity In Today's Session, source:Benzinga, summary: No summary, Headline: 5 High-Yielding Dividend Stocks That Are Bargain Buys, source:Yahoo, summary: If you're in search of bargain stocks to buy, the healthcare industry is a great place to start looking.  Among them are Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Amgen (NASDAQ: AMGN), and Pfizer (NYSE: PFE) -- all of which pay dividends and offer great value., Headline: Amgen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. dropped 0.07% to $221.16 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: What Will Amgen Buy Next?, source:Yahoo, summary: Biotech heavyweight Amgen (NASDAQ: AMGN) will probably continue to be an active player in the merger and acquisition (M&A) scene, regardless of what happens with its proposed $28 billion buyout of Horizon Therapeutics (NASDAQ: HZNP).  If this acquisition goes through, for instance, Amgen will probably be limited to smaller deals under $10 billion., Headline: Moody's: Pharma outlook stable for next 12-18 months, but with caveats, source:Yahoo, summary: Moody's, in a note, sees a stable outlook for the drug industry. But there are a few headwinds that might mess up the semi-optimistic picture.",AMGN
255,2023-06-30,"Headline: Cheaper competition for Humira is hitting the market, but savings will depend on your insurance, source:Finnhub, summary: Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July. 
  But lower pharmacy bills may not happen right away — or at all ..., Headline: Amgen Inc. Dividend Stock Analysis, source:TalkMarkets, summary: No summary, Headline: Amgen: A Healthcare Bargain With A 4% Yield, source:SeekingAlpha, summary: Amgen's stock price decline has already priced in much of the bad news, making it an attractive investment. Click here to read my analysis of the AMGN stock., Headline: 15 Stocks Up, 15 Stocks Down: A Look At The Dow Jones Industrial Average Halfway Through 2023, source:Benzinga, summary: No summary, Headline: Medicare revises guidance on drug price negotiations amid lawsuits, source:Seeking Alpha, summary: No summary, Headline: 10 Health Care Stocks With Whale Alerts In Today's Session, source:Benzinga, summary: No summary, Headline: Amgen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.39% higher to $222.02 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: Amgen (AMGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Amgen (AMGN) closed at $222.02, marking a +0.39% move from the previous day.",AMGN
256,2023-07-01,"Headline: Organon launches biosimilar of AbbVie's Humira, source:Seeking Alpha, summary: No summary",AMGN
257,2023-07-02,"Headline: Insiders At Amgen Sold US$1.9m In Stock, Alluding To Potential Weakness, source:Yahoo, summary: Many Amgen Inc. ( NASDAQ:AMGN ) insiders ditched their stock over the past year, which may be of interest to the...",AMGN
258,2023-07-03,"Headline: Not A Market For The Dogs Of The Dow, source:SeekingAlpha, summary: With the first half of 2023 coming to a close this past Friday, the equity markets rewarded investors with strong performance., Headline: Top Analyst Reports for Apple, Verizon & Amgen, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Verizon Communications Inc. (VZ) and Amgen Inc. (AMGN)., Headline: India's Biocon Biologics launches biosimilar for AbbVie's Humira in US, source:Yahoo, summary: India's Biocon Biologics said on Monday it has launched a biosimilar version of AbbVie's blockbuster rheumatoid arthritis drug Humira in the United States.  The launch of the copycat version, branded as Hulio, adds to a list of biosimilars introduced by drugmakers on Monday by Coherus Biosciences and Germany's Fresenius.  Boehringer Ingelheim and Swiss drugmaker Sandoz launched their Humira biosimilars on Saturday.",AMGN
259,2023-07-04,"Headline: FTC : Amgen-Horizon Deal Would Cement Monopoly For Treatment Of Two Diseases, source:Finnhub, summary: Commission pauses major biopharma transaction involving drugs priced in the hundreds of thousands of dollars. As part of the Federal Trade Commission's promised campaign to protect competition in the...",AMGN
260,2023-07-05,"Headline: Why the 5 Highest-Yielding Nasdaq Stocks Could Rip Higher With the Red-Hot Summer Rally, source:247WallSt, summary: No summary, Headline: 3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025, source:InvestorPlace, summary: No summary, Headline: 5 Top Dividend Stocks For July 2023, source:SeekingAlpha, summary: The S&P 500 gained 16% through the first half of 2023. Click here to read more about the five dividend stocks to consider buying in July 2023., Headline: Why I'm Buying DIA This Month Instead Of VOO, source:SeekingAlpha, summary: We explore the idea of alternating new investments between VOO and DIA to make tax loss harvesting easier. Explore more about tax loss harvesting here., Headline: Celltrion launches biosimilar of AbbVie's Humira in US, source:Seeking Alpha, summary: No summary, Headline: The Zacks Analyst Blog Highlights Apple, Verizon Communications, Amgen, Charles Schwab and The Cigna Group, source:Yahoo, summary: Apple, Verizon Communications, Amgen, Charles Schwab and The Cigna Group are part of the Zacks top Analyst Blog., Headline: Amgen Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.39% higher to $225.88 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P..., Headline: Cramer examines the worst performers from the first half of 2023, explains why the market seems narrow, source:CNBC, summary: CNBC's Jim Cramer told investors on Wednesday that if they're waiting for the market to broaden for a rally, they might be waiting forever., Headline: Go with what's working instead of waiting for what is not working, says Jim Cramer, source:CNBC, summary: 'Mad Money' host Jim Cramer takes a closer look at market underperformers and what they say about the economy at large., Headline: 3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025, source:Yahoo, summary: Investing in the biotech sector is mostly about risk and reward. When a company achieves FDA approval on a drug or therapeutic, it frequently has a source of revenue and profit that can last for years. And investors who buy and hold these stocks are typically rewarded with handsome total returns. Even penny stocks can become triple-digit return biotech stocks. However, that payoff can take a long time. Just getting a drug through the clinical trial stage can take several years. And some candidat",AMGN
261,2023-07-06,"Headline: Amgen: Are Its Golden Days Over?, source:TalkMarkets, summary: No summary, Headline: U.S. Wide-Moat Stocks On Sale - The July 2023 Heat Map, source:SeekingAlpha, summary: Our 3-step process focuses on wide-moat stocks. We're only interested in targets attractively valued in historical comparison. Read what investors need to know., Headline: AMGN August 25th Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: Treasury Yields Spiking As Market Looks Ahead To Jobs Data, Raising Valuation Concerns, source:Benzinga, summary: No summary, Headline: 4 Big Pharma Stocks On Sale Right Now , source:MarketWatch, summary: The key is to buy a basket of the cheap ones, so that gains in a few of them can offset disappointing performance in others., Headline: 4 Big Pharma Stocks On Sale Right Now, source:Yahoo, summary: The key is to buy a basket of the cheap ones, so that gains in a few of them can offset disappointing performance in others., Headline: Amgen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slid 1.28% to $222.98 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: Rose's Income Garden 80 Stock Portfolio: Update H1 2023 Green With 7 June Raises, source:SeekingAlpha, summary: Rose's Income Garden portfolio saw 39 companies pay dividends in June, with seven raises and one cut. Click here for a detailed analysis.",AMGN
262,2023-07-07,"Headline: Amgen: Is The 3.79% Dividend Yield Worth The Fuss?, source:SeekingAlpha, summary: Amgen offers an attractive 3.79% dividend yield, with a dividend payout that reached $4.2 billion in FY 2022. Read more about AMGN stock here., Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Amgen price target lowered to $275 from $325 at Jefferies, source:Thefly.com, summary: No summary, Headline: Bristol-Myers Squibb: Battling Exclusivity Headwinds, source:SeekingAlpha, summary: Bristol-Myers Squibb Company is battling the loss of exclusivity of Revlimid with some new product growth engines. Click for more on BMY stock., Headline: Amgen (NASDAQ:AMGN) shareholders have earned a 5.8% CAGR over the last five years, source:Yahoo, summary: Amgen Inc. ( NASDAQ:AMGN ) shareholders might be concerned after seeing the share price drop 12% in the last quarter..., Headline: What Does Amgen's Debt Look Like?, source:Benzinga, summary: No summary, Headline: 2 Struggling Dividend Growth Stocks That Could Make You Richer, source:Yahoo, summary: Despite lingering economic issues, the broader stock market has recovered this year.  Take AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN), two drugmakers that have significantly underperformed the stock market this year.  AbbVie started the year with a lot to prove., Headline: Amgen Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slid 1.94% to $218.65 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Buy 3 July Dogs Of The Dow, Watch 6, source:SeekingAlpha, summary: Analyst 1-year targets showed 10 highest-yield Dow stocks producing 1.62% LESS gain from $5k invested in the lowest-priced 5. Click for our exclusive stock lists., Headline: Amgen (AMGN) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: In the latest trading session, Amgen (AMGN) closed at $218.65, marking a -1.94% move from the previous day.",AMGN
263,2023-07-09,"Headline: Fly Intel: Top five weekend stock stories, source:Thefly.com, summary: No summary, Headline: Pfizer among big pharma stocks on sale right now, Barron's says, source:Thefly.com, summary: No summary, Headline: New M&A rules likely to delay deals by months, add significant costs, source:Seeking Alpha, summary: No summary, Headline: Goldman Sachs sees rays of hope in underperforming health sector, source:Seeking Alpha, summary: No summary, Headline: B. Riley biotechnology analysts to hold an analyst/industry conference call, source:Thefly.com, summary: No summary",AMGN
264,2023-07-10,"Headline: Amgen (AMGN) Gets a Hold from RBC Capital, source:TipRanks, summary: No summary, Headline: AbbVie's R&D Pipeline: Driving Long-Term Growth, source:GuruFocus, summary: No summary, Headline: Dow up 182 points on gains for Amgen, Walgreens Boots stocks, source:MarketWatch, summary: The Dow Jones Industrial Average is climbing Monday morning with shares of Amgen and Walgreens Boots leading the way for the index. The Dow is trading 182..., Headline: These companies have beaten the Rule of 40 year after year, source:MarketWatch, summary: Morgan Stanley applied a VC filter to the stock market. Here's what it found., Headline: Dow up nearly 100 points on gains in shares of Amgen, Walgreens Boots, source:MarketWatch, summary: Buoyed by positive momentum for shares of Amgen and Walgreens Boots, the Dow Jones Industrial Average is climbing Monday morning. Shares of Amgen and..., Headline: AbbVie slips as Cigna adds more Humira biosimilars for coverage, source:Seeking Alpha, summary: No summary",AMGN
265,2023-07-11,"Headline: Amgen price target lowered to $210 from $225 at Barclays, source:Thefly.com, summary: No summary, Headline: Barclays Sticks to Its Sell Rating for Amgen (AMGN), source:TipRanks, summary: No summary, Headline: European Regulator Expands Ozempic Probe To Include Other Weight Loss Drugs Over Suicide Risks, source:Benzinga, summary: No summary, Headline: iRobot, Seagen, Horizon gain amid Microsoft win in Activision case, source:Seeking Alpha, summary: No summary, Headline: Barclays Maintains AMGEN (AMGN) Underweight Recommendation, source:Fintel, summary: nan, Headline: Is There An Opportunity With Amgen Inc.'s (NASDAQ:AMGN) 45% Undervaluation?, source:Yahoo, summary: Key Insights The projected fair value for Amgen is US$407 based on 2 Stage Free Cash Flow to Equity Amgen is estimated..., Headline: EU expands Wegovy, Ozempic probe over suicide risks to include other weight loss, diabetes drugs, source:CNBC, summary: The European Medicines Agency didn't specify which additional GLP-1 drugs are now being investigated, but it could potentially include Eli Lilly's Mounjaro. , Headline: Amgen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slipped 0.39% to $223.86 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: We've only seen the beginning of Moderna's story, says Goldman Sachs' Salveen Richter, source:CNBC, summary: Salveen Richter, Goldman Sachs lead biotech analyst, joins 'Closing Bell Overtime' to discuss the biotech sector and how investors should play in the space., Headline: Analyst Expectations for Amgen's Future, source:Benzinga, summary: No summary",AMGN
266,2023-07-12,"Headline: Amgen price target lowered to $200 from $220 at Credit Suisse, source:Thefly.com, summary: No summary, Headline: ClearBridge Small Cap Growth Strategy Q2 2023 Portfolio Manager Commentary, source:SeekingAlpha, summary: The growth rally expanded to smaller stocks in the second quarter. Click here to read the full fund letter., Headline: Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know, source:Yahoo, summary: No summary, Headline: Credit Suisse Maintains AMGEN (AMGN) Outperform Recommendation, source:Fintel, summary: nan, Headline: Drugmakers’ deal making will plow ahead despite antitrust scrutiny, analysts say, source:MarketWatch, summary: Big pharma goes shopping as ""patent cliff"" puts more than $225 billion in revenues at risk., Headline: Let's Check the Safety and Efficacy of Amgen's Charts Ahead of Earnings, source:Yahoo, summary: AMGN's quarterly report is due in early August, so will buying the stock now pose any side effects?",AMGN
267,2023-07-13,"Headline: Preserving The Patent Bargain : U.S. Supreme Court Limits Amgen's Monopoly, source:Finnhub, summary: Amgen Inc. et al. v Sanofi et al, No. 21-757  On May 18, 2023, the Supreme Court of the United States  issued a long-awaited decision regarding the scope of the enablement requirement in Section 112..., Headline: Lucy Scientific Scores Richard Nanula as CEO After Senior Roles at Disney, Amgen, Starwood, source:Yahoo, summary: By Daniella Parra Psychotropic industry innovator Lucy Scientific Discovery Inc. (Nasdaq: LSDI), has appointed Richard Nanula, former CFO at Amgen Inc. (Nasdaq: AMGN) and The Walt Disney Co. (NYSE: DIS), as its new CEO. With a career spanning senior executive positions at global giants like Starwood Hotels and Resorts, now part of Marriott International, Inc. […], Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.88% higher to $227.66 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?, source:Yahoo, summary: An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market., Headline: Is Amgen's Dividend Safe?, source:Yahoo, summary: Despite multiple headwinds, the biotech's dividend appears to be a safe play for income investors., Headline: Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed the most recent trading day at $227.66, moving +0.88% from the previous trading session., Headline: SCHD vs. VYM: Which is the Better Dividend ETF?, source:TipRanks, summary: No summary, Headline: Catalyst Watch: Microsoft-Activision Blizzard drama, Splunk event and Nasdaq 100 rebalancing countdown, source:Seeking Alpha, summary: No summary, Headline: Venturing Beyond The Magic Kingdom: Former Disney CFO And Fortune 500 Veteran Takes The Reins At Lucy Scientific, source:Benzinga, summary: No summary, Headline: Nicholas Ward's Dividend Growth Portfolio: June 2023 Review, source:SeekingAlpha, summary: The significant dividend growth is attributed to rapid rise in interest rates over past 12-18 months, with cash position now yielding nearly 5%. Read more here.",AMGN
268,2023-07-14,"Headline: ClearBridge Large Cap Value Strategy Q2 2023 Portfolio Manager Commentary, source:SeekingAlpha, summary: U.S. equities continued to make gains in Q2, driven by excitement over generative AI and improving market sentiment., Headline: Zai Lab treats first patient in mainland China in Phase 3 FORTITUDE-101 study, source:Thefly.com, summary: No summary, Headline: (AMGN) - Analyzing Amgen's Short Interest, source:Benzinga, summary: No summary, Headline: 2 Best Biotech Stocks to Buy Right Now, source:Yahoo, summary: Many investors appreciate and rely on the regular cash flow that dividend stocks can generate for them.  Investors should seek out businesses with current products that can finance dividends, and future products that can sustain those dividends.  Here are two companies that could do just that, which income seeking investors should consider purchasing for their portfolios., Headline: MOORE KUEHN ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM, source:Finnhub, summary: NEW YORK, July 14, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against:

    
                
           ..., Headline: Amgen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Amgen Inc. slumped 0.10% to $227.43 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Dividend Income Update June 2023, source:SeekingAlpha, summary: The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. ",AMGN
269,2023-07-16,"Headline: Eli Lilly, Merck among top pharma picks in Barclays Q2 preview, source:Seeking Alpha, summary: No summary",AMGN
270,2023-07-17,"Headline: Amgen Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.18% higher to $227.84 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: Amgen (AMGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Amgen (AMGN) closed at $227.84, marking a +0.18% move from the previous day.",AMGN
271,2023-07-18,"Headline: 3 Biotech Stocks for Getting Rich in 2023, source:Yahoo, summary: The biotech industry is constantly evolving due to being on the cutting edge of the healthcare industry’s research and development. Large biotech companies such as Johnson and Johnson (NYSE:JNJ), Merck (NYSE:MRK), and AbbVie (NYSE:ABBV) offer investors steady and continual growth as well as decent dividends. But, a large portion of the industry involves much more volatile stocks. Many companies’ significant volatility in the biotech market attracts investors looking for a stock that will experie, Headline: Amgen Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. rose 2.08% to $232.57 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Regional banks, Dow Theory: Key technical levels to watch, source:Yahoo, summary: PNC Financial kicked off regional bank earnings with a mixed report. Freedom Capital Markets Chief Global Strategist Jay Woods breaks down what price levels he is watching for the regional banks. For the broader market, with the Dow Jones Industrials Average and the Dow Transports making new 52-week highs, Woods says ""that's as bullish as you can get"" for stocks., Headline: Softbank, Amgen-Backed Neumora Therapeutics Unveils Plans For Three Phase 3 Studies For Major Depressive Disorder, source:Yahoo, summary: Neumora Therapeutics unveiled plans for three late-stage studies for its major depressive disorder (MDD) candidate Navacaprant. The U.S.-based clinical-stage biopharmaceutical is backed by Softbank Group Corp (OTC: SFTBY) (OTC: SFTBF) and Amgen Inc (NASDAQ: AMGN) via a $100 million equity investment. Neumora's KOASTAL Phase 3 program, comprising three Phase 3 studies, is designed to evaluate 80 mg of the once-daily navacaprant (NMRA-140) oral monotherapy for MDD. The U.S. trial, the KOASTAL-1 st, Headline: Amgen, FTC said they are no ongoing talks to settle over Horizon Therapeutics deal, source:Seeking Alpha, summary: No summary, Headline: Amgen, FTC said there are no ongoing talks to settle over Horizon Therapeutics deal, source:Seeking Alpha, summary: No summary, Headline: Amgen, FTC said there are no ongoing talks, though open to settlement over Horizon, source:Seeking Alpha, summary: No summary, Headline: Tesla On Tap: ""Mega-cap"" Reporting Season Gets Underway After Close With EV Giant's Earnings, source:Benzinga, summary: No summary",AMGN
272,2023-07-19,"Headline: ClearBridge Large Cap Value ESG Strategy Q3 2023 Portfolio Manager Commentary, source:SeekingAlpha, summary: ClearBridge takes a fundamental-driven approach to proxies. Click here to read the full fund letter., Headline: Prediction: This Beaten-Down Stock Will Be a Biotech Giant by 2030, source:Yahoo, summary: When you think of biotech giants, you may think of Amgen or Biogen. These companies have brought significant treatments to market over time -- and have generated billions of dollars in earnings, too. Most investors would be happy to find the next company set to follow in their footsteps., Headline: Amgen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. dropped 0.22% to $232.05 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: 12 Highest Yielding Dow Jones Dividend Stocks, source:Yahoo, summary: In this article, we discuss 12 highest yielding Dow Jones dividend stocks. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Highest Yielding Dow Jones Dividend Stocks. The Dow Jones Industrial Average, commonly referred to as the Dow, is one of the most […], Headline: Lawmakers reintroduce bill to offer Medicare coverage for weight loss drugs, source:Seeking Alpha, summary: No summary, Headline: See Which Of The Latest 13F Filers Holds Amgen, source:Preferred Stock Channel, summary: No summary, Headline: Key Horizon drug Tepezza has hearing loss warning added to labeling, source:Seeking Alpha, summary: No summary",AMGN
273,2023-07-20,"Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.51% higher to $233.23 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow..., Headline: M&A Scrutiny May Constrain Large Companies, source:SeekingAlpha, summary: The FTCâs recent push against some large M&A deals may ultimately limit the ability of major companies to take advantage of business development opportunities.",AMGN
274,2023-07-21,"Headline: Mirati fails to win EU backing for lung cancer therapy, source:Seeking Alpha, summary: No summary, Headline: Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 77% of the company, source:Yahoo, summary: Key Insights Institutions' substantial holdings in Amgen implies that they have significant influence over the..., Headline: Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.68% higher to $234.82 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023, source:Yahoo, summary: Pharma stocks experienced an abysmal first half due to various factors. Rotation from defensive to cyclical sectors, drug price negotiations and upcoming patent cliffs have muddied the outlook. As a result, they have underperformed, creating undervalued pharma stocks to buy. Overall, the VanEck Pharmaceutical ETF (NASDAQ:PPH) is flat for the year. Only a few stocks have performed well. For instance, as of this writing, Eli Lilly (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are up 23% and 16.67%, r",AMGN
275,2023-07-24,"Headline: Amgen: Huge Potential With Biosimilars And GLP-1, source:SeekingAlpha, summary: Amgen is now down nearly 20% since last November as money continues to rotate from defensive sectors into tech. Click here to read my latest analysis of AMGN stock., Headline: Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It, source:Yahoo, summary: No summary, Headline: Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing, source:Yahoo, summary: Per the CHMP, Mirati's (MRTX) regulatory filing for Krazati in KRASG12C mutated NSCLC does not fulfill certain requirements to support a conditional marketing authorization., Headline: Amgen Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.26% higher to $235.42 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: Amgen (AMGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Amgen (AMGN) closed the most recent trading day at $235.42, moving +0.26% from the previous trading session.",AMGN
276,2023-07-25,"Headline: Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer, source:Finnhub, summary: CAMBRIDGE - Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the appointment of David..., Headline: Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Janux: Merck Deal, Loads Of Cash, Solid Early Data, source:SeekingAlpha, summary: Janux Therapeutics is a small company with a deal from Merck & Co. and some solid early data. Click here for my look at JANX stock prospects., Headline: Oppenheimer Reiterates AMGEN (AMGN) Outperform Recommendation, source:Fintel, summary: nan, Headline: 2 Cheap High-Yield Dividend Stocks to Buy Now, source:Yahoo, summary: High-yield dividend stocks can offer remarkable benefits for investors who aim to maximize their returns over the long run.  One sector that has many attractive high-yield dividend stocks is healthcare.  Many healthcare companies can afford to pay generous dividends to their shareholders and still invest in growth opportunities., Headline: Amgen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slumped 0.05% to $235.31 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",AMGN
277,2023-07-26,"Headline: AbbVie says Skyrizi beat Amgen’s Otezla in plaque psoriasis trial, source:Seeking Alpha, summary: No summary, Headline: Seven Humira Biosimilars: Increased Competition In Arthritis Drug Market Sparks Need For Reform Of Drug Pricing Intermediaries, source:Benzinga, summary: No summary, Headline: AbbVie under pressure ahead of Q2 results amid Humira cliff, source:Seeking Alpha, summary: No summary, Headline: AbbVie's Skyrizi Achieves Superiority Versus Amgen's Drug In Head-to-Head Study In Moderate Plaque Psoriasis, source:Benzinga, summary: No summary, Headline: AbbVie may see less pain from Humira sales decline as rival lags, source:Yahoo, summary: AbbVie Inc is likely to beat Wall Street sales estimates for Humira in the second quarter as the only copycat in the U.S. market for the blockbuster arthritis drug struggled to gain traction.  Humira sales are likely to decline when the company reports on Thursday but that would mostly be due to the discounts AbbVie has offered to shield itself from prescription share erosion, analysts have said.  The first biosimilar of one of the world's biggest selling drug, Amjevita from Amgen Inc, has not been able to switch Humira patients as much as analysts had estimated since its launch in January., Headline: Amgen Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. dropped 0.04% to $235.21 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Building The Dividend Growth Portfolio In 2023, source:SeekingAlpha, summary: My US dividend growth portfolio, constructed in 2015, has outperformed the market by over 2% annually. Check out my dividend growth portfolio in 2023., Headline: Check Out What Whales Are Doing With AMGN, source:Benzinga, summary: No summary",AMGN
278,2023-07-27,"Headline: Inside AbbVie: Signs of stabilization in Humira sales?, source:Seeking Alpha, summary: No summary, Headline: AMGN September 8th Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: How AbbVie’s Humira Still Reigns, Despite New Competition, source:Yahoo, summary: Revenue for blockbuster arthritis drug declined in the second quarter, largely due to discounts for middlemen., Headline: Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.36% higher to $236.05 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P..., Headline: AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View, source:Yahoo, summary: AbbVie's (ABBV) second-quarter 2023 earnings and sales beat estimates. The company raises its EPS guidance. Stock rises post the announcement., Headline: INVESTIGATION ALERT : Scott+Scott Attorneys at Law LLP Investigates Amgen Inc's Directors and Officers for Breach of Fiduciary Duties – AMGN, source:Finnhub, summary: Scott+Scott Attorneys at Law LLP , an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Amgen Inc.   breached their fiduciary..., Headline: Catalyst watch: Amazon earnings, jobs report and will Apple talk AI?, source:Seeking Alpha, summary: No summary, Headline: Catalyst Watch: Amazon earnings, jobs report, and will Apple talk AI?, source:Seeking Alpha, summary: No summary, Headline: Earnings week ahead: Amazon, Apple, Pfizer, Starbucks, Uber and more, source:Seeking Alpha, summary: No summary, Headline: The Dow Breaks 13-Day Winning Streak, Fed Raises Interest Rates To 2001 Levels And AI Is The Buzzword For Big Tech Earnings: The Week In The Markets, source:Benzinga, summary: No summary",AMGN
279,2023-07-28,"Headline: Big Pharma's Balancing Act : Navigating Patent Thickets In The Age Of Biosimilars, source:Finnhub, summary: The rise of biosimilars is transforming the pharmaceutical landscape, and Big Pharma is keenly aware that the fate of their blockbuster biologic drugs' exclusivity is at stake. These drugs, which..., Headline: Amgen (NASDAQ:AMGN) Seems To Use Debt Quite Sensibly, source:Yahoo, summary: Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously..., Headline: Unveiling AbbVie's Hidden Risks: Cautionary Notes For Investors, source:SeekingAlpha, summary: AbbVie's Q2 2023 financial results exceeded expectations, driven by strong sales of innovative drugs Skyrizi and Rinvoq. Click here to read more., Headline: Amgen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.14% higher to $236.37 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: With Hurricane Season Looming, Florida Faces an Insurance Meltdown , source:MarketWatch, summary: Florida has long had hurricanes. But climate change is kicking in, the population of the state is growing, and private insurers are leaving the state. The...",AMGN
280,2023-07-31,"Headline: Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Icon (ICLR) and Edwards Lifesciences (EW), source:TipRanks, summary: No summary, Headline: Amgen To Report Q2 Earnings: Here's What To Expect, source:TalkMarkets, summary: No summary, Headline: Rising Stars, Falling Trends: July's Industry ETF Winners And Losers, source:Benzinga, summary: No summary, Headline: August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An Edge, source:SeekingAlpha, summary: Breakout Stocks for Week 31 curated by the MDA model for 10% short-term upside and additional model selections. Read more to see the full update., Headline: Amgen (AMGN) to Report Q2 Earnings: Here's What to Expect, source:Yahoo, summary: Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs., Headline: Amgen Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. dropped 0.94% to $234.15 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: Pfizer Stock Wavers Despite Earnings Beat. Revenue and Outlook Aren’t So Good., source:MarketWatch, summary: The company is seeking new sources of revenue because patent expirations are expected to hit seven of its key products by the end of the decade., Headline: AMGEN ANNOUNCES WEBCAST OF 2023 SECOND QUARTER FINANCIAL RESULTS, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 3, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team., Headline: Looking At Amgen's Recent Unusual Options Activity, source:Benzinga, summary: No summary, Headline: Amgen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary, Headline: Amgen declares $2.13 dividend, source:Seeking Alpha, summary: No summary",AMGN
281,2023-08-01,"Headline: AMGEN ANNOUNCES 2023 THIRD QUARTER DIVIDEND, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the third quarter of 2023. The dividend will be paid on September 8, 2023, to all stockholders of record as of the close of business on August 18, 2023., Headline: Amgen looks to Q2 top, bottom line beats after missing in Q1, source:Seeking Alpha, summary: No summary, Headline: Amgen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: No summary",AMGN
282,2023-08-02,"Headline: Video: Daily Dividend Report: AMGN, SYK, GD, KHC, KMB, source:Market News Video, summary: No summary, Headline: NEW YORK MARKET CLOSE: Fitch downgrade sparks retreat on Wall Street, source:Alliance News, summary: No summary, Headline: GLOBAL BRIEFING: China's services see strong growth in July, source:Alliance News, summary: No summary, Headline: Stocks Mitigate Losses Ahead Of Apple, Amazon Earnings; Treasury Yields Rocket On Debt Frenzy: Thursday's Market Drivers, source:Benzinga, summary: No summary, Headline: Notable companies reporting after market close, source:Thefly.com, summary: No summary, Headline: September 22nd Options Now Available For Amgen (AMGN), source:Stock Options Channel, summary: No summary, Headline: Amgen reports Q2 adjusted EPS $5.00, consensus $4.08, source:Thefly.com, summary: No summary, Headline: Amgen raises FY23 adjusted EPS view to $17.80-$18.80 from $17.60-$18.70, source:Thefly.com, summary: No summary, Headline: Amgen sees FY23 CapEx about $925M, source:Thefly.com, summary: No summary, Headline: Amgen Non-GAAP EPS of $5.00 beats by $0.51, revenue of $6.98B beats by $300M, source:Seeking Alpha, summary: No summary, Headline: Amgen stock jumps after the biotech’s record earnings beats expectations, and full-year outlook is raised, source:MarketWatch, summary: No summary, Headline: Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains, source:MarketWatch, summary: No summary, Headline: Amgen (AMGN) Gets a Hold from Mizuho Securities, source:TipRanks, summary: No summary",AMGN
283,2023-08-03,"Headline: Amgen guides 2023 EPS above consensus while revenue in-line, source:Seeking Alpha, summary: No summary, Headline: Amgen stock jumps after record earnings beat expectations, and biotech raises full-year outlook, source:MarketWatch, summary: No summary, Headline: Amgen says FTC has ignored commitments it made to address Horizon deal concerns, source:Seeking Alpha, summary: No summary, Headline: Amgen says FTC has ignored commitments it made to address Horizon deal concerns (update), source:Seeking Alpha, summary: No summary, Headline: US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month, source:Benzinga, summary: No summary, Headline: Amgen Insiders Sold US$1.9m Of Shares Suggesting Hesitancy, source:Yahoo, summary: Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have..., Headline: 3 Dividend Stocks That Hiked Payouts by 60% in Just 5 Years, source:Yahoo, summary: Want a good dividend stock to own?  When it comes to long-term dividend income, it's important to consider businesses that are growing and that have the potential to increase their payouts, allowing your dividend income to rise over the years.  Three companies that have been generously increasing their dividend payments over the past five years include Amgen (NASDAQ: AMGN), Microsoft (NASDAQ: MSFT), and Mondelez International (NASDAQ: MDLZ)., Headline: Amgen stock jumps after record earnings beat expectations, and biotech raises full-year outlook , source:MarketWatch, summary: Amgen's stock jumped in after-hours trading Thursday, after the biotechnology giant reported record second-quarter earnings that rose above expectations., Headline: Amgen 2Q Profit Up as Revenue Rises 6%, source:Finnhub, summary: By Brenda León 


  Amgen posted higher profit and revenue in the second quarter, helped by an increase in product sales across most therapeutic categories. 

  The Thousand Oaks, Calif.-based..., Headline: Stocks making the biggest moves after hours: Apple, Amazon, Airbnb, Coinbase and more, source:CNBC, summary: These are the stocks posting the largest moves in extended trading. , Headline: Stock futures rise slightly as investors weigh Big Tech earnings, await key jobs data: Live updates, source:CNBC, summary: The three major indexes are on pace for week-to-date losses., Headline: AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2023., Headline: Amgen quarterly revenue rises 6%, profit beats Street estimates, source:Yahoo, summary: (Reuters) -Amgen, which is facing U.S. Federal Trade Commission (FTC) delays to its planned acquisition of Horizon Therapeutics, on Thursday reported higher quarterly profit on strong sales of treatments for cholesterol, osteoporosis and other drugs.  The biotech company, which slightly raised its outlook for full-year revenue and profit, said it currently expects the Horizon deal to close by mid-December.  For the second quarter, Amgen reported revenue of $6.99 billion, up 6% from a year earlier, exceeding analysts' estimates of $6.68 billion, according to Refinitiv data., Headline: Amgen earnings beat estimates on revenue, adjusted EPS, source:Yahoo, summary: Amgen beat on estimates with its Q2 earnings. Yahoo Finance Health Care Reporter Anjalee Khemlani joins the Live show to discuss the report, including Amjevita and LUMAKRAS sales numbers., Headline: Amgen Inc. (AMGN) Q2 2023 Earnings Call Transcript, source:SeekingAlpha, summary: Amgen Inc. (NASDAQ:NASDAQ:AMGN) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ETCompany ParticipantsArvind Sood â Vice President of Investor RelationsBob Bradway â Chairman and..., Headline: UPDATE 1-Amgen quarterly revenue rises 6%, profit beats Street estimates, source:Yahoo, summary: Amgen, which is facing U.S. Federal Trade Commission (FTC) delays to its planned acquisition of Horizon Therapeutics, on Thursday reported higher quarterly profit on strong sales of treatments for cholesterol, osteoporosis and other drugs.  The biotech company, which slightly raised its outlook for full-year revenue and profit, said it currently expects the Horizon deal to close by mid-December.  For the second quarter, Amgen reported revenue of $6.99 billion, up 6% from a year earlier, exceeding analysts' estimates of $6.68 billion, according to Refinitiv data., Headline: The Small Drawback In Amgen's Earnings Beat, According To One Analyst, source:Yahoo, summary: Amgen beat second-quarter expectations Thursday and raised its outlook for the year, helping push Amgen stock higher in late action., Headline: Amgen (AMGN) Q2 Earnings and Revenues Top Estimates, source:Yahoo, summary: Amgen (AMGN) delivered earnings and revenue surprises of 12.61% and 5.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?, Headline: Amgen (AMGN) Reports Q2 Earnings: What Key Metrics Have to Say, source:Yahoo, summary: While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values., Headline: Amazon shares rally 10%, but Apple’s dip, and other stocks on the move, source:MarketWatch, summary: No summary, Headline: Looking Into Amgen's Recent Short Interest, source:Benzinga, summary: No summary, Headline: Amgen Inc. 2023 Q2 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Amgen Inc., Headline: Amgen (AMGN) Gets a Sell from Barclays, source:TipRanks, summary: No summary, Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",AMGN
284,2023-08-04,"Headline: Dividend Roundup: IBM, Walmart, BP, Kimberly-Clark, and more, source:Seeking Alpha, summary: No summary, Headline: Amgen (AMGN) Gets a Hold from BMO Capital, source:TipRanks, summary: No summary, Headline: Amgen second quarter profit grows amid Repatha and Evenity boost, source:Alliance News, summary: No summary, Headline: Amgen raises full-year earnings and revenue outlook, source:Yahoo, summary: Investing.com -- Shares in Amgen (NASDAQ:AMGN) rose in premarket U.S. trading on Friday after the U.S. biotech company improved its annual earnings and revenue forecast, and said it expects to close its planned multibillion-dollar acquisition of Horizon Therapeutics (NASDAQ:HZNP) by mid-December., Headline: Amgen Raises FY23 Outlook, Discloses Brief Readout From Tarlatamab Lung Cancer, Lumakras Colorectal Cancer Studies, source:Benzinga, summary: No summary, Headline: Amgen, Microsoft share gains lead Dow's 175-point climb, source:MarketWatch, summary: No summary, Headline: Amgen, Microsoft share gains contribute to Dow's 265-point jump, source:MarketWatch, summary: No summary, Headline: Amgen, Intel share gains contribute to Dow's 175-point jump, source:MarketWatch, summary: No summary, Headline: Amgen Is 'Confident' It Can Wrap The Horizon Takeover By December, source:Yahoo, summary: Amgen stock jumped Friday after topping Wall Street's second-quarter views, but investors remain zeroed in on the takeover of Horizon., Headline: If You Had Invested $5,000 in Amgen in 2013, This Is How Much You Would Have Today, source:Yahoo, summary: Pharmaceutical giant Amgen (NASDAQ: AMGN) is a component within the S&P 500 index.  Since its founding in 1980, Amgen has devoted itself to fostering a culture of innovation.  In fact, Amgen's total revenue has steadily grown from $18.7 billion in 2013 to a projected $26.6 billion in 2023., Headline: Amgen (AMGN) Q2 Earnings Beat Estimates, 2023 View Raised, source:Yahoo, summary: Amgen (AMGN) beats Q2 estimates for earnings and sales. It slightly raises its earnings and sales guidance for 2023., Headline: US STOCKS-Wall St rises on Amazon boost; bond yields fall, source:Yahoo, summary: Wall Street rose and bond yields fell on Friday after July jobs data showed a slowing in the U.S. labor market with wage gains, while Amazon's stellar earnings countered Apple's tepid sales forecast.  The yield on the 10-year benchmark note dipped on Friday after the jobs data, but still remained above 4%, partly boosting some megacap stocks.  ""At this point in some ways the jobs data doesn't do much to the Fed. The drama is now pivoting from the Fed to the Treasury,"" said David Russell, vice president of market intelligence at TradeStation., Headline: Is Amgen Inc (AMGN) Stock Fairly Valued? An In-depth Analysis, source:Yahoo, summary: Amgen Inc (NASDAQ:AMGN) recently recorded a daily gain of 5.81%, with an Earnings Per Share (EPS) (EPS) of $14.71.  Given these figures, a pertinent question arises: is Amgen (NASDAQ:AMGN) fairly valued?  Amgen is a leading biotechnology company specializing in human therapeutics, notably in renal disease and cancer supportive-care products., Headline: RBC Capital Maintains AMGEN (AMGN) Sector Perform Recommendation, source:Fintel, summary: nan, Headline: Amgen Inc: A Strong Contender in the Drug Manufacturers Industry with a GF Score of 85, source:Yahoo, summary: Amgen Inc (NASDAQ:AMGN), a leading player in the drug manufacturers industry, is currently trading at $245.67 with a market capitalization of $131.27 billion.  According to the GF Score, Amgen has a score of 85 out of 100, indicating good outperformance potential.  This article will delve into the components of the GF Score and compare Amgen's performance with its main competitors., Headline: US STOCKS-U.S. stocks rises on Amazon boost; bond yields fall, source:Yahoo, summary: Wall Street gained and bond yields fell on Friday after July jobs data showed a slowing in the U.S. labor market with wage gains.  Data for June additions was revised lower to 185,000 jobs, from 209,000 reported previously., Headline: Dow Jones Reverses Lower On Reports Of Cyberattack; Fortinet Slammed After Earnings, source:Yahoo, summary: The Dow Jones faded off highs on reports that hospital systems in multiple states were hit by a cyberattack. Apple tanked on earnings., Headline: US STOCKS-Wall Street ends lower after US jobs report; Apple weighs, source:Yahoo, summary: Wall Street closed lower on Friday after a report of slowing U.S. labor market growth, and all three major indexes posted weekly losses as investors braced for more possible downside surprises a day after disappointing earnings from Apple.  Apple's shares fell 4.8%, its biggest daily percentage decline since Sept. 29, 2022 that dented the S&P 500 by about 16 points the day after the iPhone maker forecast a continued slide in sales.  A partial counterweight to Apple for the S&P 500 and Nasdaq was Amazon.com.",AMGN
285,2023-08-05,"Headline: Amgen's (NASDAQ:AMGN) Dividend Will Be Increased To $2.13, source:Yahoo, summary: Amgen Inc. ( NASDAQ:AMGN ) will increase its dividend from last year's comparable payment on the 8th of September to..., Headline: 1 Top Dividend Growth Stock to Buy on the Dip, source:Yahoo, summary: Its shares are down by 12% since 2023 started, and the company has faced several issues recently that have harmed its financial results, leading many investors to abandon the stock.  Let's find out why income seekers should strongly consider adding shares of Amgen to their portfolios now.  Amgen is one of the largest biotechnology companies in the world, with a presence in dozens of countries and a portfolio that boasts more than 20 products., Headline: 2023 shaping up to be biggest year for biopharma M&A since pandemic, source:Seeking Alpha, summary: No summary",AMGN
286,2023-08-06,"Headline: Is Amgen (AMGN) Stock Fairly Valued? A Comprehensive Analysis, source:GuruFocus, summary: No summary, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Cigna (CI) and Ultragenyx Pharmaceutical (RARE), source:TipRanks, summary: No summary, Headline: Nearly half of U.S. adults want weight-loss drugs – KFF poll, source:Seeking Alpha, summary: No summary, Headline: Stock futures rise as Wall Street comes off a losing week: Live updates, source:CNBC, summary: Last week was the worst for the S&P 500 and Nasdaq Composite since March., Headline: Dow up 425 points on gains in shares of Amgen, Boeing, source:MarketWatch, summary: No summary, Headline: Amgen Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: No summary",AMGN
287,2023-08-07,"Headline: Longeveron Announces Key Additions To Its Leadership Team And Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions, source:Benzinga, summary: No summary, Headline: Amgen Gives You Growth, Dividend Growth, And Value, source:SeekingAlpha, summary: Amgen appears to remain undervalued for value and income investors. Read more to see a detailed analysis of AMGN stock., Headline: Monday’s Top Wall Street Analyst Upgrades and Downgrades: Amazon, Apple, Block, Coinbase, Datadog, Fortinet, Gilead Sciences, Moderna, Nvidia, PayPal, Petrobras and More, source:247WallSt, summary: No summary, Headline: Boeing, Amgen share gains lead Dow's 337-point jump, source:MarketWatch, summary: No summary, Headline: Amgen (AMGN) Shares Cross Above 200 DMA, source:Dividend Channel, summary: No summary, Headline: Amgen Inc: A Strong Contender in the Drug Manufacturers Industry with a High GF Score, source:GuruFocus, summary: No summary, Headline: Amgen Is Back!, source:SeekingAlpha, summary: Amgen's stock has rebounded by 10% and is showing improving fundamentals, with strong volume and revenue growth in core drugs. Find out why AMGN stock is a Buy., Headline: 10 Health Care Stocks With Whale Alerts In Today's Session, source:Benzinga, summary: No summary, Headline: August MDA Breakout Stocks Week 32 - 2023: High-Frequency Gainers To Give You An Edge, source:SeekingAlpha, summary: Two new Breakout Stocks for Week 32 curated by the MDA model for 10% short-term upside and additional model selections. Click here to read more., Headline: CNBC Daily Open: Playing the T-bill game, source:CNBC, summary: The U.S. economy has remained resilient and seemingly largely impervious to the Fed's highest rates in more than two decades., Headline: Dow Jones Today: Index Rebounds with 400-Point Gain, source:Yahoo, summary: Following last week’s downward turn, the Dow Jones Industrial Average bounced back, rising 407 points, or 1.2%, as investors readied for new inflation data to close out the week., Headline: CNBC Daily Open: Treasury bets, source:CNBC, summary: The U.S. economy has remained resilient and seemingly largely impervious to the Fed's highest rates in more than two decades., Headline: Amgen Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: No summary",AMGN
288,2023-08-08,"Headline: Amgen (AMGN) Receives a Sell from Robert W. Baird, source:TipRanks, summary: No summary, Headline: Watch weight loss stocks after cardiovascular data for Wegovy, source:Seeking Alpha, summary: No summary, Headline: Amgen a Top 25 Dividend Giant With 3.37% Yield (AMGN), source:ETF Channel, summary: No summary, Headline: Amgen a Top Socially Responsible Dividend Stock With 3.4% Yield (AMGN), source:ETF Channel, summary: No summary, Headline: Is Amgen Inc (AMGN) Stock Fairly Valued?, source:Yahoo, summary: An In-depth Analysis of Amgen's Current Valuation, Headline: Amgen Inc: A Strong Contender in the Drug Manufacturers Industry with a GF Score of 85, source:Yahoo, summary: Amgen Inc (NASDAQ:AMGN), a leading player in the Drug Manufacturers industry, is currently trading at $262.57 with a market cap of $140.87 billion.  According to the GF Score, a stock performance ranking system developed by GuruFocus, Amgen Inc has a score of 85 out of 100, indicating good outperformance potential.  This rank measures the robustness of a company's financial situation, taking into account factors such as its debt burden, debt to revenue ratio, and Altman Z-Score., Headline: Buy 2 August Dogs Of The Dow, Watch 5, source:SeekingAlpha, summary: Discover the criteria for stocks to be added to the Dow, the highest-yield stocks in August, and analyst predictions for stocks' performance. Read more here., Headline: Barclays Sticks to Its Sell Rating for Amgen (AMGN), source:TipRanks, summary: No summary, Headline: 3 Biotech Stocks You’ll Regret Not Buying Soon, source:Yahoo, summary: The biotech industry proved itself resilient in the face of the COVID-19 pandemic. With research from Mckinsey, venture capitalist (VC) companies increased investments from 2,200 in 2016 to 3,100 in 2021 in biotechnology (biotech) startups. These startups have advanced medicine overall, improving cell therapy, tissue regeneration, genetic medicine, and more. With increasing innovation, we see an ongoing cycle. VC companies will continue to invest by providing resources and funding for these comp, Headline: Amgen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: No summary",AMGN
289,2023-08-09,"Headline: Amgen Reaches Analyst Target Price, source:ETF Channel, summary: No summary, Headline: Looking At Amgen's Recent Unusual Options Activity, source:Benzinga, summary: No summary, Headline: The 3 Best Biotech Stocks to Buy in August, source:Yahoo, summary: Many healthcare stocks suffer from COVID fatigue as profits fall amid a global decline in the virus’ spread. But medical innovations and technological breakthroughs are rapidly transforming the healthcare landscape, and biotech stocks are garnering unprecedented attention in the investment community. These companies, operating at the intersection of biology and technology, promise groundbreaking treatments, therapies and solutions to some of the world’s most persistent medical challenges. As the, Headline: Dow up 181 points on gains in shares of Walt Disney, Amgen, source:MarketWatch, summary: No summary, Headline: Here's How Much You Would Have Made Owning Amgen Stock In The Last 15 Years, source:Benzinga, summary: No summary, Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",AMGN
290,2023-08-10,"Headline: Ideaya Biosciences price target raised to $35 from $30 at Oppenheimer, source:Thefly.com, summary: No summary, Headline: Want Rising Dividend Income? Buy Amgen Stock, source:Yahoo, summary: Pharmaceutical company Amgen (NASDAQ: AMGN) is a favorite among income investors.  Here are four reasons that the stock could have a special place in a portfolio centered around dividend growth.  In the second quarter ended June 30, Amgen's total revenue increased by 5.9% year over year to $7 billion., Headline: Walt Disney, Amgen share gains contribute to Dow's 200-point climb, source:MarketWatch, summary: No summary, Headline: Amgen (NASDAQ:AMGN) jumps 13% this week, though earnings growth is still tracking behind five-year shareholder returns, source:Yahoo, summary: When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than..., Headline: Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know, source:Yahoo, summary: No summary, Headline: These 10 medications are likely targets for Medicare price negotiations this fall, source:CNBC, summary: It's still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their medications are targets., Headline: 3 Dow Jones Stocks To Watch In August 2023, source:StockMarket, summary: Dow Jones Industrial Average stocks to check out in the stock market today., Headline: Nasdaq Suffers Second Straight Week of Losses, Breaks Key Support Level As Tech Bears Return: Is This Time Different?, source:Benzinga, summary: No summary, Headline: Amgen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary, Headline: Uber Crowded, Battleground and Sweet 16 stock portfolios from Jefferies, source:Seeking Alpha, summary: No summary",AMGN
291,2023-08-12,"Headline: How To Invest $100,000 Today: 5 Strategies Including The Near-Perfect Portfolio Strategy, source:SeekingAlpha, summary: Discover five investment strategies, including the Near-Perfect Portfolio, aimed at capital preservation, sustainable income, and long-term growth. Click for more., Headline: Amgen (NASDAQ:AMGN) Could Be A Buy For Its Upcoming Dividend, source:Yahoo, summary: Amgen Inc. ( NASDAQ:AMGN ) is about to trade ex-dividend in the next four days. The ex-dividend date is one business..., Headline: Pharma under threat from bill to expand drug price negotiations, source:Seeking Alpha, summary: No summary",AMGN
292,2023-08-13,"Headline: Horizon Therapeutics, Activision among best bets for M&A deals to close, source:Seeking Alpha, summary: No summary, Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of August 13, source:SeekingAlpha, summary: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the full August 13 weekly update., Headline: The Latest Analyst Ratings for Amgen, source:Benzinga, summary: No summary, Headline: Amgen Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: No summary",AMGN
293,2023-08-14,"Headline: Amgen price target raised to $223 from $214 at Mizuho, source:Thefly.com, summary: No summary, Headline: Amgen price target raised to $310 from $275 at Jefferies, source:Thefly.com, summary: No summary, Headline: QUALCOMM, AIG And 2 Other Stocks Insiders Are Selling, source:Benzinga, summary: No summary, Headline: Tracking George Soros's Portfolio - Q2 2023 Update, source:SeekingAlpha, summary: George Soros's 13F portfolio value decreased slightly from $6.49B to $6.41B, with 172 positions. Click here to read the portfolio's Q2 2023 update., Headline: Jefferies Maintains AMGEN (AMGN) Buy Recommendation, source:Fintel, summary: nan, Headline: Mizuho Maintains AMGEN (AMGN) Neutral Recommendation, source:Fintel, summary: nan, Headline: August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February, source:SeekingAlpha, summary: The Momentum Gauges and S&P 500 Gauges have turned negative. Read why this indicates a shift in market momentum and the need for caution in stock selection., Headline: Amgen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: No summary",AMGN
294,2023-08-15,"Headline: Tuesday’s Top Wall Street Analyst Upgrades and Downgrades: Amgen, Coterra Energy, Eaton, Marriott, Monster Beverage, Mosaic, Urban Outfitters, Wayfair and More, source:247WallSt, summary: No summary, Headline: Tudor Investment boosts stakes in Big Tech, exits VMware, BAH, HRL, source:Seeking Alpha, summary: No summary, Headline: Is Amgen (AMGN) Stock Fairly Valued?, source:GuruFocus, summary: No summary, Headline: 15 Worst Performing Blue Chip Stocks in 2023, source:Yahoo, summary: In this piece, we will take a look at the 15 worst performing blue chip stocks in 2023. If you want to skip a background of what’s been going on in this lucrative sector this year, then head on over to 5 Worst Performing Blue Chip Stocks in 2023. In traditional poker, a blue chip […], Headline: I Got 99 Problems But A High Yield Ain't One (151 Trade Ideas), source:SeekingAlpha, summary: Discover how our Advanced cash covered put selling strategy can help you generate high yields while minimizing market risk. Click for our exclusive picks., Headline: Amgen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: No summary",AMGN
295,2023-08-16,"Headline: Horizon Therapeutics: Can Investors Profit From Amgen Deal Confusion?, source:Seeking Alpha, summary: No summary, Headline: February 2024 Options Now Available For Amgen (AMGN), source:Stock Options Channel, summary: No summary, Headline: Is Now The Time To Put Amgen (NASDAQ:AMGN) On Your Watchlist?, source:Yahoo, summary: For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to..., Headline: Could Amgen Stock Help You Become a Millionaire?, source:Yahoo, summary: Healthcare company Amgen (NASDAQ: AMGN) has been a reliable investment to own over what has been a turbulent year for the broader market.  A particularly promising drug involved in the deal is Tepezza, a treatment for thyroid eye disease which could bring in up to $4 billion in peak annual sales., Headline: Improved Outlook For Horizon Therapeutics And Amgen, source:SeekingAlpha, summary: Horizon Therapeutics' better-than-expected Q2 eases concerns about Amgen acquisition failing to close due to Horizon's business underperformance. Read more here., Headline: Horizon Therapeutics - Can Investors Profit From Amgen Deal Confusion?, source:SeekingAlpha, summary: Exploring the uncertain fate of the $28.5bn acquisition deal between Horizon Therapeutics and Amgen, and its potential impact on their share prices., Headline: Amgen Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark, source:Yahoo, summary: Amgen shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 68 to 80., Headline: Unusual Call Option Trade in AMGEN (AMGN)  Worth $4,395.60K, source:Fintel, summary: nan, Headline: Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains, source:MarketWatch, summary: No summary",AMGN
296,2023-08-17,"Headline: Jefferies starts BeiGene at buy, cites deep pipeline, Novartis partnership, source:Seeking Alpha, summary: No summary, Headline: The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023, source:InvestorPlace, summary: No summary, Headline: Looking At Amgen's Recent Unusual Options Activity, source:Benzinga, summary: No summary, Headline: Amgen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: No summary",AMGN
297,2023-08-18,"Headline: AARP, Public Citizen file briefs in Medicare drug price negotiations case, source:Seeking Alpha, summary: No summary",AMGN
298,2023-08-20,"Headline: With 78% ownership of the shares, Amgen Inc. (NASDAQ:AMGN) is heavily dominated by institutional owners, source:Yahoo, summary: Key Insights Given the large stake in the stock by institutions, Amgen's stock price might be vulnerable to their..., Headline: Horizon Therapeutics gains amid speculation on potential FTC settlement on Amgen, source:Seeking Alpha, summary: No summary, Headline: Amgen Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: No summary",AMGN
299,2023-08-21,"Headline: Amgen's Lumakras facing FDA advisory panel for full approval, source:Seeking Alpha, summary: No summary, Headline: First Week of September 15th Options Trading For Amgen (AMGN), source:Stock Options Channel, summary: No summary, Headline: Is Amgen Stock a Top Buy and Hold?, source:Yahoo, summary: One way to increase your odds of success is to buy shares of high-quality companies that sport strong competitive advantages, solid growth prospects, and attractive valuations.  Biotech giant Amgen (NASDAQ: AMGN) ticks many of these boxes.  Read on to find out more about this top dividend-paying biotech stock., Headline: Peering Into Amgen's Recent Short Interest, source:Benzinga, summary: No summary, Headline: Is Trending Stock Amgen Inc. (AMGN) a Buy Now?, source:Yahoo, summary: No summary, Headline: 11 Most Profitable Biotech Stocks Today, source:Yahoo, summary: In this piece, we will take a look at the 11 most profitable biotechnology stocks to buy today. If you want to skip our introduction to the biotechnology industry and want to take a look at the top five stocks in this list, then head on over to 5 Most Profitable Biotech Stocks Today. Biotechnology […], Headline: IN BRIEF: US FDA to review Amgen's Lumakras for lung cancer, source:Alliance News, summary: No summary, Headline: Medicare drug price negotiations unlikely to be derailed by lawsuits: UBS, source:Yahoo, summary: UBS believes there is little chance the lawsuits brought on by pharma companies will delay Medicare pricing negotiations., Headline: AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS® (sotorasib) for adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) at a meeting on Oct. 5, 2023., Headline: These Are the ONLY 3 Biotech Stocks to Consider in August 2023, source:Yahoo, summary: The world may be on the mend from the grip of the global pandemic, but the consistent drumbeat for medical innovation remains as unyielding as ever. Amid this backdrop, Biotech stocks present a beacon of hope for humanity and a compelling avenue for savvy investors. Delving into the best biotech stocks offers a chance to back businesses spearheading these life-altering breakthroughs and potentially reap massive dividends. American pharmaceutical giants, often overshadowed in global conversations",AMGN
300,2023-08-22,"Headline: Amgen (AMGN) Gets a Buy from Jefferies, source:TipRanks, summary: No summary, Headline: AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING, source:Finnhub, summary: THOUSAND OAKS - Amgen today announced the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee will review data supporting the supplemental New Drug Application for the full..., Headline: See How Amgen Ranks Among Analysts' Top Dow 30 Picks, source:ETF Channel, summary: No summary, Headline: Video: Dow Analyst Moves: AMGN, source:Market News Video, summary: No summary, Headline: Amgen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Amgen Inc. slid 1.18% to $257.62 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Health care stocks: What the market technicals show, source:Yahoo, summary: Why are UnitedHealth (UNH), Merck & Company (MRK), Johnson & Johnson (JNJ), and Amgen (AMGN), this strategist's top health care stock picks? Freedom Capital Markets Chief Global Strategist Jay Woods joins Yahoo Finance Live to discuss and break down the market technicals of health care stocks.  Woods says he focuses on those four health care stocks, ""because they're in Dow Jones Industrial Average. If you're looking for reasons why the Dow can rally, I give you health care.""  The Health Care Select Sector (XLV) ""continues to make higher lows, as it goes along,"" Woods notes. ""If you're a little skittish on the overall market, health care is a safety sector,"" Woods says., Headline: 12 Best Cheap Dividend Stocks To Buy Now, source:Yahoo, summary: In this article, we discuss 12 best cheap dividend stocks to buy now. You can skip our detailed analysis of dividend stocks and their performance, and go directly to read 5 Best Cheap Dividend Stocks To Buy Now. Investing in cheap stocks is like finding a great deal at a store – it’s about picking […], Headline: This Is What Whales Are Betting On Amgen, source:Benzinga, summary: No summary",AMGN
301,2023-08-23,"Headline: Amgen says FTC case to block Horizon Therapeutics deal `defies logic', source:Seeking Alpha, summary: No summary, Headline: Amgen : Joins Forces with American Heart Association on Lower Your LDL Cholesterol Now™, source:Finnhub, summary: A 2023 survey from the American Heart Association with The Harris Poll shows more than half of Americans who have had a heart attack or stroke don't prioritize lowering LDL or bad..., Headline: Amgen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slumped 0.10% to $257.36 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: Bristol-Myers Squibb: Top Defensive Pick During Recessions With A Value Proposition, source:SeekingAlpha, summary: Discover why Bristol-Myers is a strong investment, undervalued with a promising dividend yield. After a slow start, expect a bullish turnaround., Headline: Tracking David Abrams' Abrams Capital Management Portfolio - Q2 2023 Update, source:SeekingAlpha, summary: Abrams' 13F portfolio value increased from $3.16B to $3.48B this quarter. Click here for a detailed analysis.",AMGN
302,2023-08-24,"Headline: Stock buybacks spur wealth inequality and stifle innovation. But should they be banned?, source:MarketWatch, summary: No summary, Headline: GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus, source:Benzinga, summary: No summary, Headline: Akero Therapeutics: An Assessment, source:SeekingAlpha, summary: Akero's lead candidate, EFX, has shown promising results in clinical trials for both compensated cirrhotic NASH and pre-cirrhotic NASH. Read more here., Headline: Thursday’s Top Analyst Upgrades and Downgrades: Amazon, Amgen, Duke Energy, General Mills, KeyCorp, Lowe’s, Macy’s, Marvell Technology, Netflix, Walmart and More, source:247WallSt, summary: No summary, Headline: Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico, source:Seeking Alpha, summary: No summary, Headline: FTC likely to lose its challenge to the Horizon/Amgen deal, legal experts say - analyst, source:Seeking Alpha, summary: No summary, Headline: Eli Lilly And Novo Nordisk: Are Weight Loss Drugs A Global Revolution Or Short-Lived Fad?, source:SeekingAlpha, summary: Eli Lilly (LLY) and Novo Nordisk's (NVO) current valuations are not sustainable and there exist numerous adverse factors. Learn what are those adverse factors., Headline: October 6th Options Now Available For Amgen (AMGN), source:Stock Options Channel, summary: No summary, Headline: 4 Surefire Stocks to Buy in the Next Bear Market, source:Yahoo, summary: Are stocks slipping back toward a new bear market?  The economic news is sending mixed messages.  Given the prospect of a return to bear market conditions, though, it wouldn't hurt to at least make some plans for the possibility., Headline: CVS Health launches new brand Cordavis to target $100 billion biosimilar market, source:Yahoo, summary: CVS is launching a new business segment that will negotiate with drugmakers to produce private label products for it to sell, the healthcare giant said Wednesday., Headline: Amgen Inc. stock falls Thursday, still outperforms market, source:MarketWatch, summary: Shares of Amgen Inc. dropped 0.29% to $256.62 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index..., Headline: Top Merger Stocks Held By Fund Managers, Mid-Q3 2023, source:SeekingAlpha, summary: Horizon Therapeutics remains top stock held by merger-focused funds for the third consecutive quarter. Read more about top merger stocks held by fund managers., Headline: Stock buybacks spur wealth inequality and stifle innovation. Should they be banned?, source:MarketWatch, summary: Stock buybacks have become a major source of wealth inequality and have stifled innovation in the U.S., according to this academic., Headline: Horizon Therapeutics gains as FTC seeks delay of in-house trial on Amgen deal, source:Seeking Alpha, summary: No summary, Headline: Horizon Therapeutics gains as FTC granted delay in-house trial on Amgen deal, source:Seeking Alpha, summary: No summary, Headline: Horizon Therapeutics gains as FTC withdraws in-house trial on Amgen deal, source:Seeking Alpha, summary: No summary, Headline: Horizon Therapeutics jumps as FTC withdraws in-house trial on $28B Amgen deal, source:Seeking Alpha, summary: No summary",AMGN
303,2023-08-25,"Headline: Horizon Therapeutics jumps as FTC withdraws in-house trial on $28B Amgen deal (update), source:Seeking Alpha, summary: No summary, Headline: Merck starts phase 3 program for oral PCSK9 inhibitor to lower cholesterol, source:Seeking Alpha, summary: No summary, Headline: As Medicare picks 10 drugs for price negotiations, 50 million people stand to benefit — even if their drugs aren’t on the list, source:MarketWatch, summary: No summary, Headline: 11 Most Undervalued Dow Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this piece, we will take a look at the 11 most undervalued Dow stocks to buy according to hedge funds. If you want to skip our introduction to one of the most historic stock indexes in America, then head on over to 5 Most Undervalued Dow Stocks To Buy According To Hedge Funds. The […], Headline: Amgen Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slid 0.09% to $256.38 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Horizon Therapeutics Jumps On A New FTC Development In The Amgen Takeover Battle, source:Yahoo, summary: The FTC pulled back one of its efforts to block Amgen's Horizon buyout, according to a document released Friday that sent HZNP stock flying., Headline: UPDATE 2-SoftBank-backed Neumora Therapeutics files paperwork for U.S. IPO, source:Yahoo, summary: The filing comes at a time of renewed investor interest in IPOs following a flurry of deals in the United States and European markets, which have over the last year seen many high-profile startups shelve their listing plans due to market volatility.  Neumora's lead drug candidate navacaprant is a potential oral treatment of major depressive disorder.  Neumora did not disclose the size, timetable or other details of the offering in its filing with the U.S. securities regulator., Headline: Crohn's disease drugmakers set to benefit from expected rise in cases, source:Seeking Alpha, summary: No summary",AMGN
304,2023-08-26,"Headline: Amgen Presents Phase 2 OLPASIRan Data at ESC 2023, source:Finnhub, summary: Amgen announced data from the final analysis of the Phase 2 OCEAN-DOSE study of olpasiran, a small interfering RNA during the Late-Breaking Science Session at the European Society of Cardiology ..., Headline: FTC Takes A Rare Step Back, Pauses Legal Battle With Amgen Over $28B Horizon Deal, source:Benzinga, summary: No summary, Headline: US FTC suspends challenge to block Amgen's $27.8 bln deal for Horizon Therapeutics, source:Finnhub, summary: The U.S. Federal Trade Commission has suspended its challenge of Amgen's $27.8billion purchase of Horizon Therapeutics, allowing theFTC to consider whether the agency should settle the case,..., Headline: AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023, source:Yahoo, summary: Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose., Headline: FTC Pauses Challenge to Amgen’s $27.8 Billion Deal for Horizon Therapeutics, source:Yahoo, summary: The move gives the agency time to weigh a settlement that would allow the deal to close with conditions., Headline: UPDATE 2-US FTC suspends challenge to block Amgen's $27.8 bln deal for Horizon Therapeutics, source:Yahoo, summary: The U.S. Federal Trade Commission (FTC) has suspended its challenge of Amgen's $27.8 billion purchase of Horizon Therapeutics, allowing the FTC to consider whether the agency should settle the case, a filing late on Friday showed.  Amgen said the company was aware of the move and is prepared to demonstrate that there is no legal or factual reason to prohibit the acquisition to the courts.  The agency had said it opposed the deal because of concern that Amgen would leverage its big selling drugs to pressure insurance companies and pharmacy benefit managers to give favorable terms for Horizon's two key products - the fast-growing thyroid eye disease treatment Tepezza and gout drug Krystexxa., Headline: US FTC suspends challenge to block Amgen's $27.8 billion deal for Horizon Therapeutics, source:Yahoo, summary: Amgen said the company was aware of the move and is prepared to demonstrate that there is no legal or factual reason to prohibit the acquisition to the courts.  The agency had said it opposed the deal because of concern that Amgen would leverage its big selling drugs to pressure insurance companies and pharmacy benefit managers to give favorable terms for Horizon's two key products - the fast-growing thyroid eye disease treatment Tepezza and gout drug Krystexxa.  The Thousand Oaks, California-based company announced plans to buy Horizon in December last year, saying that its rare disease drugs would offer it some protection from the drug pricing provisions of the Inflation Reduction Act, which are aimed at drugs most widely used by the government's Medicare health plan.",AMGN
305,2023-08-27,"Headline: Fly Intel: Top five weekend stock stories, source:Thefly.com, summary: No summary, Headline: FTC pauses challenge to Amgen deal for Horizon Therapeutics, WSJ reports, source:Thefly.com, summary: No summary, Headline: Wall Street lists potential targets for Medicare drug price negotiations, source:Seeking Alpha, summary: No summary, Headline: What You Missed On Wall Street On Monday, source:Thefly.com, summary: No summary",AMGN
306,2023-08-28,"Headline: Biggest stock movers today: XPeng, VinFast and more, source:Seeking Alpha, summary: No summary, Headline: August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge, source:SeekingAlpha, summary: Two new sample Breakout Stocks for Week 35 curated by the MDA model for a 10% short-term upside along with a Dow pick. Click here for a detailed analysis., Headline: US Stocks Seen Opening Firmer In New Week's 1st Session As Traders Look To Week's Key Data; Analyst Constructive Despite Bearish Signals, source:Benzinga, summary: No summary, Headline: Horizon Therapeutics jumps after FTC pauses Amgen challenge for settlement talks, source:Seeking Alpha, summary: No summary, Headline: Horizon Therapeutics shares climb after FTC pauses challenge of deal with Amgen, source:MarketWatch, summary: Shares of Horizon Therapeutics PLC gained more than 5% premarket on Monday after the Federal Trade Commission last week paused its legal challenge to Amgen..., Headline: Amgen could reach settlement with FTC over Horizon in next few weeks - report, source:Seeking Alpha, summary: No summary, Headline: BMO Capital Issues a Hold Rating on Amgen (AMGN), source:TipRanks, summary: No summary, Headline: Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories, source:Benzinga, summary: No summary, Headline: Biggest stock movers today: Hawaiian Electric, RPT Realty, VinFast Auto and more, source:Seeking Alpha, summary: No summary, Headline: 5 Things to Know Before Markets Open, source:Yahoo, summary: Horizon Therapeutics shares jumped after the Federal Trade Commission paused a challenge to its acquisition by Amgen and Chinese EV maker XPeng announced a partnership with ride-hailing provider Didi. Here’s what investors need to know today., Headline: US Stocks Grind Higher As China Cuts Taxes On Trading, Eyes Further Stimulus: What's Driving Markets Monday?, source:Benzinga, summary: No summary, Headline: Amgen-Horizon Deal: FTC Pauses Proceedings to Block the Acquisition, source:TipRanks, summary: No summary, Headline: Dow 30 Stocks List: Ranked By Hedge Fund Bullishness Index, source:Yahoo, summary: In this article, we discuss Dow 30 stocks ranked in accordance with the hedge fund bullishness index. If you want to skip our detailed discussion about the stock market performance, head directly to Top 10 Dow Stocks: Ranked By Hedge Fund Bullishness Index. Dow 30 is a stock index that takes into consideration the performance […], Headline: Why Amgen (AMGN) is a Top Value Stock for the Long-Term, source:Yahoo, summary: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage., Headline: Horizon Therapeutics Shares Surge As FTC Postpones Challenge to Merger, source:Yahoo, summary: Horizon Therapeutics shares jumped more than 5% early trading Monday after the FTC said it would suspend its challenge to Amgen's acquisition of the drug maker., Headline: Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit, source:Yahoo, summary: The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises 5.8% in response., Headline: FTC suspends challenge to Amgen-Horizon Therapeutics deal, source:Yahoo, summary: The Federal Trade Commission is suspending its challenge to Amgen's (AMGN) $27.8 billion bid to acquire Horizon Therapeutics (HZNP). The FTC is concerned Amgen will be able to bundle its products to a couple of Horizon's, giving it an advantage over rivals. It's a notion Amgen rejects. The FTC is pausing its challenge in hopes of reaching a settlement that would allow the deal to close. Yahoo Finance Health Care Reporter Anjalee Khemlani breaks the story down., Headline: Amgen Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.07% higher to $256.55 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: Amgen-Horizon Takeover Seen Close to a Lock After FTC Pauses Challenge, source:Yahoo, summary: (Bloomberg) -- Traders are almost 100% certain that Amgen Inc. will complete its $28 billion takeover of Horizon Therapeutics Plc after the Federal Trade Commission paused its in-house case to block the deal.Most Read from BloombergChina’s Worsening Economic Slowdown Is Rippling Across the Globe3M Agrees to Pay More Than $5.5 Billion Over Combat EarplugsTraders Have S&P 500 Comebacks Fading at Historic PaceAuto Union Boss Wants 46% Raise, 32-Hour Work Week in ‘War’ Against Detroit CarmakersTrump, Headline: 10 drugs targeted for Medicare price negotiations as Biden pitches cost reductions, source:Associated Press, The, summary: No summary, Headline: What You Missed On Wall Street On Tuesday, source:Thefly.com, summary: No summary, Headline: Amgen Now #52 Largest Company, Surpassing NextEra Energy, source:The Online Investor, summary: No summary",AMGN
307,2023-08-29,"Headline: Nasdaq, S&P 500 Futures Flatline Ahead Of JOLTS, House Price Data; Why This Analyst Recommends 'Buying Weakness Than Selling Rallies', source:Benzinga, summary: No summary, Headline: Medicare lists first ten drugs selected for pricing negotiations, source:Seeking Alpha, summary: No summary, Headline: Biden unveils first 10 drugs subject to Medicare price negotiation, source:Thefly.com, summary: No summary, Headline: Merck, Amgen, AbbVie products among first 10 drugs selected for Medicare price negotiations, source:MarketWatch, summary: Medicare on Tuesday announced the first 10 drugs selected for price negotiations, launching a historic and highly contentious process with big implications..., Headline: Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle, source:Benzinga, summary: No summary, Headline: Eliquis, Jardiance among first 10 drugs selected for Medicare price negotiations, source:MarketWatch, summary: No summary, Headline: White House names first 10 drugs eligible for Medicare price negotiations, source:United Press International, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Biden Administration targets drugs from J&J, Merck for controversial Medicare price negotiations, source:Yahoo, summary: The Biden administration revealed the first 10 drugs that will face the Medicare negotiation process under the Inflation Reduction Act., Headline: Best Buy results, Medicare negotiations list, Hurricane Idalia: Top stories, source:Yahoo, summary: Best Buy (BBY) lowers its full-year sales outlook despite topping earnings estimates. The Biden administration has shared its list of ten prescription drugs that will be subject to pricing negotiations between manufacturers and Medicare. Tropical Storm Idalia has officially been upgraded to a hurricane. It's expected to make landfall on Florida's west coast on Wednesday.Yahoo Finance Live's Brad Smith highlights three of this morning's biggest stories., Headline: Biden admin unveils ten drugs picked for Medicare price negotiations, source:Yahoo, summary: The Biden administration has released the list of the first ten drugs that will be subject to Medicare price negotiations. The Center for Medicare Director Dr. Meena Seshamani tells Yahoo Finance Live that they are looking at ""the benefits that a drug brings to populations. Does it address an unmet need? Does it address different populations that have needs?"" When it comes to why some drugs were chosen Dr. Seshamani says the organization followed the criteria written in the Inflation Reduction Act, adding that the list will not change. These are the ten drugs Medicare will be negotiating the prices of:Eliquis- Bristol-Myers Squibb (BMY), Pfizer (PFE) Jardiance- Boehringer Ingelheim, Eli Lilly (LLY) Xarelto- Bayer (BAYRY), Johnson & Johnson (JNJ) Januvia- Merck (MRK) Farxiga- AstraZeneca (AZN) Entresto- Novartis (NVS) Enbrel- Amgen (AMGN) Imbruvica- Johnson & Johnson (JNJ), AbbVie (ABBV) Stelara- Johnson & Johnson (JNJ) Fiasp, NovoLog- Novo Nordisk (NVO), Headline: Expensive Drugs Targeted for First U.S. Price Negotiations, source:Yahoo, summary: Lower prices would take effect in 2026 depending on the talks between the U.S. and drugmakers and the outcome of industry lawsuits., Headline: Amgen Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. rose 1.20% to $259.64 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index..., Headline: NuVasive/Globus Medical spread widens amid notice of FTC meeting (update), source:Seeking Alpha, summary: No summary",AMGN
308,2023-08-30,"Headline: Court hearing on FTC's challenge to Horizon/Amgen rescheduled until next week, source:Seeking Alpha, summary: No summary, Headline: NuVasive/Globus Medical spread widens amid notice of FTC closed door meeting, source:Seeking Alpha, summary: No summary, Headline: Medicare price negotiation list: What it means for pharma companies, source:Yahoo, summary: On Tuesday, the Biden administration listed ten drugs subject to Medicare price negotiations. Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the list and how this may impact the pharmaceutical companies who profit from these drugs.   The ten drugs and pharma companies impacted are:  Eliquis - Bristol-Myers Squibb (BMY), Pfizer (PFE) Jardiance - Boehringer Ingelheim, Eli Lilly (LLY) Xarelto- Bayer (BAYRY), Johnson & Johnson (JNJ) Januvia - Merck (MRK) Farxiga - AstraZeneca (AZN) Entresto - Novartis (NVS) Enbrel - Amgen (AMGN) Imbruvica - Johnson & Johnson (JNJ), AbbVie (ABBV) Stelara - Johnson & Johnson (JNJ) Fiasp, NovoLog - Novo Nordisk (NVO), Headline: Amgen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. sank 0.68% to $257.88 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: Medicare's drug pricing list didn't impact company stocks — here's why, source:Yahoo, summary: Company stocks were unaffected by the Biden Administration's historic announcement Tuesday of Medicare's first list of drugs for negotiating prices.",AMGN
309,2023-08-31,"Headline: Rising High: Exclusive talk with psychotropics company Lucy Scientific Discovery, source:Thefly.com, summary: No summary, Headline: $1000 Invested In This Stock 15 Years Ago Would Be Worth $4,200 Today, source:Benzinga, summary: No summary, Headline: Is This the Green Light Biotech Stocks Have Been Waiting For?, source:Yahoo, summary: It looks like the Federal Trade Commission will give up on its attempt to block Amgen's acquisition of Horizon Therapeutics., Headline: Big Pharma's biggest ally gets trolled on X for attacking Medicare drug pricing list, source:Yahoo, summary: Drug lobbying firm PhRMA faced backlash on social media for its attempt to call Medicare pricing negotiations unfair., Headline: Amgen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. slipped 0.60% to $256.34 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE, source:Yahoo, summary: Amgen (NASDAQ:AMGN) will present at the 2023 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Wednesday, Sept. 6, 2023. Amgen will also present at the Citi Global Healthcare Conference at 1:00 p.m. ET on Thursday, Sept. 7, 2023. Peter H. Griffith, executive vice president and chief financial officer at Amgen, and Murdo Gordon, executive vice president of global commercial operations at Amgen will present at both conferences. The webcasts from these events will be broadcast over the internet, Headline: What You Missed On Wall Street On Friday, source:Thefly.com, summary: No summary",AMGN
310,2023-09-01,"Headline: Amgen reaches settlement with FTC on Horizon Therapeutics takeover, source:Thefly.com, summary: No summary, Headline: Horizon Therapeutics gains amid reports FTC settled with Amgen over $28B deal, source:Seeking Alpha, summary: No summary, Headline: Amgen to settle FTC and state challenges to Horizon Therapeutics takeover, source:Thefly.com, summary: No summary, Headline: Horizon Therapeutics gains after FTC settles with Amgen over $28B deal  (update), source:Seeking Alpha, summary: No summary, Headline: Amgen, Horizon Therapeutics confirm resolution of FTC lawsuit, source:Thefly.com, summary: No summary, Headline: Amgen, Horizon enter consent order agreement with FTC to close acquisition, source:Thefly.com, summary: No summary, Headline: Horizon Therapeutics gains afer FTC settles with Amgen over $28B deal  (update), source:Seeking Alpha, summary: No summary, Headline: FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics, source:MarketWatch, summary: The Federal Trade Commission reached a deal with Amgen to approve its $27.8 billion acquisition of Horizon Therapeutics plc the agency announced Friday., Headline: Amgen-Horizon Therapeutics $28B Acquisition: Federal Trade Commission Gives Green Signal, source:Benzinga, summary: No summary, Headline: As Medicare drug-price negotiations inch forward, some states are flexing new powers to cut costs for a broader swath of drugs, source:MarketWatch, summary: No summary, Headline: TOP NEWS: Amgen buy of Horizon closer as FTC lawsuit resolved, source:Alliance News, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: As Medicare drug-price negotiations inch forward, some states are flexing new powers to cut costs for a broader swath of drugs , source:MarketWatch, summary: States like Colorado are looking to set upper payment limits on certain drugs as soon as next year., Headline: Horizon Therapeutics (NASDAQ:HZNP) Gains After FTC Settlement, source:TipRanks, summary: No summary, Headline: Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock, source:Yahoo, summary: No summary, Headline: Amgen gets US FTC's go-ahead for $27.8 billion Horizon deal, source:Yahoo, summary: The U.S. Federal Trade Commission (FTC) has allowed Amgen to continue its $27.8 billion acquisition of Horizon Therapeutics, while preventing the drugmaker from using anticompetitive tactics to extend the market dominance of two Horizon drugs.  The agreement, announced on Friday, ends months of uncertainty over the deal since the FTC in May filed a lawsuit over concerns that Amgen would leverage its drugs to secure favorable insurance coverage terms for Horizon's thyroid eye disease treatment Tepezza and gout drug Krystexxa.  Under the FTC settlement, Amgen is prohibited from bundling any of its products with Tepezza or Krystexxa, and from using any product rebate or contract term to exclude or disadvantage products that would compete with those drugs., Headline: AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION, source:Yahoo, summary: Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon., Headline: Amgen’s $27.8 Billion Horizon Takeover Allowed in FTC Accord, source:Yahoo, summary: (Bloomberg) -- Amgen Inc. can move forward with its $27.8 billion takeover of Horizon Therapeutics Plc after the US Federal Trade Commission said Friday that it accepted a binding settlement that the combined company won’t bundle together two of Horizon’s blockbuster drugs.Most Read from BloombergHuawei Teardown Shows Chip Breakthrough in Blow to US SanctionsMercedes Bets on Range Boost in Swipe at Tesla’s EV LeadWhy China Is Avoiding Using ‘Bazooka’ to Spur EconomyDiamond Prices Are in Free Fal, Headline: Horizon Therapeutics Stock Rises After Settlement Clears Way for Amgen Deal, source:Yahoo, summary: Shares of Horizon Therapeutics rose Friday morning after the FTC said [it reached a settlement](https://www.wsj.com/us-news/law/ftc-settles-with-amgen-over-27-8-billion-deal-for-horizon-therapeutics-b96a2d69) with Amgen that would let it acquire the company., Headline: Amgen resolves US regulator’s challenge to $28bn Horizon deal, source:Yahoo, summary: Federal Trade Commission said it secured concessions from pharma company to resolve its competition concerns, Headline: Amgen and Horizon Therapeutics Stocks Rise After FTC Settlement Over $27.8 Billion Merger, source:Yahoo, summary: The Federal Trade Commission makes provision that prohibits “bundling” discounts for some medications., Headline: Trending : FTC Ends Challenge of Amgen/Horizon Deal, source:Finnhub, summary: 14:16 ET -- Amgen and Horizon Therapeutics are among the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The Federal Trade Commission..., Headline: CDC: Dividend ETF With Unconventional Market Timing, source:SeekingAlpha, summary: VictoryShares US EQ Income Enhanced Volatility Wtd is a defensive ETF with unconventional market timing and lower risk in drawdowns. Learn more about CDC here., Headline: Why Amgen's $28 Billion Merger News Also Bodes Well For Pfizer, Biogen, source:Yahoo, summary: Amgen stock rose Friday after the FTC dropped its lawsuit, clearing the way for the biotech to buy Horizon Therapeutics for $28 billion., Headline: Amgen’s $27.8 Billion Deal for Horizon Therapeutics Clears Key Hurdle, source:Yahoo, summary: The Federal Trade Commission said it had agreed to end its legal challenge of the deal. The pact also dismisses the antitrust claims of six states that joined the FTC in May seeking to block the transaction., Headline: NEW YORK MARKET CLOSE: Dow and dollar rise after mixed payrolls report, source:Alliance News, summary: No summary, Headline: Amgen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Amgen Inc. inched 0.14% higher to $256.71 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: Amgen gets green light from FTC for $27.8B Horizon Therapeutics deal, source:Yahoo, summary: The Federal Trade Commission will allow Amgen to continue a $27.8 billion purchase of Horizon Therapeutics. The companies anticipate closing the deal in the fourth quarter., Headline: Amgen, FTC Settle Over $27.8 Billion Horizon Deal. Stocks Rise., source:Yahoo, summary: The Federal Trade Commission prohibited the merged company from “bundling” discounts for some medications., Headline: Dow Jones Today: Index Moves Up on Jobs Report, source:Yahoo, summary: The Dow Jones finished higher by about 115 points, or 0.3%, on investors optimism that the latest employment report will help prompt the Fed to end its interest rate hikes.",AMGN
